<SEC-DOCUMENT>0001213900-23-090732.txt : 20231129
<SEC-HEADER>0001213900-23-090732.hdr.sgml : 20231129
<ACCEPTANCE-DATETIME>20231129081009
ACCESSION NUMBER:		0001213900-23-090732
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20231128
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231129
DATE AS OF CHANGE:		20231129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			180 Life Sciences Corp.
		CENTRAL INDEX KEY:			0001690080
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813832378
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38105
		FILM NUMBER:		231448540

	BUSINESS ADDRESS:	
		STREET 1:		3000 EL CAMINO REAL
		STREET 2:		BLDG 4, STE 200
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94306
		BUSINESS PHONE:		650-507-0669

	MAIL ADDRESS:	
		STREET 1:		3000 EL CAMINO REAL
		STREET 2:		BLDG 4, STE 200
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KBL MERGER CORP. IV
		DATE OF NAME CHANGE:	20161115
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea189187-8k_180life.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:ATNF="http://180lifesciences.com/20231128">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03B_ATNF_180lifesciences.com_20231128 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20231128_20231128 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001690080 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2023-11-28" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-11-28" name="dei:EntityCentralIndexKey">0001690080</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="atnf-20231128.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2023-11-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-28</xbrli:startDate>
        <xbrli:endDate>2023-11-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-282023-11-28_custom_CommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-28</xbrli:startDate>
        <xbrli:endDate>2023-11-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-282023-11-28_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-28</xbrli:startDate>
        <xbrli:endDate>2023-11-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>FORM <span id="xdx_90A_edei--DocumentType_c20231128__20231128_zp7YHuqVo3Pj"><ix:nonNumeric contextRef="AsOf2023-11-28" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>PURSUANT TO SECTION
13 OR 15(d) OF THE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SECURITIES EXCHANGE
ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Date of Report (Date of
earliest event reported): <span id="xdx_906_edei--DocumentPeriodEndDate_c20231128__20231128_zC7eLyy2NMuh"><ix:nonNumeric contextRef="AsOf2023-11-28" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">November 28, 2023</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b><span style="text-decoration: underline"><span id="xdx_907_edei--EntityRegistrantName_c20231128__20231128_zb5253zEILje"><ix:nonNumeric contextRef="AsOf2023-11-28" name="dei:EntityRegistrantName">180 LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(Exact Name of Registrant
as Specified in Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20231128__20231128_z5gAbrRl7LM9"><ix:nonNumeric contextRef="AsOf2023-11-28" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityFileNumber_c20231128__20231128_zabNGLerBl4a"><ix:nonNumeric contextRef="AsOf2023-11-28" name="dei:EntityFileNumber">001-38105</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20231128__20231128_zkBbYJkZD626"><ix:nonNumeric contextRef="AsOf2023-11-28" name="dei:EntityTaxIdentificationNumber">90-1890354</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction<br />
of Incorporation)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer<br />
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityAddressAddressLine1_c20231128__20231128_zKBcgFcBRaAe"><ix:nonNumeric contextRef="AsOf2023-11-28" name="dei:EntityAddressAddressLine1">3000 El Camino Real</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressAddressLine2_c20231128__20231128_ztNCvLemW5v1"><ix:nonNumeric contextRef="AsOf2023-11-28" name="dei:EntityAddressAddressLine2">Bldg. 4</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressAddressLine3_c20231128__20231128_zzGI1EjsSgH6"><ix:nonNumeric contextRef="AsOf2023-11-28" name="dei:EntityAddressAddressLine3">Suite 200</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityAddressCityOrTown_c20231128__20231128_zYSQvlTjl1j4"><ix:nonNumeric contextRef="AsOf2023-11-28" name="dei:EntityAddressCityOrTown">Palo Alto</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20231128__20231128_zgsUUZGwP3Sa"><ix:nonNumeric contextRef="AsOf2023-11-28" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></b></p></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityAddressPostalZipCode_c20231128__20231128_z9GyWrcG4ewc"><ix:nonNumeric contextRef="AsOf2023-11-28" name="dei:EntityAddressPostalZipCode">94306</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of Principal Executive Offices)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Registrant&#8217;s telephone
number, including area code: <b><span style="text-decoration: underline">(<span id="xdx_90C_edei--CityAreaCode_c20231128__20231128_zPR3gR7egao5"><ix:nonNumeric contextRef="AsOf2023-11-28" name="dei:CityAreaCode">650</ix:nonNumeric></span>) <span id="xdx_906_edei--LocalPhoneNumber_c20231128__20231128_zqVBe1zznSFg"><ix:nonNumeric contextRef="AsOf2023-11-28" name="dei:LocalPhoneNumber">507-0669</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (<i>see </i>General Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15pt; text-align: justify; text-indent: -0.15pt; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--WrittenCommunications_c20231128__20231128_zZtUf7MQSCnl"><ix:nonNumeric contextRef="AsOf2023-11-28" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--SolicitingMaterial_c20231128__20231128_z9hSk5sQ7Qd"><ix:nonNumeric contextRef="AsOf2023-11-28" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--PreCommencementTenderOffer_c20231128__20231128_z7dsic0mGfR4"><ix:nonNumeric contextRef="AsOf2023-11-28" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--PreCommencementIssuerTenderOffer_c20231128__20231128_zF7Xj3X3ljQe"><ix:nonNumeric contextRef="AsOf2023-11-28" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Securities registered
pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="white-space: nowrap; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="white-space: nowrap; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--Security12bTitle_c20231128__20231128__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zE70o0S5j3Ub"><ix:nonNumeric contextRef="From2023-11-282023-11-28_custom_CommonStockParValue0.0001PerShareMember" name="dei:Security12bTitle">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--TradingSymbol_c20231128__20231128__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zWmoShUdOMqh"><ix:nonNumeric contextRef="From2023-11-282023-11-28_custom_CommonStockParValue0.0001PerShareMember" name="dei:TradingSymbol">ATNF</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_905_edei--SecurityExchangeName_c20231128__20231128__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zWlzNyQ4qZ8i"><ix:nonNumeric contextRef="From2023-11-282023-11-28_custom_CommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--Security12bTitle_c20231128__20231128__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zV6ciYyo1xdi"><ix:nonNumeric contextRef="From2023-11-282023-11-28_custom_WarrantsToPurchaseSharesOfCommonStockMember" name="dei:Security12bTitle">Warrants to purchase shares of Common Stock</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20231128__20231128__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zYJYYvR8wtEe"><ix:nonNumeric contextRef="From2023-11-282023-11-28_custom_WarrantsToPurchaseSharesOfCommonStockMember" name="dei:TradingSymbol">ATNFW</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_90E_edei--SecurityExchangeName_c20231128__20231128__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zGTMVc4mWMsi"><ix:nonNumeric contextRef="From2023-11-282023-11-28_custom_WarrantsToPurchaseSharesOfCommonStockMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Emerging growth company <span id="xdx_907_edei--EntityEmergingGrowthCompany_c20231128__20231128_z5zNbY9rJmHe"><ix:nonNumeric contextRef="AsOf2023-11-28" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01. Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
previously reported on our Current Report on Form 8-K filed on August 14, 2023, 180 Life Sciences Corp., a Delaware corporation (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;),
agreed to issue and sell to certain investors, including a certain institutional investor (the &#8220;<span style="text-decoration: underline">Purchaser</span>&#8221;), an aggregate
of: (i) 666,925 shares (the &#8220;<span style="text-decoration: underline">August Shares</span>&#8221;) of the Company&#8217;s common stock, $0.0001 par value (the &#8220;<span style="text-decoration: underline">Common
Stock</span>&#8221;), (ii) pre-funded warrants (the &#8220;<span style="text-decoration: underline">August Pre-Funded Warrants</span>&#8221;) to purchase up to 3,948,460 shares of
Common Stock, and (iii) warrants (the &#8220;<span style="text-decoration: underline">August Common Warrants</span>&#8221;) to purchase up to 4,615,385 shares of Common Stock,
in the case of the Purchaser, pursuant to a securities purchase agreement, dated as of August 9, 2023, between the Company and the Purchaser
(the &#8220;<span style="text-decoration: underline">August SPA</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
previously reported on our Current Report on Form 8-K filed on October 13, 2023, the Company received written notice from the Listing
Qualifications Department of The Nasdaq Stock Market LLC (&#8220;<span style="text-decoration: underline">Nasdaq</span>&#8221;) notifying the Company that it was not in compliance
with the shareholder approval requirements set forth in Nasdaq Listing Rule 5635(d).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On November 28, 2023, the Company entered into Amendment No. 1 to the
August SPA with the Purchaser (the &#8220;<span style="text-decoration: underline">SPA Amendment</span>&#8221;), pursuant to which (i) the Purchaser agreed to pay an additional
$830,769.30 in connection with the repricing of the August Shares and August Pre-Funded Warrants (the &#8220;<span style="text-decoration: underline">Repricing Amount</span>&#8221;),
(ii) the Company agreed to issue to the Purchaser (x) pre-funded warrants to purchase up to 4,886,878 shares of Common Stock, with an
exercise price of $0.0001 per share (the &#8220;<span style="text-decoration: underline">Pre-Funded Warrants</span>&#8221;), and (y) warrants to purchase up to 9,064,098 shares
of Common Stock, with an exercise price of $0.17 per share (the &#8220;<span style="text-decoration: underline">Common Warrants</span>&#8221; and, together with the Pre-Funded
Warrants, the &#8220;<span style="text-decoration: underline">Warrants</span>&#8221;), and (iii) the Company and the Purchaser agreed to enter into the Warrant Amendment Agreement
(as defined and described below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Warrants will not be exercisable until the Company obtains Stockholder Approval (as defined in the SPA Amendment) with respect to the
issuance of the 13,950,976 shares of Common Stock upon exercise of the Warrants (the &#8220;<span style="text-decoration: underline">Warrant Shares</span>&#8221;), at which point
the Pre-Funded Warrants will remain exercisable until all of the Pre-Funded Warrants are exercised in full, and the Common Warrants will
remain exercisable until the fifth anniversary of the Stockholder Approval Date (as defined in the SPA Amendment).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
SPA Amendment contains certain customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification
obligations of the Company, other obligations of the parties, and termination provisions. Pursuant to the SPA Amendment, the Company has
agreed that, subject to certain exceptions, it will not conduct any issuances of Common Stock (or equivalents thereof) from the Closing
Date until 15 days after the Stockholder Approval Date. The SPA Amendment also requires the Company to file a registration statement with
the Securities and Exchange Commission (the &#8220;<span style="text-decoration: underline">SEC</span>&#8221;) to register the resale by the Purchaser of the Warrant Shares within
sixty (60) days of the date of the SPA Amendment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
accordance with the SPA Amendment, the Company entered into a warrant amendment agreement with the Purchaser, dated November 28, 2023
(the &#8220;<span style="text-decoration: underline">Warrant Amendment Agreement</span>&#8221;), whereby the Company agreed to amend the following outstanding warrants held by
the Purchaser: (i) warrants to purchase up to 2,571,429 shares of Common Stock, issued on December 22, 2022, and amended in January 2023,
April 2023 and August 2023; (ii) warrants to purchase up to 306,604 shares of Common Stock, issued on July 20, 2022 and amended in April
2023 and August 2023; (iii) warrants to purchase up to 1,570,680 shares of Common Stock, issued on April 10, 2023 and August 2023; and
(iv) warrants to purchase up to 4,615,385 shares of Common Stock underlying the August Common Warrants (collectively, the &#8220;<span style="text-decoration: underline">Existing
Common Warrants</span>&#8221;). Pursuant to the Warrant Amendment Agreement, the Existing Common Warrants will be amended (the &#8220;<span style="text-decoration: underline">Warrant
Amendment</span>&#8221;) such that they will not be exercisable until the company obtains stockholder approval for the issuance of up to
9,064,098 shares of Common Stock upon exercise of the Existing Common Warrants (the &#8220;<span style="text-decoration: underline">Existing Common Warrant Shares</span>&#8221;).
The Existing Common Warrants will have an exercise price equal to $0.17 per share, and the Existing Common Warrants will expire on the
fifth anniversary of the Stockholder Approval Date. The other terms of the Existing Common Warrants will remain unchanged.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">The
closing of the transactions is expected to occur on December 1, 2023 (the &#8220;<span style="text-decoration: underline">Closing Date</span>&#8221;). Upon the closing of
the transactions, the Company expects to regain compliance with Nasdaq Listing Rule 5635(d).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">For purposes of obtaining Stockholder
Approval of the issuance of the Warrant Shares and the Existing Common Warrant Shares, the Company has agreed to hold a Stockholder
Meeting (as defined in the SPA Amendment) on or prior to the date that is ninety (90) days following the Closing Date. If the
Company does not obtain Stockholder Approval at the first Stockholder Meeting, the Company will call a Stockholder Meeting every
ninety (90) days thereafter until the earlier of: (i) the date on which Stockholder Approval is obtained or (ii) the Warrants and
the Existing Common Warrants are no longer outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Simultaneously
with the closing of the transactions, the Company expects to enter into a warrant agent agreement (the &#8220;<span style="text-decoration: underline">Warrant Agent Agreement</span>&#8221;)
with Continental Stock Transfer &amp; Trust Company (&#8220;<span style="text-decoration: underline">Continental</span>&#8221;), pursuant to which Continental will act as warrant
agent with respect to the Warrants to be issued by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
form of Warrant Agent Agreement, the form of Pre-Funded Warrant, the form of Common Warrant, the Warrant Amendment Agreement and the SPA
Amendment are filed as Exhibits 4.1, 4.2, 4.3, 4.4 and 10.1 respectively, to this Current Report on Form 8-K and are incorporated herein
by reference. The above descriptions of the terms of the Warrant Agent Agreement, the Pre-Funded Warrant, the Common Warrant, the Warrant
Amendment Agreement and the SPA Amendment are qualified in their entirety by reference to such exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 3.02. Unregistered Sales of Equity Securities</b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
information contained above in Item 1.01 related to the Warrants and Warrant Shares is hereby incorporated by reference into this Item
3.02. The Warrants and the Warrant Shares have not been registered under the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration: underline">Securities
Act</span>&#8221;), and are instead being offered pursuant to the exemption provided in Section&#160;4(a)(2)&#160;under the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01. Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>(d) Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea189187ex4-1_180life.htm">Form of Warrant Agent Agreement for Pre-Funded Warrants and Common Warrants</a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="ea189187ex4-1_180life.htm#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant (included as Annex A to Exhibit 4.1)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="ea189187ex4-1_180life.htm#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Warrant (included as Annex B to Exhibit 4.1)</span></a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea189187ex4-4_180life.htm">Warrant Amendment Agreement, dated November 28, 2023, by and between the Company and the Purchaser</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1+</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="ea189187ex10-1_180life.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No.1 to the Securities Purchase Agreement, dated November 28, 2023, by and between 180 Life Sciences Corp. and the Purchaser </span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive
    Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to Item 601(a)(5) of Regulation S-K, schedules have been omitted and will be furnished on a supplemental basis to the SEC upon request.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>180 LIFE SCIENCES CORP.</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 29, 2023 </span></td>
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ James N. Woody</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James N. Woody, M.D., Ph.D.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">3</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJx1kdFOwjAUhp+AdzhZvCTQVY2yO12QGEEXIOhtGWfSsPUspx3CI/mWdh1ELrRp0pyc8/3/f9Io6kcTetIlMnw8zqewxKoulUOYY4GMJkc/kT6/JODfOX5q61gZF8ozmJJn0DO3AynWvhFG99riJoE4Hsr7obwGMUpu7iCbRb22n5Ip9AaN06oEZTaQMdWs0Sk+dgpLdSBD1TFYrZCtJuPlBqJrf4MUsYRX2qsv4p2F6TSNev1wetGEqan91Pjg0LQkjEusvJ3t6N8b0uSNdVQl74rb5eySsobzrbK42CpG+1b4FSsyC0f5bobVGtlDsZAyFg+nPGcWHEF9osEGHKiATgCCwh/OF/qZ4pUqGxQDIUScIYcM/7heyvahVgz7loWrjobaf08Icfb8AXaRlgw= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea189187ex4-1_180life.htm
<DESCRIPTION>FORM OF WARRANT AGENT AGREEMENT FOR PRE-FUNDED WARRANTS AND COMMON WARRANTS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WARRANT AGENT AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS WARRANT AGENT AGREEMENT,
dated as of December 1, 2023 (this &ldquo;<U>Agreement</U>&rdquo;), between 180 Life Sciences Corp., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
and Continental Stock Transfer &amp; Trust Company, a New York corporation (the &ldquo;<U>Warrant Agent</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, on August 9, 2023, the
Company entered into a Securities Purchase Agreement (the &ldquo;<U>SPA</U>&rdquo;) with Armistice Capital Master Fund Ltd., as the purchaser
(the &ldquo;<U>Purchaser</U>&rdquo;) and agreed to issue and sell to certain investors, including the Purchaser, an aggregate of: (i)
666,925 shares of the Company&rsquo;s common stock, $0.0001 par value (the &ldquo;<U>Common Stock</U>&rdquo;), (ii) pre-funded warrants
to purchase up to 3,948,460 shares of Common Stock and (iii) warrants to purchase up to 4,615,385 shares of Common Stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, on November 28, 2023,
the Company entered into Amendment No. 1 to the SPA (the &ldquo;<U>SPA Amendment</U>&rdquo;) with the Purchaser, pursuant to which the
Company issued (i) pre-funded warrants (the &ldquo;<U>Pre-Funded Warrants</U>&rdquo;) to purchase up to 4,866,878 shares of Common Stock
at an exercise price of $0.0001 per share of Common Stock (the &ldquo;<U>Pre-Funded Warrant Shares</U>&rdquo;), and (ii) warrants (the
&ldquo;<U>Common Warrants</U>&rdquo; and, together with the Pre-Funded Warrants, the &ldquo;<U>Warrants</U>&rdquo;) to purchase up to
9,064,098 shares of Common Stock at an exercise price of $0.17 per Share (the &ldquo;<U>Common Warrant Shares</U>&rdquo; and, together
with the Pre-Funded Warrant Shares, the &ldquo;<U>Warrant Shares</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company desires
the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, registration,
transfer, exchange, redemption and exercise of the Warrants;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company desires
to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and the respective rights,
limitation of rights, and immunities of the Company, the Warrant Agent, and the holders of the Warrants; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, all acts and things
have been done and performed which are necessary to make the Warrants, when executed on behalf of the Company and countersigned by or
on behalf of the Warrant Agent, as provided herein, the valid, binding and legal obligations of the Company, and to authorize the execution
and delivery of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the mutual agreements herein contained, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;<U>Capitalized
Terms</U>. Capitalized terms used but not otherwise defined herein shall have the meaning ascribed to such terms in the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;<U>Appointment
of the Warrant Agent</U>. The Company hereby appoints the Warrant Agent to act as agent for the Company for the Warrants, and the Warrant
Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">3.&nbsp;<U>Warrants</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1.&nbsp;<U>Form
of Warrant</U>. The Warrants, together with the form of election to purchase Common Stock (&ldquo;<U>Notice of Exercise</U>&rdquo;) and
the form of assignment printed on the reverse thereof, shall be in the form of <U>Annex A</U> to this Agreement for the Pre-Funded Warrants
and in the form of <U>Annex B</U> to this Agreement for the Common Warrants, the provisions of which are incorporated herein, and signed
by, or bear the electronic or facsimile signature of, the Chief Executive Officer of the Company. In the event the person whose electronic
or facsimile signature has been placed upon any Warrant shall have ceased to serve in the capacity in which such person signed the Warrant
before such Warrant is issued, it may be issued with the same effect as if he or she had not ceased to be such at the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2.&nbsp;<U>Effect
of Countersignature</U>. Unless and until countersigned by the Warrant Agent pursuant to this Agreement, a Warrant shall be invalid and
of no effect and may not be exercised by the holder thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3.&nbsp;<U>Registration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.3.1.&nbsp;<U>Warrant
Register</U>. The Warrant Agent shall maintain books (the &ldquo;<U>Warrant Register</U>&rdquo;) for the registration of the original
issuance and transfers of the Pre-Funded Warrants and the Common Warrants. Upon the initial issuance of the Warrants, the Warrant Agent
shall register the Warrants in the names of the respective holders thereof in such denominations and otherwise in accordance with instructions
delivered to the Warrant Agent by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.3.2.&nbsp;<U>Beneficial
Owner; Holder</U>. Prior to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent may deem and
treat the person in whose name such Warrant shall be registered upon the Warrant Register (the &ldquo;<U>registered holder</U>&rdquo;),
as the absolute owner of such Warrant and of each Warrant represented thereby (notwithstanding any notation of ownership or other writing
on the Warrant made by anyone other than the Company or the Warrant Agent), for the purpose of any exercise thereof, and for all other
purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&nbsp;<U>Terms
and Exercise of Warrants</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1.&nbsp;<U>Duration
of Warrants</U>. Each Warrant shall be exercisable commencing on the applicable Initial Exercise Date. Each Warrant shall cease to be
exercisable as set forth in the applicable Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2.&nbsp;<U>Exercise
of Warrants</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2.1.&nbsp;<U>Payment</U>.
Subject to the foregoing and to Section 2(c) of the Warrant, the registered holder of a Warrant may exercise the Warrant in whole or in
part pursuant to Section 2 of the applicable Warrant. Payment of the Exercise Price, may be made, at the option of the registered holder,
by wire transfer or by certified or official bank check in United States dollars, as set forth in the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2.2.&nbsp;<U>Notice
of Exercise</U>. The registered holder shall deliver the executed Notice of Exercise and the payment of the Exercise Price as described
herein. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2.3.&nbsp;<U>Cashless
Exercise</U>. If at the time of exercise, there is no effective registration statement registering, or the prospectus contained therein
is not available for the issuance of the Warrant Shares to the registered holder, then upon receipt of a Notice of Exercise for a cashless
exercise as provided in Section 2(c) of the Warrant (&ldquo;<U>Cashless Exercise</U>&rdquo;), the Company will promptly calculate and
transmit to the Warrant Agent the number of Warrant Shares issuable in connection with such Cashless Exercise and deliver a copy of the
Notice of Exercise to the Warrant Agent, which shall issue such number of Warrant Shares in connection with such Cashless Exercise. Any
Warrants outstanding on the Termination Date will be automatically exercised via Cashless Exercise pursuant to Section 2 of the applicable
Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2.4.&nbsp;<U>Issuance
of Certificates</U>. Upon the exercise of a Warrant pursuant to the terms of Section 2 of the applicable Warrant, the Warrant Agent shall
cause the Warrant Shares underlying such Warrant to be delivered to or upon the order of the registered holder of such Warrant, registered
in such name or names as may be designated by such registered holder, by the date that is the earlier of (i) two (2) Trading Days and
(ii) the number of Trading Days comprising the Standard Settlement Period following the date of exercise as aforesaid (the &ldquo;<U>Warrant
Share Delivery Date</U>&rdquo;). If the Company is then a participant in the DWAC system of the depositary and either (A) there is an
effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the registered holder
or (B) the Warrant is being exercised via Cashless Exercise, then the Warrant Shares shall be transmitted by the Warrant Agent to the
registered holder by crediting the account of the registered holder&rsquo;s broker with the depositary through its DWAC system. Notwithstanding
anything else to the contrary in this Agreement, except in the case of a Cashless Exercise, if any registered holder fails to duly deliver
payment to the Warrant Agent of an amount equal to the aggregate Exercise Price of the Warrant Shares to be purchased upon exercise of
such registered holder&rsquo;s Warrant as set forth in Section 4 hereof by the Warrant Share Delivery Date, the Warrant Agent will not
be obligated to deliver such Warrant Shares (via DWAC or otherwise) until following receipt of such payment, and the applicable Warrant
Share Delivery Date shall be deemed extended by one day for each day (or part thereof) until such payment is delivered to the Warrant
Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2.5.&nbsp;<U>New
Warrants</U>. In case the registered holder of any Warrant shall exercise fewer than all Warrants evidenced thereby, a new Warrant evidencing
the number of Warrants equivalent to the number of Warrants remaining unexercised may be issued by the Warrant Agent to the registered
holder of such Warrant or to his duly authorized assigns in accordance with Section 2(d)(ii) of the Warrant, subject to the provisions
of Section 7.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2.6.&nbsp;<U>Valid
Issuance</U>. All shares of Common Stock issued upon the proper exercise of a Warrant in conformity with this Agreement shall be validly
issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2.7.&nbsp;<U>Date
of Issuance</U>. Each person in whose name any such certificate for shares of Common Stock is issued shall for all purposes be deemed
to have become the holder of record of such shares on the date on which the Warrant was surrendered and payment of the Exercise Price
was made, irrespective of the date of delivery of such certificate, except that, if the date of such surrender and payment is a date when
the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the close
of business on the next succeeding date on which the stock transfer books are open.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">5.&nbsp;<U>Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1.&nbsp;<U>Adjustments
to Warrants</U>. The Exercise Price, the number of Warrant Shares and the number of Warrants outstanding are subject to adjustment from
time to time as provided in Section 3 of the Warrant. In the event that at any time, as a result of an adjustment made pursuant to Section
3 of the Warrant, the registered holder of any Warrant thereafter exercised shall become entitled to receive any shares of capital stock
of the Company other than shares of Common Stock, thereafter the number of such other shares so receivable upon exercise of any Warrant
shall be subject to adjustment from time to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect
to the shares contained in Section 3 of the Warrant and the provisions of Sections 4 and 5 of this Agreement with respect to the shares
of Common Stock shall apply on like terms to any such other shares. All Warrants originally issued by the Company subsequent to any adjustment
made to the Exercise Price pursuant to the Warrant shall evidence the right to purchase, at the adjusted Exercise Price, the number of
shares of Common Stock purchasable from time to time hereunder upon exercise of the Warrants, all subject to further adjustment as provided
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2.&nbsp;<U>Notices
of Changes in Warrant</U>. Whenever the Exercise Price or the number of shares of Common Stock issuable upon the exercise of each Warrant
is adjusted as provided in Section 5.1 or 5.3, the Company shall give written notice thereof to the Warrant Agent, which notice shall
state the Exercise Price resulting from such adjustment and the increase or decrease, if any, in the number of shares purchasable at such
price upon the exercise of a Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation
is based. Upon the occurrence of an adjustment as provided in Section 5.1 or 5.3, then, in any such event, the Company shall promptly
deliver written notice by email to each registered holder setting forth the Exercise Price of each Warrant as so adjusted, any resulting
adjustment to the number of Warrant Shares and a brief statement of the facts requiring such adjustment. Failure to give such notice,
or any defect therein, shall not affect the legality or validity of such event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3.&nbsp;<U>No
Fractional Shares</U>. The Company shall not issue fractions of shares of Common Stock upon exercise of Warrants or distribute stock certificates
which evidence fractional shares of Common Stock. Whenever any fraction of a share of Common Stock would otherwise be required to be issued
or distributed, the actual issuance or distribution in respect thereof shall be made in accordance with Section 2(d)(v) of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4.&nbsp;<U>Form
of Warrant</U>. The form of Warrant need not be changed because of any adjustment pursuant to this Section 5, and Warrants issued after
such adjustment may state the same Exercise Price and the same number of shares as is stated in the Warrants initially issued pursuant
to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.&nbsp;<U>Transfer
and Exchange of Warrants.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1.&nbsp;<U>Registration
of Transfer</U>. The Warrant Agent shall register the transfer, from time to time, of any outstanding Warrant in the Warrant Register,
upon surrender of such Warrant for transfer, properly endorsed with signatures properly medallion guaranteed and accompanied by appropriate
instructions for transfer. Upon any such transfer, a new Warrant representing an equal aggregate number of Warrants shall be issued and
the old Warrant shall be cancelled by the Warrant Agent. The Warrants so cancelled may be delivered by the Warrant Agent to the Company
from time to time upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2.&nbsp;<U>Procedure
for Surrender of Warrants</U>. Warrants may be surrendered to the Warrant Agent, together with a written request for exchange or transfer,
and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested by the registered holder of the
Warrants so surrendered, representing an equal aggregate number of Warrants; provided, however, that in the event that a Warrant surrendered
for transfer bears a restrictive legend, the Warrant Agent shall not cancel such Warrant and issue new Warrants in exchange therefor until
the Warrant Agent has received an opinion of counsel for the Company stating that such transfer is exempt from registration under the
U.S. Securities Act of 1933, as amended, and indicating whether the new Warrants must also bear a restrictive legend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.3.&nbsp;<U>Service
Charges</U>. No service charge shall be made for any exchange or registration of transfer of Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.4.&nbsp;<U>Warrant
Execution and Countersignature</U>. The Warrant Agent is hereby authorized to countersign and to deliver, in accordance with the terms
of this Agreement, the Warrants required to be issued pursuant to the provisions of this Section 6, and the Company, whenever required
by the Warrant Agent, will supply the Warrant Agent with Warrants duly executed on behalf of the Company for such purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.&nbsp;<U>Other
Provisions Relating to Rights of Registered Holders of Warrants</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.1.&nbsp;<U>No
Rights as Stockholder</U>. A Warrant does not entitle the registered holder thereof to any of the rights of a stockholder of the Company,
including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive rights to vote or to consent
or to receive notice as stockholders in respect of the meetings of stockholders or the election of directors of the Company or any other
matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.2.&nbsp;<U>Lost,
Stolen, Mutilated, or Destroyed Warrants</U>. If any Warrant is lost, stolen, mutilated or destroyed, the Company and the Warrant Agent
may, on such terms as to indemnity or otherwise as they may in their discretion impose (which terms shall, in the case of a mutilated
Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor and date as the Warrant so lost, stolen, mutilated
or destroyed. Any such new Warrant shall constitute a substitute contractual obligation of the Company, whether or not the allegedly lost,
stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.3.&nbsp;<U>Reservation
of Common Stock</U>. The Company shall at all times reserve and keep available a number of its authorized but unissued shares of Common
Stock that will be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.&nbsp;<U>Concerning
the Warrant Agent and Other Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1.&nbsp;<U>Payment
of Taxes</U>. The Company will from time to time promptly pay all taxes and charges that may be imposed upon the Company or the Warrant
Agent in respect of the issuance or delivery of Warrant Shares, but the Company shall not be obligated to pay any transfer taxes in respect
of the Warrants or such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2.&nbsp;<U>Resignation,
Consolidation, or Merger of Warrant Agent</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.2.1.&nbsp;<U>Appointment
of Successor Warrant Agent</U>. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and be discharged
from all further duties and liabilities hereunder after giving sixty (60) days&rsquo; notice in writing to the Company. If the office
of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint in writing a successor
Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of 30 days after it has
been notified in writing of such resignation or incapacity by the Warrant Agent or by the holder of the Warrant (who shall, with such
notice, submit his, her or its Warrant for inspection by the Company), then the holder of any Warrant may apply to the Supreme Court of
the State of New York for the County of New York for the appointment of a successor Warrant Agent at the Company&rsquo;s cost. Any successor
Warrant Agent, whether appointed by the Company or by such court, shall be a corporation organized and existing under the laws of the
State of New York, in good standing and having its principal office in the Borough of Manhattan, City and State of New York, and authorized
under such laws to exercise corporate trust powers and subject to supervision or examination by federal or state authority. After appointment,
any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations of its predecessor
Warrant Agent with like effect as if originally named as Warrant Agent hereunder, without any further act or deed; but if for any reason
it becomes necessary or appropriate, the predecessor Warrant Agent shall execute and deliver, at the expense of the Company, an instrument
transferring to such successor Warrant Agent all the authority, powers, and rights of such predecessor Warrant Agent hereunder; and upon
request of any successor Warrant Agent the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for
more fully and effectually vesting in and confirming to such successor Warrant Agent all such authority, powers, rights, immunities, duties,
and obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.2.2.&nbsp;<U>Notice
of Successor Warrant Agent</U>. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof to the
predecessor Warrant Agent and the transfer agent for the Common Stock not later than the effective date of any such appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.2.3.&nbsp;<U>Merger
or Consolidation of Warrant Agent</U>. Any corporation into which the Warrant Agent may be merged or with which it may be consolidated
or any corporation resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the successor Warrant
Agent under this Agreement without any further act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.3.&nbsp;<U>Fees
and Expenses of Warrant Agent</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.3.1.&nbsp;<U>Remuneration</U>.
The Company agrees to pay the Warrant Agent reasonable remuneration for its services as such Warrant Agent hereunder and will reimburse
the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably incur in the execution of its duties hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.3.2.&nbsp;<U>Further
Assurances</U>. The Company agrees to perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and delivered
all such further and other acts, instruments and assurances as may reasonably be required by the Warrant Agent for the carrying out or
performing of the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.4.&nbsp;<U>Liability
of Warrant Agent</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.4.1.&nbsp;<U>Reliance
on Company Statement</U>. Whenever in the performance of its duties under this Agreement the Warrant Agent shall deem it necessary or
desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact
or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established
by a statement signed by the Chief Executive Officer or Chief Financial Officer of the Company and delivered to the Warrant Agent. The
Warrant Agent may rely upon such statement for any action taken or suffered in good faith by it pursuant to the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.4.2.&nbsp;<U>Indemnity</U>.
The Warrant Agent shall be liable hereunder only for its own gross negligence, willful misconduct or bad faith. The Company agrees to
indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, costs and reasonable counsel fees,
for anything done or omitted by the Warrant Agent in the execution of this Agreement, except as a result of the Warrant Agent&rsquo;s
gross negligence, willful misconduct or bad faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.4.3.&nbsp;<U>Exclusions</U>.
The Warrant Agent shall have no responsibility with respect to the validity of this Agreement or with respect to the validity or execution
of any Warrant (except its countersignature thereof); nor shall it be responsible for any breach by the Company of any covenant or condition
contained in this Agreement or in any Warrant; nor shall it be responsible to make any adjustments required under the provisions of Section
4 hereof or responsible for the manner, method or amount of any such adjustment or the ascertaining of the existence of facts that would
require any such adjustment; nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization
or reservation of any shares of Common Stock to be issued pursuant to this Agreement or any Warrant or as to whether any shares of Common
Stock will when issued be valid and fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.5.&nbsp;<U>Acceptance
of Agency</U>. The Warrant Agent hereby accepts the agency established by this Agreement and agrees to perform the same upon the terms
and conditions herein set forth and, among other things, shall account promptly to the Company with respect to Warrants exercised and
concurrently account for, and pay to the Company, all moneys received by the Warrant Agent for the purchase of shares of Common Stock
through the exercise of Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.&nbsp;<U>Miscellaneous
Provisions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1.&nbsp;<U>Successors</U>.
All the covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure to the
benefit of their respective successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.2.&nbsp;<U>Notices</U>.
Any notice, statement or demand authorized by this Agreement to be given or made by the Warrant Agent or by the holder of any Warrant
to or on the Company shall be delivered by hand or sent by registered or certified mail or overnight courier service, addressed (until
another address is filed in writing by the Company with the Warrant Agent) as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">180 Life Sciences Corp.<BR>
3000 El Camino Real, Bldg. 4, Suite 200<BR>
Palo Alto, California 94306</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Any notice, statement or demand
authorized by this Agreement to be given or made by the holder of any Warrant or by the Company to or on the Warrant Agent shall be delivered
by hand or sent by registered or certified mail or overnight courier service, addressed (until another address is filed in writing by
the Company with the Warrant Agent) as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Continental Stock Transfer &amp; Trust Company<BR>
1 State Street, 30th Floor<BR>
New York, NY 10004-1561<BR>
Attn: Compliance Department</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any notice, sent pursuant to this Agreement shall
be effective, if delivered by hand, upon receipt thereof by the party to whom it is addressed, if sent by overnight courier, on the next
business day of the delivery to the courier, and if sent by registered or certified mail on the third day after registration or certification
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.3.&nbsp;<U>Applicable
Law</U>. The validity, interpretation and performance of this Agreement and of the Warrants shall be governed in all respects by the laws
of the State of New York, without giving effect to conflicts of law principles that would result in the application of the substantive
laws of another jurisdiction. The Company hereby agrees that any action, proceeding or claim against it arising out of or relating in
any way to this Agreement shall be brought and enforced in the courts of the State of New York or the United States District Court for
the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby
waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any such process or summons
to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested,
postage prepaid, addressed to it at the address set forth in Section 9.2 hereof. Such mailing shall be deemed personal service and shall
be legal and binding upon the Company in any action, proceeding or claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.4.&nbsp;<U>Persons
Having Rights under this Agreement</U>. Nothing in this Agreement expressed and nothing that may be implied from any of the provisions
hereof is intended, or shall be construed, to confer upon, or give to, any person or corporation other than the parties hereto and the
registered holders of the Warrants, any right, remedy, or claim under or by reason of this Agreement or of any covenant, condition, stipulation,
promise, or agreement hereof. All covenants, conditions, stipulations, promises, and agreements contained in this Agreement shall be for
the sole and exclusive benefit of the parties hereto and their successors and assigns and of the registered holders of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.5.&nbsp;<U>Examination
of this Agreement</U>. A copy of this Agreement shall be available at all reasonable times at the office of the Warrant Agent in the Borough
of Manhattan, City and State of New York, for inspection by the registered holder of any Warrant. The Warrant Agent may require any such
holder to submit his, her or its Warrant for inspection by it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.6.&nbsp;<U>Counterparts</U>.
This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts shall for all purposes
be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.7.&nbsp;<U>Effect
of Headings</U>. The section headings herein are for convenience only and are not part of this Agreement and shall not affect the interpretation
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.8.&nbsp;<U>Amendments</U>.
This Agreement may be amended by the parties hereto without the consent of any registered holder for the purpose of curing any ambiguity,
or curing, correcting or supplementing any defective provision contained herein or adding or changing any other provisions with respect
to matters or questions arising under this Agreement as the parties may deem necessary or desirable and that the parties deem shall not
adversely affect the interest of the registered holders. All other modifications or amendments, including any amendment to increase the
Exercise Price or shorten the exercise period, shall require the written consent of the registered holders of a majority of the then outstanding
Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.9.&nbsp;<U>Severability</U>.
Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective
only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature page follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, this Agreement
has been duly executed by the parties hereto as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>180 LIFE SCIENCES CORP.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONTINENTAL STOCK TRANSFER &amp; TRUST COMPANY</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B><U>ANNEX A &ndash; FORM OF PRE-FUNDED WARRANT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U></U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">NEITHER THIS SECURITY NOR THE
SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>CERTIFICATE NO. 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON
STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>180
Life Sciences Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify; font-size: 10pt">Warrant Shares: 4,886,878</TD>
    <TD STYLE="width: 50%; text-align: right; font-size: 10pt">Issuance Date: December 1, 2023</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify">THIS PRE-FUNDED WARRANT TO PURCHASE
SHARES OF COMMON STOCK (this &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, Armistice Capital Master Fund Ltd. or its
assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time or times on or after the Stockholder Approval Date (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) until this
Warrant is exercised in full (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from 180 Life
Sciences Corp., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to 4,886,878 <FONT STYLE="font-size: 10pt">shares of Common
Stock, par value $0.0001 per share (the &ldquo;<U>Common Stock</U>&rdquo;), of the Company</FONT> (as subject to adjustment hereunder,
the &ldquo;<U>Warrant Shares</U>&rdquo;). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><U>Section 1</U>.&nbsp;<U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Securities Purchase Agreement, dated
August 9, 2023 (the &ldquo;<U>Purchase Agreement</U>&rdquo;), as amended by Amendment No. 1 to the Securities Purchase Agreement (the
&ldquo;<U>SPA Amendment</U>&rdquo;), dated November 28, 2023, between the Company and the purchaser signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><U>Section 2</U>.&nbsp;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;<U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the office of the Warrant Agent, or at the office
of its successor as Warrant Agent, and to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment)
of the Notice of Exercise in the form attached hereto as <U>Exhibit A</U> (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier
of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i)
herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified
in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise
procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall
be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder
has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise
is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares
available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal
to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business
Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of
the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;<U>Exercise
Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.0001 per Warrant Share, was pre-funded
to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise
price of $0.0001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The
Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance
or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination Date. The remaining
unpaid exercise price per share of Common Stock under this Warrant shall be $0.0001, subject to adjustment hereunder (the &ldquo;Exercise
Price&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;<U>Cashless
Exercise</U>. Notwithstanding anything to the contrary set forth herein, if at the time of exercise hereof there is no effective registration
statement registering the issuance of the Warrant Shares to the Holder, or the prospectus contained therein is not available for the issuance
of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless
exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing
[(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 168px; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 40px; text-align: justify; font-size: 10pt">(A) =</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (x) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (y) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 168px">&nbsp;</TD>
    <TD STYLE="width: 40px; text-align: justify; font-size: 10pt">(B) =</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">the Exercise Price of this Warrant, as adjusted hereunder; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 168px">&nbsp;</TD>
    <TD STYLE="width: 40px; text-align: justify; font-size: 10pt">(X) =</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;The Company
agrees not to take any position contrary to this Section 2(c), except to the extent required by applicable law, rules or regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the
Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed
or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in
all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by
the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so
reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt"> d) <U>Mechanics of Exercise</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">i.&nbsp;<U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depositary Trust Company
(&ldquo;<U>DTC</U>&rdquo;) through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a
participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to
or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale
limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of the Warrant Shares,
registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which
the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is
the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery
of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the
delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of
the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares
with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment
of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading
Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the
Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery
Date applicable to such exercise, the Holder may upon written demand to the Company require the Company to pay (and the Company shall
pay) to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based
on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until
such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant
in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any
Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at
any time after the Stockholder Approval Date, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m.
(New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes
hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant
Share Delivery Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">ii.&nbsp;<U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">iii.&nbsp;<U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise by delivering written notice to the Company
at any time prior to the Company delivering such Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">iv.&nbsp;<U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (other than any failure solely due to any action or
inaction by the Holder with respect to such exercise), and if after such date the Holder is required by its broker to purchase (in an
open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction
of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including
brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number
of Warrant Shares that the Company was required to deliver, but did not timely deliver, to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">v.&nbsp;<U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">vi.&nbsp;<U>Charges,
Taxes and Expenses</U>. The issuance and delivery of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as <U>Exhibit B</U> duly executed
by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax
incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees
to DTC (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">vii.&nbsp;<U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> e) <U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of this Warrant that are not in compliance with the Beneficial Ownership Limitation (other than to the extent that information on the number of outstanding shares of Common Stock is provided by the Company, either directly or through one or more public filings, and relied upon by the Holder). In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of this Warrant that are not in compliance with the Beneficial Ownership Limitation (other than to the extent that information on the number of outstanding shares of Common Stock is provided by the Company, either directly or through one or more public filings, and relied upon by the Holder). For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be [4.99/9.99]% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><U>Section 3</U>.&nbsp;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;<U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of this Warrant),
(ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split)
outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares
of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be
the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise
of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment
made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled
to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision,
combination or reclassification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to the extent that the Holder&rsquo;s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as
a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;<U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (other than dividends or distributions subject to Section
3(a)) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall
be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held
the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for
such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined
for the participation in such Distribution (<U>provided</U>, <U>however</U>, that, to the extent that the Holder&rsquo;s right to participate
in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled
to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution
to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever,
as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;<U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person and the Company is not the surviving entity, (ii) the Company
(or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of
all or substantially all of the consolidated assets of the Company in one or a series of related transactions, (iii) any, direct or indirect,
purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common
Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders
of 50% or more of the outstanding voting securities, or (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property (each, a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the
event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable
at any time concurrently with, or within thirty (30) days after, the consummation of the Fundamental Transaction (or, if later, the date
of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an
amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of
the consummation of such Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental Transaction is not within
the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, the Holder shall only be entitled to receive from the
Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the
unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the
Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of
Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction;
<U>provided</U>, <U>further</U>, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental
Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity
may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means
the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined
as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate
corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental
Transaction and the Termination Date, (B) an expected volatility equal to the 100 day volatility obtained from the HVT function on Bloomberg
(determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable
Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price
per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction
and (ii) the highest VWAP during the five (5) trading days immediately prior to the consummation of such Fundamental Transaction and (D)
a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the
Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available
funds (or such other consideration) within the later of (i) five Business Days of the Holder&rsquo;s election and (ii) the date of consummation
of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not
the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant
and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and
substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction
and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced
by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of
shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable
upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction,
and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number
of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder.
Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and
after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo;
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations
of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named
as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;<U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share of Common Stock, as the case
may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)&nbsp;<U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">i.&nbsp;<U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">ii.&nbsp;<U>Notice
to Allow Exercise by Holder</U>. If, while the Warrant is outstanding, (A) the Company declares a dividend (or any other distribution
in whatever form) on the shares of Common Stock, (B) the Company declares a cash dividend on or a redemption of the shares of Common Stock,
(C) the Company authorizes the granting to all holders of the shares of Common Stock rights or warrants to subscribe for or purchase any
shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company is required in connection with
a Fundamental Transaction, or (E) the Company authorizes the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile
number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable
record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the shares
of Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the
date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close,
and the date as of which it is expected that holders of the shares of Common Stock of record shall be entitled to exchange their shares
of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or
share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the
validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes,
or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file
such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during
the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be
expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)&nbsp;<U>Voluntary
Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of
this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and for any period
of time deemed appropriate by the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><U>Section 4</U>.&nbsp;<U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;<U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of
Section 5 of the SPA Amendment, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant, substantially in the form attached hereto as <B>Exhibit B</B>, duly executed by the Holder or its agent or
attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer, accompanied by reasonable evidence of
authority of the party making such request that may be required by the Warrant Agent including but not limited to, the signature guarantee
of a guarantor institution which is a participant in a signature guarantee program approved by the Securities Transfer Association. Upon
such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee
or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the
assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder
has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days
of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned
in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;<U>New
Warrants</U>. <FONT STYLE="background-color: white">This Warrant</FONT> may be divided or combined with other Warrants upon presentation
hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants
are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may
be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant
or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the
initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;<U>Warrant
Register</U>. The Warrant Agent shall maintain books (the &ldquo;<U>Warrant Register</U>&rdquo;) for the registration of the original
issuance and registration of transfers of the Warrants. Upon the initial issuance of the Warrants, at the Company&rsquo;s written request,
the Warrant Agent shall issue and register the Warrants in the names of the respective holders thereof in such denominations and otherwise
in accordance with the instructions delivered to the Warrant Agent by the Company. The Company and the Warrant Agent may deem and treat
the Holder of each Warrant as the absolute owner of the Warrants represented thereby for the purpose of any exercise thereof or any distribution
to such Holder, and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;<U>Transfer
Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this
Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable
state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information
requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of
this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;<U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><U>Section 5</U>.&nbsp;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;<U>Currency</U>.
All dollar amounts referred to in this Warrant are in United States Dollars (&ldquo;<U>U.S. Dollars</U>&rdquo;). All amounts owing under
this Warrant shall be paid in U.S. Dollars. All amounts denominated in other currencies shall be converted in the U.S. Dollar equivalent
amount in accordance with the Exchange Rate on the date of calculation. &ldquo;<U>Exchange Rate</U>&rdquo; means, in relation to any amount
of currency to be converted into U.S. Dollars pursuant to this Warrant, the U.S. Dollar exchange rate as published in the Wall Street
Journal (NY edition) on the relevant date of calculation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;<U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set
forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to
Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required
to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;<U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;<U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;<U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0 0pt 1in; text-align: justify">The Company covenants that, during the
period the Warrant is outstanding, it will reserve from its authorized and unissued shares of Common Stock a sufficient number of shares
to provide for the issuance of the Warrant Shares underlying the Warrant upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the
duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such
reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable
law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that
all Warrant Shares underlying this Warrant which may be issued upon the exercise of the purchase rights represented by this Warrant will,
upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized,
validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue
thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)&nbsp;<U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)&nbsp;<U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and if the Holder does
not utilize cashless exercise, will have restrictions upon resale imposed by state, federal or foreign securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)&nbsp;<U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant, the Purchase Agreement, or the SPA Amendment, if the Company willfully and knowingly fails to comply with any provision of this
Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient
to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)&nbsp;<U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in
accordance with the notice provisions of the Purchase Agreement, as amended by the SPA Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)&nbsp;<U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any shares of Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)&nbsp;<U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)&nbsp;<U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)&nbsp;<U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)&nbsp;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">o)&nbsp;<U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">p)&nbsp;<FONT STYLE="background-color: white"><U>Warrant
Agent Agreement.</U> This Warrant is issued subject to the Warrant Agent Agreement. To the extent any provision of this Warrant conflicts
with the express provisions of the Warrant Agent Agreement, the provisions of this Warrant shall govern and be controlling; provided,
however, that all provisions with respect to the rights, duties, obligations, protections, immunities and liability of the Warrant Agent
only shall be determined and interpreted solely by the provisions of the Warrant Agent Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="text-transform: uppercase"><B>180 Life Sciences Corp.</B></FONT> </TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="width: 31%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-weight: bold">ACCEPTED:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-weight: bold">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-weight: bold">CONTINENTAL STOCK TRANSFER &amp; TRUST COMPANY,</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">as Warrant Agent</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="width: 31%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">TO: 180
LIFE SCIENCES CORP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) The undersigned hereby
elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and
tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) Payment shall take the
form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.75pt; text-align: justify; text-indent: 0.5in">&#9744; in lawful
money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.75pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.75pt; text-align: justify">&#9744; if permitted the cancellation
of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant
with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3) Please issue said Warrant
Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -58.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -58.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -58.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 53.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: right"><B>EXHIBIT B</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 50%">Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 50%"></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>(Please Print)</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>(Please Print)</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left">Phone Number: </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"> </TD></TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left">Email Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>Dated: _______________ __, ______</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 16%">Holder&rsquo;s Signature:<U></U></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 33%">&nbsp;</TD>
    <TD STYLE="width: 51%">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>Holder&rsquo;s Address:<U STYLE="text-decoration: none; vertical-align: baseline"></U></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A><B><U>ANNEX B &ndash; FORM OF COMMON WARRANT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">NEITHER THIS SECURITY NOR THE
SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>CERTIFICATE NO. 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WARRANT TO PURCHASE SHARES OF COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>180
Life Sciences Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Warrant Shares: 9,064,098 &nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Issuance Date: December 1, 2023</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">THIS WARRANT TO PURCHASE SHARES OF
COMMON STOCK (this &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, Armistice Capital Master Fund Ltd. or its assigns
(the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time or times on or after the Stockholder Approval Date (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior
to 5:00 p.m. (New York City time) on the fifth anniversary of the Stockholder Approval Date (the &ldquo;<U>Termination Date</U>&rdquo;)
but not thereafter, to subscribe for and purchase from 180 Life Sciences Corp., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
up to 9,064,098 shares of Common Stock, par value $0.0001 per share (the &ldquo;<U>Common Stock</U>&rdquo;), of the Company (as subject
to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;). The purchase price of one share of Common Stock under this Warrant
shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><U>Section
1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the
Securities Purchase Agreement, dated August 9, 2023 (the &ldquo;Purchase Agreement&rdquo;), as amended by Amendment No. 1 to the
Securities Purchase Agreement (the &ldquo;<U>SPA Amendment</U>&rdquo;), dated November 28, 2023, between the Company and the
purchaser signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 25; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><U>Section
2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the office of the Warrant Agent, or at
the office of its successor as Warrant Agent, and to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail
(or e-mail attachment) of the Notice of Exercise in the form attached hereto as <U>Exhibit A</U> (the &ldquo;<U>Notice of
Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard
Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the
aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s
check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the
applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other
type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the
Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant
Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the
Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the
Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the
applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1)
Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that,
by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of
Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;<U>Exercise
Price</U>. The exercise price under this Warrant shall be <B>$</B>0.17 per share of Common Stock, subject to adjustment hereunder (the
&ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;<U>Cashless
Exercise</U>. Notwithstanding anything to the contrary set forth herein, if at the time of exercise hereof there is no effective registration
statement registering the issuance of the Warrant Shares to the Holder, or the prospectus contained therein is not available for the issuance
of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless
exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing
[(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt">(A) <FONT STYLE="font-family: Times New Roman, Times, Serif">=</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (x) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (y) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt">(B) <FONT STYLE="font-family: Times New Roman, Times, Serif">=</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt">the Exercise Price of this Warrant, as adjusted hereunder; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt">(X) =</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;&nbsp;The Company
agrees not to take any position contrary to this Section 2(c), except to the extent required by applicable law, rules or regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the
Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed
or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in
all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by
the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so
reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify"><U>Mechanics of Exercise</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.&nbsp;<U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depositary Trust Company
(&ldquo;<U>DTC</U>&rdquo;) through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a
participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to
or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale
limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of the Warrant Shares,
registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which
the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is
the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery
of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the
delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of
the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares
with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment
of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading
Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the
Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery
Date applicable to such exercise, the Holder may upon written demand to the Company require the Company to pay (and the Company shall
pay) to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based
on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until
such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant
in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any
Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at
any time after the Stockholder Approval Date, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m.
(New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes
hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant
Share Delivery Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.&nbsp;<U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.&nbsp;<U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise by delivering written notice to the Company
at any time prior to the Company delivering such Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.&nbsp;<U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (other than any failure solely due to any action or
inaction by the Holder with respect to such exercise), and if after such date the Holder is required by its broker to purchase (in an
open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction
of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including
brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number
of Warrant Shares that the Company was required to deliver, but did not timely deliver, to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.&nbsp;<U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.&nbsp;<U>Charges,
Taxes and Expenses</U>. The issuance and delivery of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as <U>Exhibit B</U> duly executed
by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax
incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees
to DTC (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.&nbsp;<U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">e)</TD><TD STYLE="text-align: justify"><U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant,
and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that
after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of
the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties
shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is
being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion
of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock
Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the
Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section
2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.
To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in
relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant
is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises
of this Warrant that are not in compliance with the Beneficial Ownership Limitation (other than to the extent that information on the
number of outstanding shares of Common Stock is provided by the Company, either directly or through one or more public filings, and relied
upon by the Holder). In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder and the Company shall have no obligation to verify
or confirm the accuracy of such determination and shall have no liability for exercises of this Warrant that are not in compliance with
the Beneficial Ownership Limitation (other than to the extent that information on the number of outstanding shares of Common Stock is
provided by the Company, either directly or through one or more public filings, and relied upon by the Holder). For purposes of this Section
2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common
Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B)
a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth
the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within one Trading
Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of
outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company,
including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares
of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be [4.99/9.99]% of the number of shares of
the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this
Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section
2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions
of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP>
day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise
than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective
or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable
to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><U>Section 3</U>.&nbsp;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;<U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of this Warrant),
(ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split)
outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares
of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be
the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise
of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment
made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled
to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision,
combination or reclassification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to the extent that the Holder&rsquo;s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as
a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;<U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (other than dividends or distributions subject to Section
3(a)) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall
be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held
the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for
such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined
for the participation in such Distribution (<U>provided</U>, <U>however</U>, that, to the extent that the Holder&rsquo;s right to participate
in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled
to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution
to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever,
as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;<U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person and the Company is not the surviving entity, (ii) the Company
(or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of
all or substantially all of the consolidated assets of the Company in one or a series of related transactions, (iii) any, direct or indirect,
purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common
Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders
of 50% or more of the outstanding voting securities, or (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property (each, a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the
event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable
at any time concurrently with, or within thirty (30) days after, the consummation of the Fundamental Transaction (or, if later, the date
of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an
amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of
the consummation of such Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental Transaction is not within
the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, the Holder shall only be entitled to receive from the
Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the
unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the
Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of
Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction;
<U>provided</U>, <U>further</U>, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental
Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity
may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means
the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined
as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate
corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental
Transaction and the Termination Date, (B) an expected volatility equal to the 100 day volatility obtained from the HVT function on Bloomberg
(determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable
Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price
per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction
and (ii) the highest VWAP during the five (5) trading days immediately prior to the consummation of such Fundamental Transaction and (D)
a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the
Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available
funds (or such other consideration) within the later of (i) five Business Days of the Holder&rsquo;s election and (ii) the date of consummation
of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not
the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant
and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and
substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction
and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced
by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of
shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable
upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction,
and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number
of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder.
Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and
after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo;
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations
of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named
as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;<U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share of Common Stock, as the case
may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)&nbsp;<U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.&nbsp;<U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.&nbsp;<U>Notice
to Allow Exercise by Holder</U>. If, while the Warrant is outstanding, (A) the Company declares a dividend (or any other distribution
in whatever form) on the shares of Common Stock, (B) the Company declares a cash dividend on or a redemption of the shares of Common Stock,
(C) the Company authorizes the granting to all holders of the shares of Common Stock rights or warrants to subscribe for or purchase any
shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company is required in connection with
a Fundamental Transaction, or (E) the Company authorizes the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile
number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable
record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the shares
of Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the
date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close,
and the date as of which it is expected that holders of the shares of Common Stock of record shall be entitled to exchange their shares
of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or
share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the
validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes,
or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file
such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during
the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be
expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)&nbsp;<U>Voluntary
Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of
this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and for any period
of time deemed appropriate by the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><U>Section 4</U>.&nbsp;<U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;<U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of
Section 5 of the SPA Amendment, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant, substantially in the form attached hereto as <B>Exhibit B</B>, duly executed by the Holder or its agent or
attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer, accompanied by reasonable evidence of
authority of the party making such request that may be required by the Warrant Agent including but not limited to, the signature guarantee
of a guarantor institution which is a participant in a signature guarantee program approved by the Securities Transfer Association. Upon
such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee
or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the
assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder
has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days
of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned
in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;<U>New
Warrants</U>. <FONT STYLE="background-color: white">This Warrant</FONT> may be divided or combined with other Warrants upon presentation
hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants
are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may
be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant
or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the
initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;<U>Warrant
Register</U>. The Warrant Agent shall maintain books (the &ldquo;<U>Warrant Register</U>&rdquo;) for the registration of the original
issuance and registration of transfers of the Warrants. Upon the initial issuance of the Warrants, at the Company&rsquo;s written request,
the Warrant Agent shall issue and register the Warrants in the names of the respective holders thereof in such denominations and otherwise
in accordance with the instructions delivered to the Warrant Agent by the Company. The Company and the Warrant Agent may deem and treat
the Holder of each Warrant as the absolute owner of the Warrants represented thereby for the purpose of any exercise thereof or any distribution
to such Holder, and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;<U>Transfer
Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this
Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable
state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information
requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of
this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;<U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><U>Section 5</U>.&nbsp;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;<U>Currency</U>.
All dollar amounts referred to in this Warrant are in United States Dollars (&ldquo;<U>U.S. Dollars</U>&rdquo;). All amounts owing under
this Warrant shall be paid in U.S. Dollars. All amounts denominated in other currencies shall be converted in the U.S. Dollar equivalent
amount in accordance with the Exchange Rate on the date of calculation. &ldquo;<U>Exchange Rate</U>&rdquo; means, in relation to any
amount of currency to be converted into U.S. Dollars pursuant to this Warrant, the U.S. Dollar exchange rate as published in the Wall
Street Journal (NY edition) on the relevant date of calculation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;<U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set
forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to
Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required
to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;<U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;<U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;<U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants that, during the
period the Warrant is outstanding, it will reserve from its authorized and unissued shares of Common Stock a sufficient number of shares
to provide for the issuance of the Warrant Shares underlying the Warrant upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the
duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such
reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable
law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that
all Warrant Shares underlying this Warrant which may be issued upon the exercise of the purchase rights represented by this Warrant will,
upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized,
validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue
thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)&nbsp;<U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)&nbsp;<U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and if the Holder does
not utilize cashless exercise, will have restrictions upon resale imposed by state, federal or foreign securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)&nbsp;<U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant, the Purchase Agreement, or the SPA Amendment, if the Company willfully and knowingly fails to comply with any provision of this
Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient
to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)&nbsp;<U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in
accordance with the notice provisions of the Purchase Agreement, as amended by the SPA Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)&nbsp;<U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any shares of Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)&nbsp;<U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)&nbsp;<U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)&nbsp;<U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)&nbsp;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">o)&nbsp;<U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">p)&nbsp;<FONT STYLE="background-color: white"><U>Warrant
Agent Agreement.</U> This Warrant is issued subject to the Warrant Agent Agreement. To the extent any provision of this Warrant conflicts
with the express provisions of the Warrant Agent Agreement, the provisions of this Warrant shall govern and be controlling; provided,
however, that all provisions with respect to the rights, duties, obligations, protections, immunities and liability of the Warrant Agent
only shall be determined and interpreted solely by the provisions of the Warrant Agent Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>180 Life Sciences Corp.</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">ACCEPTED:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">CONTINENTAL STOCK TRANSFER &amp; TRUST COMPANY,</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">as Warrant Agent</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Name:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">TO: 180
LIFE SCIENCES CORP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) The undersigned hereby
elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and
tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) Payment shall take the
form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 80pt; text-align: justify; text-indent: 0pt">&#9744; in
lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.75pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 80pt; text-align: justify; text-indent: 0pt">&#9744; if permitted the cancellation
of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant
with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3) Please issue said Warrant
Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -58.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -58.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -58.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Investing Entity: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 55%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature of Authorized Signatory of Investing Entity</I>: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 55%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Authorized Signatory: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 55%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Authorized Signatory: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 55%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 55%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0pt; width: 50%; padding-right: 0pt; padding-left: 0pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name:</P></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-indent: 0pt; width: 50%; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt">Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt"><U></U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please Print)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt">Phone Number:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt">Email Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt">Dated: _______________ __, ______</TD>
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt; width: 16%">Holder&rsquo;s Signature:<U></U></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt; width: 33%">&nbsp;</TD>
    <TD STYLE="width: 51%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt">Holder&rsquo;s Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">B-16</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>3
<FILENAME>ea189187ex4-4_180life.htm
<DESCRIPTION>WARRANT AMENDMENT AGREEMENT, DATED NOVEMBER 28, 2023, BY AND BETWEEN THE COMPANY AND THE PURCHASER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WARRANT AMENDMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Warrant Amendment Agreement (this &ldquo;<U>Amendment</U>&rdquo;)
is entered into as of the 28<SUP>th</SUP> day of November 2023, by and among 180 Life Sciences Corp., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;)
and Armistice Capital Master Fund Ltd. (the &ldquo;<U>Holder</U>&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>WHEREAS</B>, the Company had previously issued
(i) warrants to purchase up to 306,604 shares of the Company&rsquo;s common stock, $0.0001 par value (the &ldquo;<U>Common Stock</U>&rdquo;),
on July 20, 2022, as amended on April 5, 2023 and August 14, 2023 (the &ldquo;<U>July Warrants</U>&rdquo;); (ii) warrants to purchase
up to 2,571,429 shares of Common Stock, on December 22, 2022, as amended on January 12, 2023, April 5, 2023 and August 14, 2023 (the &ldquo;<U>December
Warrants</U>&rdquo;); and (iii) warrants to purchase up to 1,570,680 shares of Common Stock, on April 10, 2023, as amended on August 14,
2023 (the &ldquo;<U>April Warrants</U>&rdquo;) to the Holder, in each case pursuant to a securities purchase agreement, dated as of such
date, between the Company and the Holder;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>WHEREAS</B>, the Company previously issued warrants
to purchase up to 4,615,385 shares of Common Stock, on August 14, 2023 (the &ldquo;<U>August Warrants</U>&rdquo; and together with the
July Warrants, the December Warrants and the April Warrants, the &ldquo;<U>Warrants</U>&rdquo;) to certain investors, including the Holder
(in the case of the Holder, pursuant to a securities purchase agreement, dated as of such date, between the Company and the Holder);</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>WHEREAS</B>, each series of the Warrants may
be modified or amended with the written consent of the holders of a majority of the then-outstanding Warrants of such series, and the
Holder is the holder of a majority of each series of the outstanding Warrants;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>WHEREAS</B>, the Company and the Holder desire
to amend all of the Warrants as set forth below; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>WHEREAS</B>, in connection with this Amendment,
the Company intends to seek stockholder approval with respect to the issuance of up to 9,064,098 shares of Common Stock upon exercise
of the Warrants (the &ldquo;<U>Stockholder Approval</U>&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREFORE</B>, the parties
do hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">1.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Effective upon the execution of this Amendment, the exercise price of the Warrants shall be amended to $0.17 per share, subject to further adjustment as set forth in the Warrants.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">2.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Effective upon the execution of this Amendment, and subject to Stockholder Approval, the term of the warrants shall be extended such that the Warrants shall be immediately exercisable from the date the Company obtains Stockholder Approval (the &ldquo;<U>Stockholder Approval Date</U>&rdquo;) until the fifth anniversary of the Stockholder Approval Date.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">3.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Effective upon the execution of this Amendment, the Warrants shall not be exercisable until Stockholder Approval has been obtained.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">4.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Except as modified herein, the terms of the Warrants shall remain in full force and effect.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">5.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">This Amendment may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and shall be binding upon all parties, their successors and assigns, and all of which taken together shall constitute one and the same Amendment. A signature delivered by facsimile or email shall constitute an original.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the parties have executed
this Amendment as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>180 LIFE SCIENCES CORP.  &nbsp;</B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font-size: 10pt; text-align: justify"><I>/s/ James N. Woody</I></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Name:</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">James N. Woody</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Title:</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Chief Executive Officer, <BR> 180 Life Sciences Corp.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>ARMISTICE CAPITAL MASTER FUND LTD. &nbsp;</B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font-size: 10pt; text-align: justify"><I>/s/ Steven Boyd</I></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Name:</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Steven Boyd</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Title:</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">CIO of Armistice Capital, LLC<BR> the Investment Manager</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>ea189187ex10-1_180life.htm
<DESCRIPTION>AMENDMENT NO.1 TO THE SECURITIES PURCHASE AGREEMENT, DATED NOVEMBER 28, 2023, BY AND BETWEEN 180 LIFE SCIENCES CORP. AND THE PURCHASER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AMENDMENT NO. 1<BR>
TO THE<BR>
SECURITIES PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Amendment No. 1 to the Securities Purchase
Agreement (this &ldquo;<U>Amendment</U>&rdquo;) is made and entered into effective November 28, 2023, by and between 180 Life Sciences
Corp., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and the purchaser identified on the signature pages hereto (the &ldquo;<U>Purchaser</U>&rdquo;).
Capitalized terms not defined herein shall have the meaning set forth in the Securities Purchase Agreement (as defined below).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, on August
9, 2023, the Company agreed to issue and sell to certain investors, including the Purchaser (in the case of the Purchaser, pursuant to
a Securities Purchase Agreement, dated as of such date (the &ldquo;<U>Securities Purchase Agreement</U>&rdquo;), between the Company and
the Purchaser), an aggregate of: (i) 666,925 shares (the &ldquo;<U>August Shares</U>&rdquo;) of Common Stock, (ii) pre-funded warrants
(the &ldquo;<U>August Pre-Funded Warrants</U>&rdquo;) to purchase up to 3,948,460 shares of Common Stock and (iii) warrants (the &ldquo;<U>August
Common Warrants</U>&rdquo;) to purchase up to 4,615,385 shares of Common Stock, at a Per Share Purchase Price of $0.65 and the Per Pre-Funded
Warrant Purchase Price was $0.6499;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, concurrently
with this Amendment, the Company and the Purchaser agree to amend (i) the Per Share Purchase Price of the August Shares and associated
August Common Warrants (the &ldquo;<U>Amended Share Price</U>&rdquo;) and (ii) the Per Pre-Funded Warrant Purchase Price of the August
Pre-Funded Warrants and associated August Common Warrants (the &ldquo;<U>Amended Pre-Funded Warrant Price</U>&rdquo;), respectively;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Purchaser
will to pay an additional $830,769.30 (the &ldquo;<U>Repricing Amount</U>&rdquo;) in connection with the Amended Share Price and Amended
Pre-Funded Warrant Price on behalf of the investors (the &ldquo;<U>Repricing</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, in connection
with the Repricing, the Company and the Purchaser agree to enter into a Warrant Amendment Agreement with respect to the following outstanding
warrants to purchase up to: (i) 2,571,429 shares of Common Stock, issued on December 22, 2022, and amended in January 2023, April 2023
and August 2023; (ii) 306,604 shares of Common Stock, issued on July 20, 2022 and amended in April 2023 and August 2023; (iii) 1,570,680
shares of Common Stock, issued on April 10, 2023 and August 2023; and (iv) 4,615,385 shares of Common Stock underlying the August Common
Warrants (collectively, the &ldquo;<U>Existing Common Warrants</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, pursuant to
the Warrant Amendment Agreement, the Existing Common Warrants will be amended such that: (i) the Existing Common Warrants will not be
exercisable until the Company obtains Stockholder Approval (as defined below) for the issuance of up to 9,064,098 shares of Common Stock
upon exercise of the Existing Common Warrants, (ii) the exercise price of the Existing Common Warrants will be equal to $0.17 per share
(such amended exercise price, the &ldquo;<U>Amended Exercise Price</U>&rdquo;), and (iii) the expiration date of the Existing Common Warrants
will be extended such that they will expire on the fifth anniversary of the Stockholder Approval Date (as defined below) (such extended
expiration date, the &ldquo;<U>Amended Expiration Date</U>&rdquo; and such amendments in clauses (i), (ii) and (iii), the &ldquo;<U>Warrant
Amendment</U>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="text-align: justify; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: justify; margin: 0pt"></P></DIV>
    <DIV STYLE="text-align: justify; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: justify; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, in connection
for the Repricing and the Warrant Amendment, and for no additional consideration, the Company agrees to issue to the Purchaser (i) a Common
Stock purchase warrant to purchase up to 9,064,098 shares of Common Stock, with an exercise price equal to $0.17 per share (the &ldquo;<U>New
Common Warrants</U>&rdquo;) and (ii) pre-funded warrants to purchase up to 4,886,878 shares of Common Stock, with an exercise price equal
to $0.0001 (the &ldquo;<U>New Pre-Funded Warrants</U>&rdquo; and, together with the New Common Warrants, the &ldquo;<U>New Warrants</U>&rdquo;),
provided, however that the New Warrants will not be exercisable until the Company obtains Stockholder Approval for the issuance of up
to 13,950,976 shares of Common Stock upon exercise of the New Warrants (the &ldquo;<U>New Warrant Shares</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the terms defined
elsewhere in this Amendment, for all purposes of this Amendment, the following terms have the meanings set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Amendment Closing</U>&rdquo; means the
closing of the Repricing, the Warrant Amendment, and the issuance of New Warrants pursuant to Section 1.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Amendment Closing Date</U>&rdquo; means
the Trading Day on which all of the Amendment Transaction Documents have been executed and delivered by the applicable parties thereto,
and the covenants and conditions set forth in Sections 2 and 3 (other than those covenants and conditions that by their terms are to be
performed or satisfied, as applicable, at the Amendment Closing, but subject to the performance, satisfaction or waiver of such covenants
and conditions) have been performed, satisfied or waived, as applicable, but in no event later than the second (2nd) Trading Day following
the date hereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Amendment Disclosure Time</U>&rdquo;
means, (i) if this Amendment is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight
(New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, and
(ii) if this Amendment is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later
than 9:01 a.m. (New York City time) on the date hereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Amendment Transaction Documents</U>&rdquo;
means this Amendment, the Warrant Amendment Agreement, and the New Warrants and all exhibits and schedules thereto and hereto and any
other documents or agreements executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Stockholder Approval</U>&rdquo; means
such approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity) from the
stockholders of the Company with respect to issuance of the shares of Common Stock upon exercise of the Existing Common Warrants and/or
the New Warrants (collectively, the &ldquo;<U>Warrant Shares</U>&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Stockholder Approval Date</U>&rdquo;
means the date on which Stockholder Approval is obtained under Delaware law.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE, IN CONSIDERATION</B>
of the mutual covenants contained in this Amendment, and for other good and valuable consideration the receipt and adequacy of which are
hereby acknowledged, the Company and the Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.  <U>Closing</U>. Upon performance,
satisfaction or waiver of the covenants and conditions, as applicable, set forth in Sections 2 and 3 (other than those covenants and conditions
that by their terms are to be performed or satisfied, as applicable, at the Amendment Closing, but subject to the performance, satisfaction
or waiver of such covenants and conditions), the Amendment Closing shall occur electronically or such other location as the parties shall
mutually agree. Upon the Amendment Closing, on the terms and subject to the conditions set forth herein, the Purchaser shall pay the Repricing
Amount to the Company by wire transfer of immediately available funds to a bank account(s) designated by the Company, the Company shall
issue the New Warrants to the Purchaser and the Warrant Amendment shall take effect.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.   <U>Deliveries.</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">(a)   On
or prior to the Amendment Closing Date, the Company shall deliver or cause to be delivered to the Purchaser the following:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.35in; text-align: left">(i)</TD><TD STYLE="text-align: justify">this Amendment duly executed by the Company;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.35in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">the Warrant Amendment Agreement duly executed by the Company,
in substantially the form of <U>Exhibit A</U> attached hereto;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.35in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">the Company shall provide the Purchaser with the Company&rsquo;s
wire instructions;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.35in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">a certificate executed by the Chief Executive Officer and
Chief Financial Officer of the Company, dated as of the date of the Amendment Closing Date, in a form substantially similar to what was
delivered in connection with the Securities Purchase Agreement;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.35in; text-align: left">(v)</TD><TD STYLE="text-align: justify">a secretary&rsquo;s certificate executed by the Secretary
of the Company, dated as of the Amendment Closing Date, in a form substantially similar to what was delivered in connection with the
Securities Purchase Agreement;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.35in; text-align: left">(vi)</TD><TD STYLE="text-align: justify">a legal opinion of Company Counsel, in a form substantially
similar to what was delivered in connection with the Securities Purchase Agreement;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.35in; text-align: left">(vii)</TD><TD STYLE="text-align: justify">a New Common Warrant registered in the name of the Purchaser
to purchase up to 9,064,098 shares of Common Stock, with an exercise price equal to $0.17 per share, in substantially the form of <U>Exhibit
B</U> attached hereto;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.35in; text-align: left">(viii)</TD><TD STYLE="text-align: justify">a New Pre-Funded Warrant registered in the name of the Purchaser
to purchase up to a number of shares of Common Stock equal to 4,886,878 shares of Common Stock, with an exercise price equal to $0.0001,
in substantially the form of <U>Exhibit C</U> attached hereto;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in">(b)   On
or prior to the Amendment Closing Date, the Purchaser shall deliver or cause to be delivered to the Company, the following:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">this Amendment duly executed by the Purchaser;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">the Warrant Amendment Agreement duly executed by the Purchaser;
and</TD>
</TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">the Repricing Amount.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.   <U>Closing Conditions</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in">(a)   The
obligations of the Company hereunder in connection with the Amendment Closing are subject to the following conditions being met:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">the accuracy in all material respects (or, to the extent
representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Amendment
Closing Date of the representations and warranties of the Purchaser contained herein (unless as of a specific date therein in which case
they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality, in all
respects) as of such date);</TD>
</TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">all obligations, covenants and agreements of the Purchaser
required to be performed at or prior to the Amendment Closing Date shall have been performed; and</TD>
</TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">the delivery by the Purchaser of the items set forth in Section
2(b) of this Amendment.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(b)   The
respective obligations of the Purchaser hereunder in connection with the Amendment Closing are subject to the following conditions being
met:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">the accuracy in all material respects (or, to the extent
representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Amendment
Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case
they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality, in all
respects) as of such date);</TD>
</TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">all obligations, covenants and agreements of the Company
required to be performed at or prior to the Amendment Closing Date shall have been performed;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">the delivery by the Company of the items set forth in Section
2(a) of this Amendment; and</TD>
</TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">there shall have been no Material Adverse Effect with respect
to the Company since the date hereof.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4.   <U>Representations and
Warranties of the Company</U>. The Company agrees to the representations, warranties and covenants set forth on <U>Annex A</U> attached
hereto.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5.   <U>Representations and
Warranties of the Purchaser</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">(a)   The
Purchaser represents and warrants that, as of the date hereof, the Purchaser is fully aware of, and has reviewed all of the Company&rsquo;s
public filings and acknowledges that the Company&rsquo;s Common Stock may be delisted from the Nasdaq Capital Market at a future date
if the Company does not regain compliance with the continued listing requirements under Nasdaq rules.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">(b)   The
Purchaser represents and warrants that, as of the date hereof it is, and on each date on which it exercises any New Warrants it will be,
an &ldquo;accredited investor&rdquo; as defined in Rule 501 of Regulation D promulgated under the Securities Act, and agrees that the
New Warrants will contain restrictive legends when issued, and neither the New Warrants nor the New Warrant Shares will be registered
under the Securities Act. Also, the Purchaser represents and warrants that it is acquiring the New Warrants as principal for its own account
and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of the
New Warrants or the New Warrant Shares (this representation is not limiting Purchaser&rsquo;s right to sell the New Warrant Shares pursuant
to an effective registration statement under the Securities Act or otherwise in compliance with applicable federal and state securities
laws).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">(c)   The
Purchaser understands that the New Warrants and the New Warrant Shares are not, and may never be, registered under the Securities Act,
or the securities laws of any state and, accordingly, each certificate, if any, representing such securities shall bear a legend substantially
similar to the following:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0.5in">&ldquo;[NEITHER] THIS SECURITY [NOR THE SECURITIES INTO
WHICH THIS SECURITY IS EXERCISABLE] [HAS NOT] [HAVE] BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &ldquo;ACCREDITED
INVESTOR&rdquo; AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.&rdquo;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 49.5pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">(d)   Upon
the Purchaser&rsquo;s exercise of the New Warrants, certificates evidencing the New Warrant Shares shall not contain any legend (including
the legend set forth above), (i) while a registration statement covering the resale of such New Warrant Shares is effective under the
Securities Act, (ii) following any sale of such New Warrant Shares pursuant to Rule 144 under the Securities Act, (iii) if such New Warrant
Shares are eligible for sale under Rule 144 (assuming cashless exercise of the New Warrants), without the requirement for the Company
to be in compliance with the current public information requirement under Rule 144 as to such New Warrant Shares and without volume or
manner-of-sale restrictions, (iv) if such New Warrant Shares may be sold under Rule 144 (assuming cashless exercise of the New Warrants)
and the Company is then in compliance with the current public information requirement under Rule 144 as to such New Warrant Shares, or
(v) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements
issued by the staff of the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) and the earliest of clauses (i) through
(v), the &ldquo;<U>Delegend Date</U>&rdquo;). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly
after the Delegend Date if required by the Company and/or the Transfer Agent to effect the removal of the legend hereunder, or at the
request of the Purchaser, which opinion shall be in form and substance reasonably acceptable to the Purchaser. From and after the Delegend
Date, such New Warrant Shares shall be issued free of all legends, provided that, upon request of the Company (which request shall also
include a form of customary representation letter), the Purchaser has delivered in advance to the Company a customary representation letter
that is reasonably satisfactory to the Company and its counsel. The Company agrees that following the Delegend Date or at such time as
such legend is no longer required under this Section, it will, no later than two (2) Trading Days following the delivery by the Purchaser
to the Company or the Transfer Agent of a certificate representing the New Warrant Shares issued with a restrictive legend (such second
(2nd) Trading Day, the &ldquo;<U>Legend Removal Date</U>&rdquo;), deliver or cause to be delivered to the Purchaser a certificate representing
such shares that is free from all restrictive and other legends or, at the request of the Purchaser, shall credit the account of the Purchaser&rsquo;s
prime broker with the Depository Trust Company System as directed by the Purchaser.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">(e)   In
addition to the Purchaser&rsquo;s other available remedies, the Company shall pay to the Purchaser, in cash, (i) as partial liquidated
damages and not as a penalty, for each $1,000 of New Warrant Shares (based on the VWAP of the Common Stock on the date such New Warrant
Shares are submitted to the Transfer Agent) delivered for removal of the restrictive legend, $10 per Trading Day (increasing to $20 per
Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day after the Legend Removal Date until such
certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to the Purchaser
by the Legend Removal Date a certificate representing the New Warrant Shares free from all restrictive and other legends and (b) if after
the Legend Removal Date the Purchaser purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction
of a sale by the Purchaser of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock
equal to all or any portion of the number of shares of Common Stock that the Purchaser anticipated receiving from the Company without
any restrictive legend, then, an amount equal to the excess of the Purchaser&rsquo;s total purchase price (including brokerage commissions
and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket
expenses, if any) (the &ldquo;<U>Buy-In Price</U>&rdquo;) over the product of (A) such number of New Warrant Shares that the Company was
required to deliver to the Purchaser by the Legend Removal Date and for which the Purchaser was required to purchase shares to timely
satisfy delivery requirements, multiplied by (B) the weighted average price at which the Purchaser sold that number of shares of Common
Stock.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6.   <U>Other Agreements of
the Parties</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">(a)   <U>Reservation
of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all
times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue New Warrant
Shares pursuant to any exercise of the New Warrants.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">(b)   <U>Registration
Statement</U>. As soon as practicable (and in any event within 60 calendar days of the Stockholder Approval Date), the Company shall file
a registration statement on Form S-1 (or any other available form) providing for the resale of the Warrant Shares issuable upon exercise
of the Existing Common Warrants and New Warrants applicable (the &ldquo;<U>Resale Registration Statement</U>&rdquo;). The Company shall
cause the Resale Registration Statement to become effective within 90 days (120 days in the event the Commission elects to review such
registration statement) following the filing date of such registration statement and to keep the Resale Registration Statement effective
at all times until the Purchaser no longer owns any Existing Common Warrants, New Warrants or Warrant Shares issuable upon exercise thereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">(c)   <U>Securities
Laws Disclosure; Publicity</U>. The Company shall by the Amendment Disclosure Time, file a Current Report on Form 8-K, including the Amendment
Transaction Documents required to be filed as exhibits thereto, with the Commission (the &ldquo;<U>Form 8-K</U>&rdquo;). From and after
the filing of such Form 8-K, the Company represents to the Purchaser that it shall have publicly disclosed all material, non-public information
delivered to the Purchaser by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates
or agents, in connection with the transactions contemplated by the Amendment Transaction Documents. In addition, effective upon the filing
of such Form 8-K, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether
written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or
agents, on the one hand, and Purchaser or any of its Affiliates on the other hand, shall terminate and be of no further force or effect.
The Company understands and confirms that the Purchaser shall be relying on the foregoing covenant in effecting transactions in securities
of the Company. The Company and the Purchaser shall consult with each other in issuing any press releases with respect to the transactions
contemplated hereby, and neither the Company nor the Purchaser shall issue any such press release nor otherwise make any such public statement
without the prior consent of the Company, with respect to any press release of the Purchaser, which consent shall not unreasonably be
withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other
party with prior notice of such public statement or communication, or if such disclosure is consistent with the Form 8-K. Notwithstanding
the foregoing, the Company shall not publicly disclose the name of the Purchaser, or include the name of the Purchaser in any filing with
the Commission or any regulatory agency or Trading Market, without the prior written consent of the Purchaser, except (a) as required
by federal securities law in connection with the filing of final Amendment Transaction Documents with the Commission and (b) to the extent
such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchaser with prior notice
of such disclosure permitted under this clause (b) and reasonably cooperate with the Purchaser regarding such disclosure.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7.   <U>Miscellaneous</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">(a)   <U>No
Further Amendment</U>. Except as amended or waived by the Amendment Transaction Documents, all terms and provisions of the Transaction
Documents shall continue unmodified and remain in full force and effect.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">(b)   <U>Entire
Agreement</U>. The Transaction Documents, as amended by the Amendment Transaction Documents, together with the Preliminary Prospectus
and the Prospectus, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede
all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged
into such documents, exhibits and schedules.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">(c)   <U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Amendment shall be determined in accordance
with the provisions of the Securities Purchase Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">(d)   <U>Survival</U>.
The representations and warranties contained herein shall survive the Amendment Closing and the delivery of the New Warrants.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">(e)   <U>Execution</U>.
This Amendment may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery
of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo; signature page was an original
thereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">(f)   <U>Severability</U>.
If any term, provision, covenant or restriction of this Amendment is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">(g)   <U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Amendment Transaction
Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of the Amendment Transaction Documents or any amendments thereto. In addition, each and every
reference to share prices and shares of Common Stock in any Amendment Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the
date of this Amendment.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5IN">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Amendment to be duly executed by their respective authorized signatories as of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt; text-align: justify"><B>180 LIFE SCIENCES CORP.</B></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><U>Address for Notice</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="background-color: white">3000 El Camino Real, Bldg. 4, Suite 200 <BR>
Palo Alto,
    CA&nbsp;94306</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt; text-align: justify; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: justify; width: 35%"><I>/s/ James N. Woody</I></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify; width: 10%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt; text-align: justify">Name:</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James N. Woody</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: jwoody@180lifesciences.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt; text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, <BR>
180 Life Sciences Corp.</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">Fax:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt; text-align: justify">With a copy to (which shall not constitute notice):</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt; text-align: justify">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DLA Piper LLP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One Liberty Place</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1650 Market Street, Suite 5000</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Philadelphia, Pennsylvania 19103</P></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">Email: fahd.riaz@us.dlapiper.com;<BR>
 stephen.alicanti@us.dlapiper.com</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt; text-align: justify">Attention: Fahd M.T. Riaz; Stephen Alicanti</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">Fax:</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK<BR>
SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[PURCHASER SIGNATURE PAGE TO AMENDMENT NO. 1 TO
THE SECURITIES<BR>
 PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of Purchaser: Armistice Capital Master Fund Ltd.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35%; text-align: left"><I>Signature of Authorized Signatory of Purchaser:</I></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 65%"><I>/s/
                                            Steven Boyd</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of Authorized Signatory: Steven Boyd</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title of Authorized Signatory: CIO of Armistice Capital, LLC, the Investment
Manager</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email Address of Authorized Signatory: sboyd@armisticecapital.com</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(w/ copies to: smiller@armisticecapital.com; jglickstein@armisticecapital.com)</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice to Purchaser:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">c/o Armistice Capital, LLC<BR>
510 Madison Avenue, 7th Floor<BR>
New York, NY 10022</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Delivery of New Warrant Shares to the Purchaser (if not
same address for notice):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">c/o Armistice Capital, LLC<BR>
Attention: Ying Wu<BR>
510 Madison Avenue, 7th Floor<BR>
New York, NY 10022</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Repricing Amount: $830,769.30</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares of Common Stock underlying the New Pre-Funded Warrants: 4,886,878</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Beneficial Ownership Blocker &#9744; 4.99% or <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
9.99%</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares of Common Stock underlying the New Common Warrants: 9,064,098</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Beneficial Ownership Blocker <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
4.99% or &#9744; 9.99%</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">EIN Number: 98-1058273</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;
</FONT>Notwithstanding anything contained in this Amendment to the contrary, by checking this box (i)&nbsp;the obligations of the above-signed
to pay the Repricing Amount set forth in this Amendment by the above-signed, and the obligations of the Company to amend and/or issue
such securities to the above-signed, shall be unconditional and all conditions to the Amendment Closing shall be disregarded, (ii) the
Amendment Closing shall occur on the second (2nd) Trading Day following the date of this Amendment and (iii) any condition to Amendment
Closing contemplated by this Amendment (but prior to being disregarded by clause (i) above) that required delivery by the Company or
the above-signed of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition
and shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument,
certificate or the like or purchase price (as applicable) to such other party on the Amendment Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Annex A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Representations, Warranties
and Covenants of the Company</U>. The Company hereby makes the following representations and warranties to the Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">a)   <U>Subsidiaries</U>.
All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. The Company owns, directly or indirectly,
all of the capital stock or other equity interests of each Subsidiary, free and clear of any Liens, except as set forth in the SEC Reports,
and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable
and free of preemptive and similar rights to subscribe for or purchase securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">b)   <U>SEC
Reports</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under
the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for one (1) year preceding the date hereof
(the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, the &ldquo;<U>SEC Reports</U>&rdquo;)
on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration
of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities
Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in
all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as
in effect at the time of filing. Such financial statements have been prepared in all material respects in accordance with United States
generally accepted accounting principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except
as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not
contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated
Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the
case of unaudited statements, to normal, immaterial, year-end audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">c)   <U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Amendment and each of the other Amendment Transaction Documents to which it is a party and otherwise to carry out its obligations
hereunder and thereunder. The execution and delivery of this Amendment and each of the other Amendment Transaction Documents by the Company
and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the
part of the Company and no further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection
herewith or therewith other than in connection with the Stockholder Approval. This Amendment and each other Amendment Transaction Document
to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with
the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance
with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to
the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">d)   <U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Amendment and the other Amendment Transaction Documents
to which it is a party, the issuance of the New Warrants and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets
of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration
or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing
a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property
or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in
a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority
to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property
or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as would not
have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">e)   <U>Trading
Market</U>. Except for as related to the Stockholder Approval, if applicable, the transactions contemplated under this Amendment comply
with all the rules and regulations of the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">f)   <U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to,
or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection
with the execution, delivery and performance by the Company of this Amendment, other than: (i) the filings required pursuant to this Amendment&#894;
(ii) application(s) or notice to each applicable Trading Market for the listing of the New Warrants and New Warrant Shares for trading
thereon in the time and manner required thereby, (iii) the filing of form D with the Commission and such filings as are required to be
made under applicable state securities laws, and (iv) Stockholder Approval, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">g)   <U>Listing
of Common Stock</U>. The Company hereby agrees to use reasonable best efforts to maintain the listing or quotation of the Common Stock
on the principal Trading Market on which it is currently listed, and concurrently with the Amendment Closing, the Company shall apply
to list or quote all of the New Warrant Shares on such Trading Market and promptly secure the listing of all of the New Warrant Shares
on such Trading Market. The Company agrees that if the Company applies to have the Common Stock traded on any other Trading Market, it
will then include in such application all of the New Warrant Shares, and will take such other action as is necessary to cause all of the
New Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action
reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with
the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain
the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation,
including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation
in connection with such electronic transfer. In addition, and if applicable, the Company shall hold an annual or special meeting of stockholders
for the purpose of obtaining Stockholder Approval (a &ldquo;<U>Stockholder Meeting</U>&rdquo;) on or prior to the date that is ninety
(90) days following the Amendment Closing Date, with the recommendation of the Company&rsquo;s Board of Directors that such proposals
are approved, and the Company shall solicit proxies from its stockholders in connection therewith in the same manner as all other management
proposals in such proxy statement and all management-appointed proxyholders shall vote their proxies in favor of such proposals. The Company
shall set the record date for the first Stockholder Meeting as soon as practicable. If the Company does not obtain Stockholder Approval
at the first Stockholder Meeting, the Company shall call a Stockholder Meeting every ninety (90) days thereafter until the earlier of
the date on which Stockholder Approval is obtained or the Existing Common Warrants and New Warrants are no longer outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7in">h)   <U>Capitalization</U>.
The capitalization of the Company as of the date hereof is as set forth on <U>Schedule 3.1(g)</U>. The Company has not issued any capital
stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee equity awards
under the Company&rsquo;s equity incentive plans, the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s
employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of
the most recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation,
or any similar right to participate in the transactions contemplated by the Amendment Transaction Documents. Except as a result of this
Amendment and as set forth on Schedule 3.1(g), there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments
of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or
giving any Person any right to subscribe for or acquire, any shares of Common Stock or capital stock of any Subsidiary, or contracts,
commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of
Common Stock, Common Stock Equivalents or capital stock of any Subsidiary. The issuance of the New Warrants will not obligate the Company
or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchaser). There are no outstanding
securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset
price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities
or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments,
understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such
Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar
plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and non-assessable,
have been issued in compliance in all material respects with all federal and state securities laws where applicable, and none of such
outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. Except
for the Stockholder Approval, no further approval or authorization of any stockholder, the Board of Directors or others is required for
the issuance of the New Warrants. There are no stockholders agreements, voting agreements or other similar agreements with respect to
the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&rsquo;s
stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">i)   <U>Material
Changes&#894; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included
within the SEC Reports, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result
in a Material Adverse Effect, (ii) the Company has not incurred any material liabilities (contingent or otherwise) other than (A) trade
payables and accrued expenses incurred in the ordinary course of business consistent with past practice and strategic acquisitions and
(B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings made
with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
of its shares and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing
Company equity incentive plans. The Company does not have pending before the Commission any request for confidential treatment of information.
Except for the issuance of the New Warrants contemplated by this Amendment, no event, liability, fact, circumstance, occurrence or development
has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective
businesses, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable
securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least one (1) Trading Day
prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">j)   <U>Registration
Rights</U>. Except as set forth in the SEC Reports, no Person has any right to cause the Company or any Subsidiary to effect the registration
under the Securities Act of any securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">k)   <U>Listing
and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company
has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common
Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration.
Except as set forth in the SEC Reports, the Company has not, in the twelve (12) months preceding the date hereof, received notice from
any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with
the listing or maintenance requirements of such Trading Market. Except as set forth in the SEC Reports, the Company is, and has no reason
to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.
The Common Stock is currently eligible for electronic transfer through The Depository Trust Company or another established clearing corporation
and the Company is current in payment of the fees to The Depository Trust Company (or such other established clearing corporation) in
connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">l)   <U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Amendment Closing Date, after giving effect to the receipt by the
Company of the proceeds from the Repricing hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds the amount that
will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known contingent liabilities)
as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on its business as now conducted
and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted
by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the current cash flow of the
Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated
uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid.
The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts
of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe
that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from
the Amendment Closing Date. <U>Schedule 3.1(aa)</U> sets forth as of the date hereof, all outstanding secured and unsecured Indebtedness
of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Amendment, &ldquo;<U>Indebtedness</U>&rdquo;
means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary
course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others to third parties,
whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto), except guaranties
by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z)
the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither
the Company nor any Subsidiary is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">m)   <U>Subsequent
Equity Sales</U>. From the date hereof until 15 days after the Stockholder Approval Date, neither the Company nor any Subsidiary shall
(i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock
Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Resale Registration Statement or
filing a registration statement on Form S-8 in connection with any employee benefit plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>FORM OF WARRANT AMENDMENT AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(See Attachment)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>EXHIBIT B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>FORM OF NEW COMMON WARRANT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(See Attachment)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>EXHIBIT C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>FORM OF NEW PRE-FUNDED WARRANT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(See Attachment)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">18</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>atnf-20231128.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kk5s7xRiXhun8uNbHcsWaaG6aPtzp95GYlBuGl2fclajywmEKNBVyHdPHbGwScC -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ATNF="http://180lifesciences.com/20231128" elementFormDefault="qualified" targetNamespace="http://180lifesciences.com/20231128">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://180lifesciences.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20231128_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20231128_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20231128_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="ATNF_CommonStockParValue0.0001PerShareMember" name="CommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" name="WarrantsToPurchaseSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>atnf-20231128_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://180lifesciences.com/role/Cover" xlink:href="atnf-20231128.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://180lifesciences.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnf-20231128.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="loc_ATNFCommonStockParValue0.0001PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFCommonStockParValue0.0001PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="atnf-20231128.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>atnf-20231128_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnf-20231128.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="ATNF_CommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATNF_CommonStockParValue0.0001PerShareMember" xlink:to="ATNF_CommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ATNF_CommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Common Stock Par Value 0. 0001 Per Share [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnf-20231128.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:to="ATNF_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ATNF_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xml:lang="en-US">Warrants To Purchase Shares Of Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>atnf-20231128_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://180lifesciences.com/role/Cover" xlink:href="atnf-20231128.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://180lifesciences.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnf-20231128.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="loc_ATNFCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnf-20231128.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140436121128928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 28,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">180 LIFE SCIENCES CORP.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001690080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">90-1890354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3000 El Camino Real<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Bldg. 4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Palo Alto<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">507-0669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember', window );">Common Stock Par Value 0. 0001 Per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNF<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember', window );">Warrants To Purchase Shares Of Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase shares of Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNFW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>ea189187-8k_180life_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ATNF="http://180lifesciences.com/20231128"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="atnf-20231128.xsd" xlink:type="simple"/>
    <context id="AsOf2023-11-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
        </entity>
        <period>
            <startDate>2023-11-28</startDate>
            <endDate>2023-11-28</endDate>
        </period>
    </context>
    <context id="From2023-11-282023-11-28_custom_CommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-28</startDate>
            <endDate>2023-11-28</endDate>
        </period>
    </context>
    <context id="From2023-11-282023-11-28_custom_WarrantsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-28</startDate>
            <endDate>2023-11-28</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2023-11-28">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2023-11-28">0001690080</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2023-11-28">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2023-11-28">2023-11-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2023-11-28">180 LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2023-11-28">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2023-11-28">001-38105</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2023-11-28">90-1890354</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2023-11-28">3000 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2023-11-28">Bldg. 4</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="AsOf2023-11-28">Suite 200</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="AsOf2023-11-28">Palo Alto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2023-11-28">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2023-11-28">94306</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2023-11-28">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2023-11-28">507-0669</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2023-11-28">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2023-11-28">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2023-11-28">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2023-11-28">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-11-282023-11-28_custom_CommonStockParValue0.0001PerShareMember">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-11-282023-11-28_custom_CommonStockParValue0.0001PerShareMember">ATNF</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-11-282023-11-28_custom_CommonStockParValue0.0001PerShareMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="From2023-11-282023-11-28_custom_WarrantsToPurchaseSharesOfCommonStockMember">Warrants to purchase shares of Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-11-282023-11-28_custom_WarrantsToPurchaseSharesOfCommonStockMember">ATNFW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-11-282023-11-28_custom_WarrantsToPurchaseSharesOfCommonStockMember">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2023-11-28">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M0T%]5T5WS0SE!   A!0  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R=
MF&]OZC84QK^*E4W3)K60A#^%#I HI1NZ+<T:=BMMV@LW,6 UB7-M!]IOO^,
M">W"";MOVB3D//GE^/@YC@=;(5_5FC%-WN(H44-KK75ZW6RJ8,UBJAHB90G\
MLA0RIAI.Y:JI4LEHF ?%4=.U[6XSICRQ1H/\FB=' Y'IB"?,DT1E<4SE^PV+
MQ'9H.=;APA-?K;6YT!P-4KIB/M-_IIZ$LV:A$O*8)8J+A$BV'%ICY_JF99N
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MHMQM>>U.M$CS;:87H;6(\\,UH]!PS WP^U((?3@Q.U?%QN/H7U!+ P04
M" !#07U7X/0ZB:H"   P#   #0   'AL+W-T>6QE<RYX;6SM5]N*VS 0_16A
M#ZB3N#5Q20)M(%!HR\+N0U^56'8$NKBRG#K[]=58MG-9S?;R6.J0>&:.9N:,
M9F235>/.DC\>.7>D4U(W:WITKGZ?),WAR!5KWIB::X^4QBKFO&JKI*DM9T4#
M3DHFB]DL2Q03FFY6NE4[Y1IR,*UV:SJCR695&GVQI#08_%*F.#DQN:9;)L7>
MBGXM4T*>@WD!AH.1QA+GJ? UG8.E>0[P/&C <HBCA#86C$G($'[WP_([8-0:
MKPHI)X(+&@R;5<V<XU;OO-(O[HTO(#+(3^?:,ZPL.\\7[^C%H;_Y)'MC"VZG
M-',ZFC8KR4N@8T5UA+LS=0*@<T9YH1"L,IKU'$:/0?!A#US*1VCAM_(F=E>2
MT(M/!;2!0*FCZ D-8@@3%(A_'2W$O@K[]J_"DEJ<C/O8^FITKW]OC>,/EI>B
MZ_6NG/)CT>=X=%;7\OQ!BDHK'FK_[82;%1O]R-%8\>RSP:0<O(%;2D[<.G&X
MMORPK'[BG1NGJ2MQSHO_G'_!N>*:6R:O2?O1CS-.AEF\&OB;<9^L!!XK:_H5
MGE;RPH'L6R&=T(-V%$7!]8NI]^$=V_O'X4U\O[[@)6NE>YK -;W(7W@A6I5/
MJQY@7X95%_DSG.YY-CW3?"ZA"][Q8CNHMMKW(O&"SSI<X'"/[/HKCF ^ 8LC
M@&%Y, :83_#"\OQ+]2S1>@*&<5M&D27JLT1]@E<,V?8?+$_<)_=7O-(\3],L
MPW9TNXTRV&+[EF7PC4?#N($'E@<R_=E>X]W&)^3U.<!Z^MJ$8)7BDXA5BN\U
M(/%] X\\CW<;RP,>6!>PV8'\\3PP4W&?-(6N8MRP$XPC>8XA,(OQ&<TR9'<R
M^,3[@YV2-,WS. )8G$&:8@B<1AS!&  '#$G3_CUX]SY*QO=4<OF/L/D)4$L#
M!!0    ( $-!?5>7BKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,
M0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BD
MMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G
M<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^
M=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"
MR0_L?@!02P,$%     @ 0T%]5ZK$(A8S 0  (@(   \   !X;"]W;W)K8F]O
M:RYX;6R-4=%NPC ,_)4J'[ 6M"$-45Y VY"F#8V)]]"ZU"*)*\>%C:^?VZH:
MTE[VE-S9NMQ=%A?BTX'HE'QY%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P
M9:P!Q+MTFF6SU%L,9KD8M;:<W@(2* 0I*-D1>X1+_)UW,#ECQ ,ZE._<]'<'
M)O$8T.,5RMQD)HDU75Z(\4I!K-L53,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:-
MY&:6J6"%'*7?Z/6M>CR#+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_
M4R-5%1:PIJ+U$&3HD<%U!D.LL8DF"=9#;E9T!N[RZ .;<L@F:NJF*9ZC#GA3
M#O9&3R54&*!\4YFHO/93;#GICEYG>O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#
M!!0    ( $-!?5<D'INBK0   /@!   :    >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z
M=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2
MO6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV
M-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^
M 5!+ P04    " !#07U799!YDAD!  #/ P  $P   %M#;VYT96YT7U1Y<&5S
M72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2
M%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;
M$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-F<!B63R-PLQJ2AFC-4H2U\7!
MZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK >MKB
MRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'
MG2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"
M[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( $-!?5<'04UB@0   +$    0
M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M0T%]5P.KP/?M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ 0T%]5YE<G",0!@  G"<  !,
M ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !#07U717?-
M#.4$  "$%   &               @($,"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ 0T%]5^#T.HFJ @  , P   T
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;72YX;6Q02P4&      D "0 ^ @  =!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea189187-8k_180life.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://180lifesciences.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>atnf-20231128.xsd</File>
    <File>atnf-20231128_def.xml</File>
    <File>atnf-20231128_lab.xml</File>
    <File>atnf-20231128_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea189187-8k_180life.htm">ea189187-8k_180life.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea189187-8k_180life.htm": {
   "nsprefix": "ATNF",
   "nsuri": "http://180lifesciences.com/20231128",
   "dts": {
    "schema": {
     "local": [
      "atnf-20231128.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "atnf-20231128_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "atnf-20231128_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atnf-20231128_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea189187-8k_180life.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 65,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 27
   },
   "report": {
    "R1": {
     "role": "http://180lifesciences.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2023-11-28",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea189187-8k_180life.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-11-28",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea189187-8k_180life.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "ATNF_CommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://180lifesciences.com/20231128",
     "localname": "CommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Par Value 0. 0001 Per Share [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "ATNF_WarrantsToPurchaseSharesOfCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://180lifesciences.com/20231128",
     "localname": "WarrantsToPurchaseSharesOfCommonStockMember",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants To Purchase Shares Of Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001213900-23-090732-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-090732-xbrl.zip
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M 8)$$&I&^03IBD:,/[':XP[G;",ZP-=SMH!G*!U1;J'J584F6JTA 0'6QR>
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M-:+0'LX)YV]2;5W6P6'GP!!*NPXK@$LUHM"^GE,UM>/=.R6?S&RSAS9$W5,
M2K\.ZWR#FG&BL'S>RK_>51@,08DU^)41=>#O58OU=I0X=NM"UI=]D1#EP1^R
MAP:@'AM8_8I/'();,Z-J=]:5.>/<#ZWAJ"X%#0=N(@Q5CW,AWGFK0O ZO&<'
M!5^'E+=,(<X&M'3,6=SGD@3G]WMF4-!UR&]+]*%P?D/$@TH7)E[=*1E3ZI[K
MZ.WY!\BP@!5 8U.'S/<H)CAW))[??+EY&69JLK\"8/T+WI<(EH/&J Y),80
MTMQ)/^^:H\F;U3V=4.466XSHTKRQ#3V$IU* XM! U>.=4& >)?%ZW2H(M$T^
MV&\WW[@?[J\;V"-_ 5!+ P04    " !#07U7D ;9H<@<  #0KP  %P   &5A
M,3@Y,3@W+3AK7S$X,&QI9F4N:'1M[3UI5^)*T]\]Q__0+\]S[]%S61(V 1V>
M@X@.CML CC/SQ=,D#60,24R"@K_^K>I.((&PJ+C,7.^B0KJKJZMK[^K.WO^&
M?9W<,=O13.-33$Y*,<(,Q50UH_LI-G [B4+L?^7-C;V>"^V@K>%\BO5<URJE
M4O?W]\G[3-*TNRFY6"RFAM@F)AJ5AI'MTI(DI[Z?GC25'NO3A&8X+C44-NZD
M:\;-?/CX=-RT;>M:J"E^XP^22<V AJ?JI$.P<3XE'H::NI%-<Z*IZS?5'#.;
MEG<6X2%:C#L,Y[65$6>8(?N^WSB9-'>CVT^:IER;&D['M/O4A35$2+F$E$ZD
M\P$@"8<I(4#P.=DU[Y;"*20RL@]G9G'",\7';>J,*:ZR*7+[8\(#Z)'.^ UM
MUID+-I^"IW[#@9/H4FJ-&W>HT^8-O0<AJ/"=;>K,B6S-GX2:JZZ=<$<6<Z)1
M@<<I?(Q]T@DI$R"+8@X,UQY%S]5[&!K*L=U9I.#+4*-*Z^QPW$HN2+K688ZB
M@6PR)ZF8?=Y8EM.%&)=.1E7X3?"?/5=S=5;>2XG?\+3/7$H05(+=#K2[3[&J
M:;C,<!,MF%&,*.+3IYC+AFY*"'$*^Z4\L'O_ETB00XWI:HDTF;M+SFB?E<A0
M'>Z2^@'_XUI*5Z\OFW^E#XXJE0OXA>B11&+5WIG]:YSQ=<1,K_V9/@)<MC#N
M]93NN>(U RZ%:<!_E3XS5/C?/=1I][I#=8<]!I0< %4S8$U&58!E4[UNJ&SX
MA8VN)5"*^:(D%:1'P,WO [D/KN5K3\&( >"KQ\!(7S=[U&;.=?J:ZU,!Q.'?
M/0;. >)RX<'*S* T%WC;5$?$<4<Z^Q3K !>6B"Q9+FEI?6ARQNY)P^Q3(RZ^
MB ,"MM;A_*YJ=WX_57,LG8Y*Q# -QA]JPQ(R+K-1(O@G3569P>4#/T+#LT$?
M8"F"]8=N S50Q3GO(*\D9#D!8D4,F"F 9UHIQ &Q,F>!O50(TM.!1_)$K#QA
MBLB14J%IX<"@)YG-A4:T0'5<<KB=!0P(-YZE'M>UU#4Z"5\LDD-'C7F/4<-]
MBCE:W]*9T '>4&'@8CC''-C^:-",KW')FS/1U)DY^_K);\KXQ,??CK_75'S2
MT9A-./HLTG!5ZU_"1)KN/!DN%3F>-YH%-#7562S >[#= ^JR\F0*/J3)LYEN
MP"AS.OE/IM$*(>!_Z9%Q/FT/;;,_&6/RU[4R<%S0F56SWS>-IFLJ-Q?4_D;U
M 9.22*X+9G,Y/67]-K/?;%$F=&9=E*S  ^^1"L@,+5U3-%?@2E30 H;P4SV#
M7VJZ0%+L7]6I ^S&)UP9:DZLC.:DM"(9]E*1(P:Q346C^Z]DKBMJ@Z_H.BWS
M E1 #WP^H?K/.P%Z_SL8[!&D^&"RTL#0!(>!4S##&7U&G8'-RI[W4((V/C#_
M47@(A#8'OEB$N4-X1."-GCS&Q.69&0?<$V#)6=IB7V[&J6O:LQSY"!I,XQ@%
M-3#H 3/,OF8L&W8Y7:;'C0+L/P]188:@GE\1\"*$4^-[;GLIZ ^_\=\]R_?V
MD*<25->Z1HDH( _,WB5]:G<U(^&:5HE(XX]MTP5=!=_$(!2R.*"@,]L8Z"QQ
M0;O<EP_ZDR%HECL+#[^[UU2WA]ZJ]%<LU+MMVH"^Z+VO4^6&I,&A=4Q=4W>)
M]]"'))[+D^?H B<<[0$<;/@V5O[[/W)>VA6$\'X&9I *36$-9/*'LZ: K>J9
M^S YC7"(*"S:,.>N#5&QFE!,W;1+Y+ZGN>"X[[7+EV?U5NV -%N55JVYEVJ7
MWQ"79JUZV:BWZK4FJ9P=D-KWZN?*V5%M<Z-Z?GI:;S;KYV=OC.%5I?FY?G;4
M.C^+DX-D-4G24BY;?$NDWIR!#L\;IV3/L:C!-30&IT6IP@/P1.+ 5 9H5C'I
M<:V,TP.31,&#M?/C\^#VFYFY^ 7@GA+,!<>(E0N)+]/!VUX*L2O_JU<)!*M1
M.VN11NWBO-%Z8RGRJ?&F2%Q<-IJ7%2!)ZYR XFF!<MG<D#/DO$'DW):Z3<X/
M2>MS[?VHQ(DZK%1;B)U<S&3_O4R-;C$Q.Z3!+--VR9;W>7.#4?!YF.,2=@<P
MB,V?,W6[-*.E\E-:ZH([U37A<D>KJ^H..QF-TF>G@]ZCU)7(\7^*:4.WI&)X
M VU[*AV- %MF1*FS$#*Q\IEY)P*F="%.$/)<+?=O9 :0%+&X05],98II\XV5
M$H$NS,9MEUAYF@MV/"X02<$&ZVH.;LNXF'6-9H)V+IW+/-3J)[_8$VU6U%BQ
MLER0R$G]L$::U7KMK HR7SUO7"3GKO2;F[6MVI J+L]/"U'TY[.Y01W2M)B"
M"0*5: :I0H #P+;?"7^ZM*TSZ*7K0$2%;[Q*,?[9HJKJ?WXTAH$890$N/!1S
M_>!MSU6G(AD_/FB+8"69FX0K=\QV-87J_KPALAB/FDG_%4646%@T>,#3H7U-
M'Y6632<8'$D8'8WE;"(^^R'QJ1L@<Y8G=CR14Q6[<553G2--N6ZE;3?TG9/3
MXE-5*FZU8G[%999MWJ&8A77J"KB!06$ZO0=MO-!]]/YTU=G%FUX:L8KCU9FW
M.#YC1H'\'?E!"O'#H:8S("08KNC%I^VSHQ-F[^M9^BQ5.AD'<Y5R(E.0I=S'
M2JYQ)5MT6/=2O@J7H$7+>K/?_G%\\_,@G\X_:UGG#!HK%Z6$7"A*F5QVQ46&
M'_9\Q1M)_)<E^!;70,2TR;G; [_N>&!KCJHI.,N]MLUW L&FAI36]I/8]K&\
M^A;$P,R]YN ^ $%1)F*=_]SYUAL0T/4MW1PQVU_M,*>3,S.Y'<W!*>Z]E#^<
MJ!=PHK+%O_RMA1>A;J2FK88T;455;>8XWJ\3"%KD:"W[95_I'BK[#5IY7AP2
M,6"LG)$DB=1T4@46-TSP[:D^1]7&9P)K><E\TM'S<<^J=R>L?Y6[D]<\GW2L
MO*^KW2299RYFYU!8,H=,]!P>CNIR[9?3['Y^GN6+&#!6;@Z ]2'ZGZE/F8D%
M7Y=_(VE5A3_/[99Y;T13ZD?SZYW>^J7+O[+KH-1DN%CY@NHFJ>BNN?)J[T3-
M@%OH<_L"8@K-4.:$+UWG\O+GT?U%IOD\#S9ZS%BY6EFRV._8AYT:%'3K&[BQ
MAU%+>V%"N*C_U*SY<6GQ:'1E*T=9=J^L8V%#(X(#F\U(^=_6=_7FA$F?"QOX
M5+.H3FI#I@Q<[8Z1\PYX,<SY<]TW6$:"Z_C.';17'GV2__O[/X6TO+/K0'^=
M63W38)L;!G?IXP3811^@=TBHS2B(D@IT?4P"=VN>^X0FH (PY\OT12/3;>RP
M+C5S3Y3IX!BQ<CXWSQ1OS]UM.#&!62^0)HLBZ-MO^TQ^>#":A]TG8CH]3JR<
MDW824CY??+\)Y1?EWU\#!\*KT8+AJST&)@W"<4(MRS8M6P-CO+G1-H>DS73S
MGF@=_O30M/NDD/A".IJ.C*PYP-4N Q950?T01^L/=)<:S!PX^H@XP,).9\1[
M>AW,-J DPCQ3@+3'LB-8G5!CY#_KF#H,#OTV-S"_J6&8[)"M/:WL,(8E/.4C
M9C ;5'#= !@#GD,@E60Z*=#>+JV-HN)G4LYA14XD<?F7FH&Q;(DD_*;O)Z0<
M1XX+[$=LULKX?E/6&J[57YE2$EE/25S9F@L,A6F1@>%E!)QH3?'3O>SLG'YM
M5@W]R5N2;=/4&35XE7U0AT2B@8M6W,EF=Y?ID2AK'<$SZZ2GAS!,/(@QL0:V
M,T#9 NG$$BZ23><\.4,!:X+C ATU&*JBN&1+WB'5PP9)9Z0D-'QE([]<37W(
M3.0.5-/D);XPX5-0VZ"[]3F.?:]YDW.^[GQ5URXOLRB\9V&98 O\*-"=E10Y
M2Q-R.B LM:'2HT:7A44E"YJ>M_R0EO<M+;X;>F$S5.MXP(A7SZ'W8D/@-L\A
MW5$=39'Z1YW&X](UJXC-?%S>L_@ U@DE@/92HR-GU41ZJ[V]FC")MA_B]+[%
M*1LM3G7'&3![J5 =[GS_E?F>T7]]?5P&_PE"-8/1GR5:&9;(;BFKB58&_#]H
M^]Y%Z[6'#WC!(AIE-E,AY S0&IKPV%+F:LP+3X&^ZPLP?_\=R<7YS0A-M3RO
MS@=(X)08GKF^M^EKUX:T\%X#7'!&E1Y1\&#>TC*:15B_S/[#.Z"337EJLSGJ
MMTU]"U/@'U2:H9)?,,J9B?EZ&O0*H ;?3+3/HIV0A?G_62&UN^VMM)2-IS.%
M>#J7VXX0Q!>>]YRLM:=V1W*ZS:4LTE.X]@['0O-YIV.OO:/"B<2*)["O'VH[
MDBDU<[\RE^V%[L>Z3KX'(^6I6<?* @CA4.+$HC:Y0T#DOP(4L?"8<F]1@>:*
M_LHJ4O2ZK.#72WC:0RB/5^2#J[[9[%VJYZ>WBT\UO  ?A*8L#GC__NO; J]H
M>HUS4^+NNZ=SCQF\T%+K#V>CK]G;GP7M=99ZNDP;U?ULA78456+ELTKSH/)U
M#C\(34%.J7W#7')R4EV3H;B:>'-OJ!)J+V8='G%]PO7#M[RB_1B9\E!]'KL\
MYOJ*A5;"!X31B.6!(MX%1^!1!(W([Z]'IIDB_3)VXE$<\>/XQX^[1N'>K2U.
M6;P01T38BZO??Z&C#,:T!EBOP7C4FA^U3K\IV?[5J?.*6N"M#<<Z\T#O->53
M-U3,J3'2'A&%%S\ N)O-C?L>XX<2IBH3-(< BP)GX9!= B#OW1[FYBRL5J .
M45E',\2!/['-*N7\+-'4'BM\*Q<S&;*%%-C9Y5NM?F,8!A;3PN."FQNF[67X
MTNU$.@)8*,TGH&;'4#';-^D7@)M<(\E?;W'GCE2;LR2+RUS]7D>\4U7TF7-(
M[^&L_:-H'_<_KS]1O0"9Y3GJWW 5'RFBG0B9V]SP5AC+Z:)$V*]4"@@OJ%O"
M=*:X()^&R=.Y _"=L!4@Y!4OX7VT&D_QBANF< $Y-^DC'/U> ^9"QC)@KJ:]
MN6&S.\V!CB#VU%!P YDJ_/Y5;(VW :O45AW"RY9P@,AD<F:+CI/)07%.DO'J
MKXGX:U_--[[H*'"14>1%1X&+D-9WT='[ICWBO OM;P>X>01@=\FYQ7>-2@C7
M9SH^*^[CS1)XZK*H8.XTN(!R.F(%\]QOM\(+SA$.SM^_:&L& 9O1FT2;@=0!
MZA:?2G#(?,2(B,9CAPRN])H7^67N=^%PZ^#4PG)(<I+4\-PV%EV:A!*_UH8<
MH/NA\1+T2M=FW 5.KAF/US$'H2I**9G3C 4FHN)@82AH8E%OZM]X@@EU<V"3
MZL"V<0_5NRD%CU@&ZE=%N\J@"T,3.2LN%XD3?A>%U@%7R[L6&D)KVTK&@=S^
M07D2.)E*ME!Y8]EW&HBS:B6W9^4]8\Y[R[O;\<T-BJO':VDUW+8&DP.!&--U
M_$9AMDO!P=2,.P91A>V$2LH#CX&4[@#'!,[P&S\-3S]:L:<Q1=-,NX!LEQ<*
MFYT2V=*V23Z?CQ?3.3\O\:0QO15I>A<#AL;UC:5'OW&UO2*R'XY(H8\3Y^-4
M^E,7"8!N;G@YE2D";&DP7V"^1&? /8A[/S_SG$GC]O^A@.>'C-,4"*9_!A9^
MS,2+V4(\FY<FZ:#-C?"F K(1( P8KP5-#_CJ*&;C>3D7SQ1R<S)6P/G N8B1
M@IV\51YS7SSD/E&0B'$4-!Z(^GHO3O">(16C,H#C85STQ;O-W'N(I(-<Q*D3
M&F]SXUF<>U&9HL@Z@Z[G:\T_4Y&?*ZZ)UT3)&7^I@TML,X6!=00Q]>JD(1#0
M%$8ZMMGG#4\@6N '#;X.8":=<<'- 0,MXO)2'. F3%>=44>EMS.Y% R]'\<N
M M"T\"!B'1YS!/%W>]0EF@OBZ_ 81C-$<*+A:T<V-WAX@NVY>/5,G1^DP*,<
MH/]@\K<#S>;"X8#LN!C;0'N X<W%F[S(-^3R&;P&[H-GEZ!TCC<53-U-%F8Z
MGBWE22'06N-[_?%^ R*C(H.VFQL3I4'&JSA61$_3T@AK/-R,X0JJ4E%V@)8[
M/.S$#;'HB-MZ5=6$1[&Y\=]"1HKOY(O)C"3XT#"\V&(\ 1!@6U/X@1^O5"IH
MU+G"G6_QGC;IQGC(2A_C\%G?BEOLD-Z?<K;$D@2I/XPV\5$&KE#(QPL[A7D&
MSL\@;&ZP(;,5#7HBOMS6S6ST/]%96^H\>([ :'O15(IQ*9^-2T5_*OPVELBY
MD,BIR#O/G<A"]P*G &)F=D6B=B(SX]EO;O@]A3@^=OC%Q--FN&C:>PCP%=<
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MB+6M-.IYW& $'S,*&9FX8MEXM;/$?ER@&,/ .;;G;*YNAW970#ID7#U3,%T
M8^[L>0N!JG/FR9ACYZ&_(>&(&N-J[;S9V!#A^F1=K.%,?LWRSV(O+N%=Z+RG
M4@G0BA&3.$HQG:7;:7P2.P6=QNDDP,8W%S2N? 'NN.()<!]&5Y*Y>S[Z7!)P
M*):TT45TT$%</?+V*=Y"A::Y =<3OR,/ \,O-]45J[NLWBCWZPS?J#PM=$QJ
MJ>\=Y>3J)D<4I5_Q%\7H2D:SQ)X9]*WS$=:]V^%3(#)'4Z9B#?R7.9Y:XDFE
MG6:!#Y1R,DTH@(C]D&?[T3)#D^G3H$^P2TZ;1B$F1LW1OLK!6HR;=8&<5A67
M,)>7LR1D\FM3*"RB\-]"91F)CV'^&?2 -5Q7V.?0VT@6!?R%24WEO"?&>39A
M%;.P S:M:7NN&DURM4HZ$.]@K+5ZAV%&S[*<3T[?HEL4^[B3;?=X6:^JSUH)
MI&2W460;WP8QQ38]<"3M:YMB!_]Y9)1>QN^[]5:<3&EGOL&^E/[]5OP<)C/\
MN=DM_.T]P#SQ%)7I9*GYU_-EETJTA3X=:F@ZO!47\RE,MY^'PWCT%J331#*M
MCC.DP);GT=5OX2^+_-+?P@7];;S-?_+DR>.37P+,B#X;')R<#0)Q>"SV3H[/
M#_<'9_V+PY-C=$.##L%R?3(K9^1"UF8D*@0L,1I<2=K_S K(99:Q#0RR9D:'
MG.>)IO9S.9(QS(%TEPB=J2.*K2GS&Z.'J'5@EO#H<YK=)#*Z1--NF<P*.'=9
M)R_^M)ZH)^\WUX&G/[UW'$WKXA.>T*ZU#7I J[F]R-U0,Z&_E?N!K)!V_X/X
MKNX'8/9V_T-EX"I^6O<L<7)W-AK-0 U#O2;/4AAFDI#Q2FTR=9)LQ.P?\CFM
MG4#4 !S@M.$2%9I1:]DR2?6+(AZ%@KT9-_J-.!F]DJZFAC\-Y[XG$L/"F(>F
M6]1;;HC:8ZYLA3'3S;6%P^LP3FC+8^B% BZA&(;I9]C&(VQPK>B)2'+2O=6'
M5?/^]E:$40&JJAI9BUBUAL?4',OPLU17$NY9P_E>(F!K79 ,V&=7(S#3.LJ!
M'S6YY1N\+6+<=GRNA3V8\0EO7.!4##UE+?MRWR16>/RD_;*X.4>8+*$$CW77
MUAC+BX$TG"CWJS8<'M<H?M'?/1J(O<'1T6E_?__P^*>_/]EX0G^?G_;W]-_W
M<P'K)H[**VQOXZ^@5%R<Z6Z =B6*/4T(:*7E)A1.8%^_IIK;6'^E=/&+_?=-
M/S^'G_WV$CD&76\M[E7?:>RTXGN+,+G0^$-\(?26&L3;=A=G." D]C(KOA3Y
MEK^LMUKS]C5?>M$7^M\6<@&H3GAS:S;$S-HRII.9!4$^P4./\C3Y?F0?A2ZH
M)&6(3CKEE%MQT</GHCNPD7^&J!2+RCEA'*GJX;_E!?IF*/&0(O!%F<]8<UYQ
MQX/GCNOEF".DJX3Q&,98RKHPN8KE&%-:X5N\!WLRA@=95^UV^,>#&,R-$0@8
M\Z/OK?7O#%H'7S4X[>L],8;62%;Y(JR()Z"?D]IT@X;830CL:76?ELC P@N)
M*UY^Z+R\-"L7<@1G5Y@;T;60N<_UT\9IU,JRWX!-Q6U<VNVLV/2/S:9+GL<A
MO' )\C*;QBEYM<;F>-[+9FDADU;&ZG:^AK-6\N^/SEA+<U8]]1;#LG&A42V(
M'=)P4D<"H(S7^\Z&)L9>QBCI=G975LD?E%?OQ*P-=WQ_!\.&(IW1A4]TAS=G
M 1C6_'V9\\(FSM_!U-[[XS#U/;A%6YRBPZ]QBE8C ,NZ13U/_<HK^F.ER-9W
M\(H:1GD,V^RVI(@E4D6>K[)"_*R0YW_PK)#OP5@K4=8NRN[3V6^%&UTW>) 2
M;L4,7^FSKV+JK#_(Y;VG(/USE1N@-;\]DQ)"J4)__!R!11D"%^@-S(;PLI].
MK=U$)I]](;22ISECBE(ER\;>^W#R;882OYC(<J42/S#1L;S@"#&9"_,1T8L(
MMM$$[\]@A$;ES!>8@1]H-B!8C[+;R4'<R (^:I[+];US]!LB_Z#=R]BC</SH
M1O'N#3SZ4??1CQ!I1(H!92H%>@RZZYZXN<*K0AIPM9HDUNVXMIYF_.K8\$UG
M<%77@)/LJ2!,UV9I(HM"N?1#@8/!N  'HTKU5*RSSD<$)$N@*FQ>#C552WD7
MJM8&OCQ1->5P833I*KB;O8=ITJQV[=VU/\K!M (_J.1Q.K>@ZFXP<SFGFH(:
MEF(YEXJ+\.M?4%4X.BLN>^!<=H?30;G$YC4;PH IEG+2?&&[V]E";UT-9^&!
M:Z9?I:+<(6&>/9BDM%E84=&@OUE2W[<&AQ>J5BK<0]NF*Q7N-A5.6S@K!6YU
MM#Z,/7M?"ISB]'M6WU;\]>#YZW>H;@;@;!G%+6Q0W%;J_1^"1Y9,@*13L"8,
MTJSM9/> %"B=PDL5CS',54=3>8#,<D].X!?*!WU65UT,%G9==^&KK!>-8)4-
MBE#@Z1-T9U,?''8G@XJ%B"Y@)GRI7-?@:\9E]B?PB%/9KB4BU"]6$6H_0OWB
MT42H;[_2_KUDP\N[R0:O_M:?XOINL_7OQ*^LL\-(/,_J8RB_H'HQ1$./^?X2
M4%K&,[I=3B@O"IL,3KD"6K^.Y8V,7,S#V@VFZ0QT\Y$8QPD!?I)*;G$9%*I@
MPYM^[J!"0T(UK, HO(8K:L$YHL)*XQD59\.Y=3NQ;^5&F630.*QK18Z@R32)
M"<K(.(+0$HY3+/20**0B93"P-<%.)-4_83%]=_B;!J_/]^2XX;?A.-">@<L"
M[=&0H2YN9J"(X &="5H0?I5WGS\N=4$!@L/4F%#A: 2V7<RP95RDQJ G6YQ]
M6/LS6#OQ<F,3AW9FD+3$/E[6F\R22[J1PJM=2>GOCQ2"B=8S%"]W.W6\9.57
M0:6OS&-V5";R4B+6 7EUN*@(MY?*6.%B5+ +TJSVI2XSI6L4V"3>;J=MU.NB
MGQ19=:LO6CM>)-BZN ,T8J&//E>@Q9R.XJG"=D8$NNPFU?@-#,N)<@/TX@BV
MT8BL;& J_DSM7'+*#7Q/0]?%:0J=$3Q7D!A@9Q>$28I-(4&',V28G/9S;FKQ
MF=_4;8_ZVK33DTM8^CJCAII,XDE,$L$0SX@M*HB*X^*"@<UM:]!=4OTQS]G4
MN^354W W,/V2"=*VD$)#Y]Q@EG2#('/PXL82<702AOTHR7MAVNIVDO"F^/Y0
M:3]8@HT:))AE/.=PJN$LMBPL'I' (+R+\=!*"4<=1).;7-\J3"@3N[QR5P9Q
MU=CSBI8A+1N!O^.N(D9'*#R2F<Z-NP!10RG9VO O(<Z@^]-I6CMHPUR$2A@M
MN/7TX/*V[\42TO]X8'K_.AX<(O[5_XF+#X?G0M4$_E7\Z_CD#(&QA%,E^/#X
MX@04T0^'>Q\J3\/GP?\.SO8.S]%X_S_QKP_]<W%\<D&??H8O=@>#8W$V^.GP
M_&)P-M@7OT"GU>;[Q_O0RMZ'_O%/ [%W\O'CX?GYX<FQJ _$_MCMG!S BUCX
MN7\Q0/BNL\'18?]X;R ^G<*[_6,<V,=3Q/(2!V<G']4@&-U+?#K>']1:[^]=
M"&AU<^<YEN^"O[&0,HQY#9]39/,?=RH-P"3@I;V]DS-T,!W]&HB/_5^1%$ "
M:/6 9@\S.C\YHMD.3B^P^O+YI_[QA;@XH0'#4WL7AS\/_+'2#*F><_NHSTQ;
M5.H9&NO_W#\\(K^73X< 'P9R]06T?WP.;^,O.,[S3[O_A/YA,(2,Y@_B;/#_
M/AV>T3#.D4@-@\!EQ(:)!K@2P#*XVOW3TZ/#/1H*+Y;SWE'_E_/U"D]A.U4&
M/(>Y80.TMHKC!CP.]U4D.9#[]&BP_]-@7X&Z'0]HCGHT8O?DN"\.#O<'\/C9
M3VK$GX"\ZG>'6W?/3OYG</9T?] _ L(#X4YPRXBC$R"P>OK@\!CF>M@_@M[.
M+PXO/A&Y+C[T+W!SP'.*<: 3:/'P8K#?[1P>_SPXOS@YT\H;\-K^ !KB(9]]
M@HF"\H;FSZ(5=\9"/^)X83]\@DUJ'UY7?=RO;*-_O]A!?\?W$6E>A\OX>5ZN
M_#R^G^?EX_3S.(SSH(K3D^X6H>Z&6'>5DM5&$U]4'29PM25X%$%9TE&#7:,5
M.U:54/?7AASJ8TIG6C,5P'DL6I4R7N1PF%W+'N/:@TD+RGC8INFC$]H86-!S
MF$@3N6X8%Q@DUG@P>J6':$!6*D')VZP54B9O:=JM#$(V\N:+%POL8"ZO%]?;
M@\%8Y5@"3\1DC1!,8Z(';3I8"\$.GE!F35A<4>;!HH7L\671;%8J@AD/C:DO
M9.*]'.9M\_9PH6BA_%5Q2LB/M#ANHY71AF2"ME&0K&@UNNLLF>%=VKS; 89/
M02YFXZ=$ .,1R+CTP74C%76;RA,& C3ZO:2SQ4.T6RPF@,GT.](H((JL.7-6
MFR?6_CD5H^=&7?ASUQFG:ROZQK'=ER"$HIBP<F(\*J8(/V*S8:9YEF8SF"HU
MIH CS54?V)OC<4,/^.;@"PB=])(H.('7D!25PE/VEUJU,<IV"?,$6BNQ Z<(
M(_R69[/+*Z)-%>M\7RHB5<"\>W[TBV467\J-"8B7,"YL[;8J'H8R\BXT1&?_
MDE8[A_:H@CH7U,!'O!'@TE5QZAVDW6=J'U::Q2K&' SEC3LA@'%%9M6Z2=8+
MJ"*!<JYA7XIBGN0/E+M03\?D'P$[TY7PT-JW(^PR++(4> F1@D=R6A);54$<
MU\4!^IK)RU>;?K?#]Z+;-JL= 7/4&$&&T9:';Y7S+]"88)'RD1)8?F6*FIIK
M/$']*S<?)D6&%^&1U:4&+T%N@G,7#M=\7G5B);*$B?2J[K^K*J!)&%T3H2KA
MZ?"VEA54+WG/#(D-?&X&KU5;Q/UN&;0YAHM-^@53?"9D!N'"K*!,B%!757 %
MBD@RV*UY5:R0JT]E; 3:H6PKH C&)[[)Q-J65^BGJ(RH-<.W%N-OWA.48.<B
M)WGNFQ;51/$6N_L:_,NJB"P7*P)Y4JU65)4N1_S6F=J151D3? 40:ONDU!HI
M( C--[1/*,:CTA_-E"A(0"Y@[3S'S,'0GO[-@D&)0@H(")7F22C%U4>=P%6.
M7#3,L\\N0M^^G&9%3$Q\D:L*W;2@Y_,"-#@*+9 _N^&JZ&/SKDK4T ]!/Z_6
M&JSKZKRD%@,:S_4HED43#B]!3F?5%4:5!;0>UK$Q%A'FZ,,420P[G5#%NITH
MG(27ZN2FBE'P44QE&B:8-(KZ(CE2_[(9;&QL5"KEF;# $/HSJ;<__](_=82T
M#5BZY9 6*L1P'DWBLK2[QA<)/6=;C2F^X9V3]=T>P/ W"/?'K3J%FA *8Q(C
MF?C+%CW2[7A%R["1M9<5 <>'GDJ<9?*I#*?+&2THQMEFLF?)Y[9IC\P&J:(*
MAF+;W8XK(&+W(-(*M/%0FSJME9CN&)B'5$WT!2D%QY;3H]HWC>*J5^.F;D=M
MW:9!WUU WT6:T>2&-#>B'1N43>/P):R&XT'E$6U34((H4YS"X4Y])B]@U&N#
MZL&PFB(; NR$'O(])8&CX=)TC852 ;C(T!1,7QMWNQ4?B%4\8Y7>#BC4[1@\
MH*_OU89X7#SX,L8P)FY*JC9QC8MK4@[<8DC F&A%S1LW(II2& D2(2/BF^%R
MECM68&H]?^ QS&<P*$L,@.08-'PPH;=G9 P,5?J0.0J&AB;F%"8I,7X._%"@
M0.7(4,^8QRUT*2S$4W1KOZ*E6RI87^FW8A[MSN9/#U-QBO/S#*3L6DD.T(^C
MV8B.ZK5^CT617=:&_59-*6&L4C?;6S-W35%9M.]5I1)6P?W7;B@;QK9OEDWK
M-1GII!10H\TTMZJB:\<&8C)+RAAL7%8?UG9[U-.-Q*@R9MI<,^V9'1"%L&$T
MY!L@(K1SOZK,_:!4DOLO [",\WM[Y?SVG=_;C]/Y_>#J]FRKQ,<3DK-]]UZ+
M<H&'5!?F420Z4@(H"+OKT&@E[O'%J>#]]@1' ^A!DAL;4M67Z_:&S@-$*:X>
MI2<_2SEU3!;,.<0[9R5/2+MZIKA,4\[M02&.B6YPAB%B=XPF_ZT*BCZG5;%U
M_%VB2T4KG'JPQJO79&FXOGQ\>)%?^$&="=\KC9'XR09D\'A4$1G#2D7&)9BF
M.:K"[(1>(]<5!X.X1#1JA?#%]@88&PDH$6&.A8JMA[JM)F.OR=0=QXD$G:XM
M5@1_'*"S[_SIIBGM6;6DT1O84SY&4F,5.]G0$O[5X%*BM[W*G0:M>U'ISDJJ
ME/775_2^,^[?);KP:+[ IPW6(AMR5]C @G;8U -%53I1,K5".QN\,&N;6^J3
MPCSE==06O7+J4X&N@D4 9CTKJ[5Y87H5MR G/QOX?=)@6Y:41%#&LN7VZ9E)
M 9.0^"$ULU"&M:\56N=G=I-R&FW;.@;^(@+'+,4?V.$/*?S\$+((L=ZJDTYY
MA%E[MM+Y6U@(C)G%9<,M)14E8-.CM4YZ0-( #H\]%84[DVCK&B'P^NG_H!=,
MVVE>6^3HJ5>B%I4;L-@!@>^;"M(EWW$*O!(E+8$N/0I_\_K1$U94U'[06\$.
MWY6 3C9R0V$MSDAV;MQQ3#*98\XODDU=2]#7PM&9GSZM!R[=&A9MUJ#CLU=W
M/I$TY[-A 2(US&..8NK?2BI/Z,)1<'4.>(@]PQE^Q K9V5SBJ_TQT@/S$"C]
M,[QD2_#.M;9K#-2XYNOB$",[[) -W.0!73:05X>$_8+E\2YQ5'/@=5!'J4]C
MS*XH+=Z!3BIU@3I4?%<'?+@ZZ,V51 [L=FYR])&R]RK'U=25[YTA!6VK\VT6
MAP+5>G$4J;(4M$I.QX79.HXPCU/<-M1[=$CSFZK&H,PG<:K]#$,Z)T!BCV<Y
M/0K\.J(0ERI#"!O:60LW95D5GQS'6.&QP;EE0I*Y3.:T"]6J@YUVF3&B"5^#
M1 Y4[('RQ.4[= HZPLZ/4E;"=[52JT:K+F:)N@E+?F,F2LPW(722"LH E%.)
M).=FM0!Y=4> 9E M/S^<U^]4Z,'IZQ35P6GO\9QW@#<(>LGFW$^P.*1]D@6,
M.<^Q@I/-3F%$ 9RY3*NQW: VM]KT6P/>ND6;I#1+G=#K4/(PKL!*1AX"B1?.
M\:H)^B#A7-.9%Y$]<&+G; "YDH0W@0_QP585OX!KA>$6I\@5)0QXU:XRWLC\
M'$V5J0&CC4=6+:H2D(*,<.3,L#0JBRR\--(X8JH57)1:"Z=NM?!:%\=9B=_J
M*R7J)-)<WZ1](R%KQPI[E9M@\7ED*@S?^I2V%M09B$/BH3@'JQ(?.5]&PE@C
MRIT1R4X=7>&;;G[V$U-4R\H*GSGC5.N.EK3CN*2HA[XDXE] :#N,[$$^!N&5
MW';V-&H1.N)10=2YG2/KU- 4XTRJ.K\N78O-94U[$#JCF:*X+DL_@8#3=V@R
M."EG!XZR;"H) <=0P+UVI:\L57IY4'KTPW#.OEHY9WWG[*N5<_9!.&=?*>?L
M1]B],DG"5&:SXD?65/Z.CMCCK-LY4(JJ.0'8S!WP28.)%O@#5V>GPNG+VBN!
MT.JQR=6\C@L7V\]YK=NQ9TW%>3M+)UG$:&$LG"<APY;A[7:E7^,/WZ7.]X-S
M86@?Z "HE<.19Z(+UEO1MCIV:9==T#*[)+/..0Q!PXW1_@%5YS3/2 6>%38_
MV7X7F/Q[4A9HN/Y=8<T64XZ&-)H,&LUQ$F*^HKZ'KGHSGXL97C,&A0@&0OI"
M3.:YB;O@,_XUY8"L4V&5L+I63V<\]UL$3OA6#]>QJQTHH8G,+U%#BU/=1&3I
M:;PU-&C$IGF,: 3:"_=/T%N+B//IB7N!FV'U*#-0.TW XD^UDPS59%U>-Q#7
M,,B(, 1E2D+!>&7]Q/$ZHI>UK"/)UKS*HJ6+NIA(RU:8SFFH2+&%E0(?VUI&
MVJ,ZRZ]C6!*UCA=7MZ)9UN K>54*:DA6Y),!>%5BQN1DK*)BG+Q)!=2H!+'9
M2Q<^TZOK**8\2LQYTB !)Z!;4D8W;AL0;NHD!]*RT"/0BS+\C/_6!X+90F3*
M1^2511^;7J "+6HC@?E\T.]4HSQ79 +;[AUI6@#A^+PBQQ/[))Q<0?8%.TXI
M>H(2P[E*@Y+Z6<9Y-FS :PF>2LGII=B-';8S%O+!NJ$FY3+%%\)26;MV+&B6
MAR-RFBIOE^,HP$D\!5W&%&*;JQ0]Y9A?GT9C?766O=X8APK)UZ\N+MAN39HT
M)SJ2,&2'9*S.5N.Q=8]971X'G\ X) &W9!@P'$IH<5SM)BX,P_2L$D!4JBIB
MJ%]H;X\E O31,#W; 5HTE)2%B9!Y?(G."5JDQQB>&IOP%":/#>-$!Z&ZG4.&
ME<#C*K!GDH509405<SVMX="#/\BM.*1[(=DLYXM,V60JR1'WFW,:"WT!C_@*
MME-"UX^";N<ZBR,&?5&G+@87 Q6G1D4]LB#I9 HXHZTAOKKWZ9P[F-YYT*3^
MLSC1;&<D2TQ CC<LYT+Z%7VG\60:DC.*G'XTH[#4^#VN.. (FFI,1:UC=FIB
MV!1A-JRKB"08#+>@"R/C6*4[<T""4DD3F#]P.8JXB0P9 @<$52S5Z4:["&,L
MM:J8] L0![WNH8H-5 -(?'VFP@[H5&_D!Y!CB@/0S2Z >Z<S;HJ%Z2@);7 1
MAX Z5%J5'K&3LCD7-]DLB5A6FT/%\@$[;N_$ =I!:D.C*C3#<\6.U2&&T^"$
M=3/T&J^*1E9];"+E4HF4/4=W=G0T8\O@2<TDYL.4%GWB7 KT@W'Z@B*MOD67
M(]BHB)/:,>0]2S&.J%(QBJI2U^(."%5&=DY.+Y8MRJF'X&TLM>QLC#M:7U'4
M4<W),+Z<Q0:#G'D;YI EE$&&:'(%>^.C')C)Q$:Z'1M40(6)0XRFT&Z3=7&K
M*:T#!:%^S 3LJU%>I#X)$E80@ CPF+K;1WEGG%%<:+G7E(BF A>+QV15.*=B
M0A@A'YI+V;DD+%R6M_ %J.^(2$59YU,XG8 7^:\HIGOYD?D"A.80HZ25G',#
M4N3&*)MNY= R9HA&;V^FX+4@#99?*:WQY]S3"M_HU=).]]<KI[OO='_]:)SN
M2X++:&[ZIG5@[N3E/R2,H>/!^;GXY</@;'!R$+@*A@9KYJ.%L@>CJBJKKH4U
M5/OT3ZEP!@I%'O\'?F:+(Z,DDPJVY3@& Y'0#4>L$2$$2(-,^>X!$(OO[N*Y
M5_'>[SPZ![K=;/51EB3AM !NUY^>$),N1G9_HAGY8E_LG> HC__^9,L,:8K'
M6GKI Y@W@M.\VWV_^7I#'!T>#,3YWN'@>(]0T<Y.81EVWRL\==W3G5O79/U]
MK2"X>!11E@<>C<<4<N:X$>+.(]C[=Z38MYG3-V_E,9/AW<')\84Y0N#(O,Q!
M2XYP;V7Y&_2EE;"KGN.%Y4$B]L))#-;JF41393>)+M?%"]BBH+!*L06/O-M%
M0IZ&22;Z29D%/+"]/H]UY\7SC>UWS[#'%?_]/OZ[8W=&?K[\ZY/WN_,WS8._
M38-Z*^[<WW/L\-WA^V?%,_'/D"3\NO@ERZ+YNV>'OU-&.H?"7[_-JE@R55J\
M_Q5Z\IZTP&^ZG?%T?3J&+9O,W]QVOM*S!6@=?!P_>5]=+;MK?_C6^7:3'*!G
M&UJ^P3G^ T[S)![+ F].@;&Z#N;@[Y16=Y[:15PF;5S0R+ -37]+ NU=Q7(L
M5) &E-,3SF<.E*0G_0=()LX5S< >SJ?K#XI;#L(O;U:GS8_3=GYAX*!1-B6G
MFL*8\@ /X<D2 =8Y([+WNZ7@'YYF*]91U;:HF7NJ)[-_U!>G,4+9@&W*]NM]
M=G>22I"50XGQS%-0K>3]=[FY_7)#YRZ?E[G$A&Y6UE^"0G___9]>Q4D8R61Z
M%8>!.)5I6LR3ZS"-0[&YL[GQG'U+CYS)5WO]P9%!J87C\"I:S^/P/_^8%>M1
M$DY16*!6^):U'U&4<GHET_40+R&G95Q][H<0LE^J(.@;<0 3$!_7+];%&<SB
M+<@ &B_8YCS>AT'M!@7-U!]\N$7OEBI\6 \;/'G_K[/!Q_XA8<F?'(C3_D]8
M,>%B<(Q8]?VCHU_%T>#@0NP>]8__A]GL_/"GX_[%I[,!/WS !0;V/O3/H8F#
MDZ.CDU_._^]^/;]5@O'_[VMQE@D:[:R"1G[0:&<5-'H@^]MNSLK.Q6(@6,:$
MZH<<GZR+38&U7/R*$NIHT8V(_D]G RKU\9VW^$.(KG$>)&53=CNUT-K"E.;[
M#;=U.P\FWG9/,OA872XU]PA1\DP0SP.$BBV'B!6GQ &LDS@JH^^-"O7G*R7]
M_.5?FPI%OSM\?VZ23V%1^I9GSQ7/SOW%,M[U.[GW%[G$MZTGGV7ZLO\#I?,:
M=,[=;!XY/O\%=:;_B%5C]79I6IDW/@G^^/?UE)NZ?;Y[AR?T8U5@!.+H:(]%
M^R'5S.0T^X]A"BI!_N<@#=F.0@?=6TE4#($9_A%J"HV80&PT_O')T'QRK=T\
M0S<P)>1F0(()9KWFC41X*WZ[!"/U,YPO<=KX1.]'S.#[L% ]8P.U&5>X__$Y
M1.5U$55'S[(66<'*\,M-]&)&<9&EH@^"="8#\:J\$@=)EN7\"';Z:Y9_#L3Q
MKW@H;VU]O^%_?Z;8=RZ2-0$45X&FUF)$^T'4"[K@Y+1D(RZ/BZ4<)]FOF$/]
MRVS%:F:QSB1F:R-9^H0L_D;\Y?7SC>#5]L[Z\XT_ Z<\>7_>G(-.!B?C5ND+
MFJ>Y?(H&#AS?^J[F&_$B>/UZ.WC]ZO6/HL;OYJ46;7E7IG+,E:Q.;E(POJ_B
M*5@*B+:>B[_]]\ZK%R_>BA?K.SM_Q<L!7YEG -/"EK;?JCR!;F<'6WQLG%5!
MQ7PC=H*-[1?!QL[CXJIOQD2&+36?_E"N^K96[.#P6!P3E#.PR>NGFQLO7V^]
M>OYG\ A^=;:280!T)A +5"#8\#H10O%>.K?VZ3I4-2U?P324>9C/ W02CJ[D
MZ#-O57AVF'W!JC],#,*:<W EE9.0W(%/M:L22S2$<P6PZY^ESHW1^E@4PHG;
MF+WPV="K@\U-=[3TS3?"%]2EKZR75$W5;]Y<J)JE6,"+;G3!/G7@-?D[\WH=
MW\ B4\0%HXUAPU1#ARY M;W!-Z440"37#Q.U\F'5$FB-EZETT1ZLS93.[:!Q
MS Y*K>Z^CFOJ-;8VG)4*CH6\R 2N;*=&'**PV+!#*K[*=[\,A%RU4IO%>.7+
M_.X:4#D:'Y@TIIN"_-DM!Z3P))/X,WVNEF\)743LGLFQTL#,0ZHNI&GCPAM@
M?S(D8- PK7!"_4Y^I<B<-Y?J&)QJ*,2.S9/TZS/=;98:L<:!4M \56<\A$*_
M9Z_]=Q.;2T1)-S=685(_3+JY\6CBI-^35;\B3OINEVXGI:G\(OI\)6FW <[N
M]^FD&^U*Z8\+=U)Y @]F*-!6 -TE1+F\9Q '?*%;AW=7Z @(%%PHJ&5]8-X"
M9E3U$S5X@7Y<.//^>PX-"I3%\G80O73XEW"[%427^J/PT+_]0Y&*+OHZGL3P
MOL+3+_S%PUH)&AL\F3/8A_XK8%PXU;YR?:N;ZAHC&HN^(5H!W>^7!;,+7<<W
MLYJK8C&$W)W(,-?ZQE$LT\*@]8;%PF$'S);.@%1=6+HF/RN-TFUO]U=&7!L7
MD8KP+Y*YVQI^C; I<Y"SB(V!R/IA4<BBP -?7>NOE[\A;4;=U.=2.*P:#(M1
M'@^Y(KRK35C%^$&%\>^_9PW&"*O;[:CE;1 KP!"J8 ,!VC 76/P_*F@Z(>@$
MA:7M0B9$BVM 5+1B<HZP8EPIL:Z-'U,(';YTRU"XA8=4@66Q^1RA0V&I-U\B
MTENIZS(1 Z2@0&[VQ!SWP12K+T:>9<'/=CMK'GJW*?-05$M@5"M9,#*-F3P\
MG.5 .6UH., 8C!=4+8[L[#BWSD6W@TC6JLB?&(9%3. <7%T**TCB,BD\+8D(
MUX52UVV]:@+13C0<G;.Z&EO>Z=H:/SS'::S+%BG102^8CIQ*6'YN#9*T"*JB
MA.";J 0A0GXDMHB&?M4!\G:K%]:A#$%0M_*(9R4HB'Y<?=V((]H8S(W($3B^
M N9,,%&DBQ>/V&=FP%BUE&RZS!;9I6=K#U6V 3T4:2[ M4PE%NQ$L4A_1UP^
MDN#_R3RVN\RPCI+2"0H[-2\PI.(<N(]KT.NR%P8&="YNX%UH-9(!7;Z9Q 4<
M"<C.O/L19STE1YW38>6$4QCT4<,IP4N+C_#9U;*R3MDF52B;M15GK?6B(GB.
M1ETRX.LN^(J"JO-Q4/5F+!#2U&!N,6Z.OQO6X4!"[+>F>5M$/Y 4TS!?Q+$>
M$B>/YE,:XQI3.248R*5,$?H^P=HF>.(BA]G)PXZ#_J<TV2GO#MKR3M$!WO81
M\+X2/E,80Q9AW]<,#[1F!<E/_?ZI7U:=SWE8ET(#4MDJ$S@)!B]&"+-6@BC#
M'!A'^A)/Z1#D YFE(<A'G%YC&]@WQ2(UT&Y( &E9R:VZ(/PX!]ZYXS#.$RY7
M(;ER2/,JE!X+4RGU!K\%Z7(E%W3($EV]VROIPNE_NB:K/AX*#[^7Y1/BG='#
M#,%O]&RL%B[&H(@7ML2>6J\2Q0UA&@<:QDAO9BP]QI4X+!DM\1#;6%G6B!!G
MBP_A<?:4'(#XC@.(]-AT&XW2JY-N:$'>=CL#B[;;K.J8PZ; ZU'FU 8>NJ&Z
M09%.%&5H,+)A!<$EJY)J5'"&EH2E3%L=)57\N^:]=!#,E YU&SH7=,J"/2:4
MO- !&K4[&T<&%M]<$$8=<JIU(S-JC:Z,I$XC^I/I(S4VJPM>.F_QOMY]_+X2
M:-&X#27Q<7@H-C5&VHM3*2/8S&(X=Z0W)0$[>;[X(#I&S8FK:Y>K+8AT;)(9
M3L$D]4:E:HCS FL]NQEBCT%3^[KZDY:AZC%3C[NPA1L+OQP*KQ*=*/RN_J/D
M<D-AVE8^I:D8)*YLR]HML6@4VFAB.MQ"1&O$9Z527X9=;N(DL8O1:TS)=LFL
MU#&+3UL_6ME48-#^.KAZP%TZ]XKQZ67 9O4H'.A%#W+/:D!UV&TR A@Y4M>_
MB:G^#2+/JYDJ%8"-=FK=/?91QEC%:!BFG_/9M!S-R5..!WR*GV&&^668*M$6
M( XRY:S/)FYU]@3K \*L=(^J8=[,INB6BT&.!CM0.T8F55RIS6BCN:B@CC\I
MZBJ7J)JA7I*I  =7"(VY)MM8:Q@C/ 0))Q@HAQ/[;9:RK8 0_7)<<6P0)5 E
MC&)%(0[R($'&8,$A>B_(JTG*H0,MJBB8%P]GO'T<,'2E^#BC=R@.$_DAI^52
MCOS-E2._XLC?7#GR'ZP:%CFE6_:R= Q;S/4Q&<4BL,<$%5^QLJ$6.&U4.I96
M-MH.KL"X,JG3!F!^\6W5DFXGRLCR)E]\K# P\*@8*3H)?=1?QUG"%1OG%HRX
M<E09_4%!M5KOJOFE$ED-\7Y*HLHJ6O\4+<9PSN>&EL'N2<-U1T97\+[KWZ.J
M='0J>.,/A*I$J$[@$!9Z'"(T-!>2=J#IU?FI"_7AV355Q0ACQIJ&?7BE@)L5
M#K]IKL<>CD #3RN7!$',*VII5S>K);90)])T*AE)&,=4%+*L%9NLTY5F=DG%
M'C(F$Q<[5F<EOJYJ;1))#78N&K)E_#2*$U:IG3JECKD6D',@D<;?!E1$SDS8
M\R'6-'-HV&DF6]!,M)Y ;:B26\"G/'JEZ'#&+3@L[9K;J+Q8DX2/.R)4[- E
MB>/$]]Y&DZ-GV_(+YY@=N)"^KE;)]0?X);4+<,7F7,@6%ZPA):'>W! 1[>@G
M Z_.3 M<Z\ (<[J.TN:UOLP5@?R-:7@-J<*[U.$U*F:);JO <5D%[-(+0&Q&
MESK]@74?EH(C"FAHPE5 \3FGA<#O@?<RD)<IMH%ZG39*'0%7I4>%&GK&:]:3
MK:LR4@B%W)=^?<:: ZX7?.7:W+8R;TW14+61E3=$6Y><=U,H/53K@ZK0!&B#
M+"7(OT0F!ZV64ZD4G=G4$>-[:YD1BH_:E]2/"#U:#-H*=?V9SVU=E47E7^'5
M+ 2/\8JMC6E]6>.W5:V;;,T 2VNX3OC%AZ53ZM*>YNQ05F<$E6J[S2E\'!91
M^&_GCBK.X)&MHZ[)<4 ^;@S>[G&U5J::$6YU7Q@0'Q42-UR1#=E/RXEU!0DO
MJK$'XBQT_6Q</IMK:01\1G(59'6%*2#98"H:Z^JN5*(T!H$7&O=%X(L\%HI*
M2JF((QQYV8B5$OZY62[:WT]A6V=IU;=BG"7?0B<-'*?,&U+JV"%-BV!IZ@8M
M_0;^]M^O=UZ\[798O%F;?:V@4]504B'N6]NU4JA6>YP3O !C:];5]-J&RT/T
MJM[^[%%)M30FW0+? W*D=$QI+M&5L/E0M;.F0 O62-YO+<ZKP@U,HY#+'OC1
MLFX' U:ZA+N==.-1%:ACX;JWC$QZ9')A*5?#ULK54'$U;*U<#0^6I76MF",6
M=63 N3=O6A/FR"2B* IF<CLEDH:@?.LZ21R#CVU)4"-1<P'FM5].Q>V6,C;8
MRB0/+_!U149GJ>>0 "&6P[Q 2\4N=.(_%I,T/Q@)6LMK;BHOCT*.S0)L4 ]8
MNBE<#>(_4_'?RF!5:=S)%,=!$E=6#YB%[1(Y&AKV5T8O"8:1XTK\A8+BM!ZD
MV%?I36>6"IKCT4SG<+68?4S.!E8B4YW'8$+>GH]\T60"Z[S! H-N^KGR.Z%?
MNG "3!2%0S:S[?)%TOK-W:%4#&!6+#*+TC0K[,NL#'[.X&C%D\VCK)TUC9CX
M0VE CGWD#UB7-G;7F3Q9JG_T'Y6%OPJ4L]# .RHBHY)#5$J9DQ+"08.J4XNS
MSHB_G=PEY9MRKL-HRT$Z'BRV$6P-YUN9SFYT'@PH@9>Q#6#4& X5)9G #/(L
MC4=LUXQI&'DVN^2-NB\I!P'A62YRD&*^GT(%.@H,<\3%E53YF7Q#Q;KE,(=%
M6>J!\?M0",.X[71FV#2<ZV#.6-H,WT7#<!CKMI%0,DTUT,BI8'4Z5$I$4<Y%
MW1KT11;J:E2%+DUGK-I3V @^3J34<L:-E'8[)K=B!L-D7P';*_ATDP(HUD(W
MW\YYXB/WX6;-"#9JO'2XB$/\(4EMZ$:BSV-M9Z,'O\R+RG6EYALH@9O@1I7Z
MTJ@I$&DV0D,<F49 Q$?/2U: -=?MH.X<TD3=FV,^D5'Y&L5XP2G[@A)U#,*#
M-G)["-J).L=.R5%E!:#.CF*->&A"6"X<*S8#,R(6^YP[V70ZI=B^]12&GV$V
M<\0/Z_'PV*^S4A<XU,/'&HOA=9:;;$?3J[?-=7TT]$MIN@-)&=Q+\1"#?#6P
M!"5'9RS7ISD*3C8>Q*%_2$699/-9F<Q-_ >+5"[NK6EGC$AB-XZ-:JXI1A26
M#TM;;A!3S-AQ GL:3E&D%<LXODVG%9'&[8*9ID.5$:GH-/BB3H/*#>:J2<FV
MG+U_YJ2)/QZ[ZQ7V?*4+&K)32OE+G)*&(^^'6O*)#T:G4A[BPD_:A_=0HJD$
M;?%\?7/MLM><[80\:C+NY[IWV"-<)2]&ZP9%PB0K2LHP)OV3$X8YBPTD/9_.
MSN'K)^ Z^2F^PX-\+?DH5IY=KE0H]4V&$,OU@2BSS5:%H;GR@,-")],T"=.B
M'LEKJ3.(WA/59U$;6:6O;L<,CTEC[R)BGZP65YH L8D>9.7>P.NX[G2]H0Q@
M)K#'.+?2N4-166^]6[]^-=8%6++* 785.@$K3H3-J=WQK$#_B'.E@AX)[)-4
M[0R-&:67J&B+=^M"T.5G_9PTKJ-6MZ]RJMT2P#7N9QR]]MPK!YQ[PYA.E,JN
MJ&P)5:=3"R>7\-E47<=2MZ3HPD,>3QLOE)190'*YX%CG!!0R%6O6(1M@0)@'
M)6"'99&AI'8S92B(8MU7@8DA^MHM,U2)2CUG'%J6(GN5_N2UIK]AW@$EI5_&
MU[H>K5I[N^Y-5V/"$7G=V/G:LGLH(%FYU],0(.7K]".Z-^20)O!#@AQX14I?
M2I,3N&2,D#S)<QT0YD 23(JDFM$[<91Z'N@#MQ,)%NS$6Z?( G5AUH )[:N5
ME.Z,S,YQIF3&WDYX58W4N]#O+.Z:(W&Q,W.OKT?C;>1X$/FVN<R-_M;2_NM#
MYIB,EYW A6PIGEUXHCYPY&)@^%5%4R4IB[$2VPYJP=P?DP[A^V+>3J!VV;YI
MW9IW?N%<*KDK'4RI:QTFR65$(M0/\[L%I4U&B!Z+W3"N* G4.7B/&P;'BC63
M'9+7YHM+XB3(SWV%PFB]Y)@AV4$<BX8(6F]$!RO:E/$U!08HP?*@9Y6]I4Y5
M'+[.5S"9+8J*P"A)F'J/K OGNN:25Q$][2J7U13AH'(O,7 N).JK1,Z=Q$!%
MFRD#5NE59$#A/2?BT\4WG>@*Q*TQ^!OFEY9+3;Q&#=._(6>4'E,M7:%ZW!<N
MR][Q'J4ZHZU5WAR!<?.HM9F!"^K'$L>6E;B%12G5*A''S<<>:ZR-17*Z(A$\
M$]CR()9E9SO08TN_.K3SFW\9*6MV;OD\V9B]X:7"!%K!_)QF-Z#Z7<H*(P?
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MT;EZ2\-7W)]@AE0QP7V12UUK:$I[E/*AH06L9/0YRR_2>(Q])SU$-?$I4@*
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M2[DV754_LB^G14HUH'(VI]%%:$!#N+RD>WJ":4_-M0Q/GB4GB22>DW[5/DE
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M2;Y?2(N\:875OS.7L2U?W)5%N8SE]&,;:W?DT'@]"/8&'V#4Z'_7US<P)V>
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M$1*I91&XC3@PT0!WHM^CW1X<'+S?W::E\&:IW[T??#I:J[$1CE,;'O;\(PU
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MFL2HF"&,HPVT(>+I:F"Z#ZJUANQF-G[[F;:GC82,$]+N5OZ\?7; W;CD:;9
M#SDH5+3!4SQD?D&#A9<U*_D0%9]C@N0H8E336/AMI7F.DO,T>+]VL!:L.,^]
M_<;+67#%MN8Z= 2Q#N9:$[R_QNJ6]\:,D+(,KS08CV!:M0/0N!<EQD"_5HD8
ML/E6P13?JO>DBR.-4@%P^9)UK5Y]A' I28N\N98D:3C3VDG=I-F"A_^*8/AR
M\M6/:6?-S!TECWT7=_%2==#7NE"W_N*%JO-DM##SG*6E6$42<"0Y_@HY[6'/
MO\:>__,&]KQ335>0Y=+.D,09)1-V^2THIC'"$ ,94+;K!&<)-1Z>&*QL$P-
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M20J4E6?1 #W4XT'F2CJ+SCG!7K,CQVL?=!8-'@RS]'M&W+ )\?KM_MZQ-?W
M=L46@=GXT2A/\^(E<D\5__3F6&W_ZU_P)V]L<Y>$'4GD*B)$=\EM9)^=%6YT
M54EK5TFI-EJ,8&VCP5EBT5+K+=]YFUL'-HFV2]MB+IJ*,>1+0'L&%;,@PJ?U
MW3+CA(&<Y(4W>& N<,\6JVM^3G6+5D/5C=%>ZK9;#F4O4%#D7(EH@Y7M:*P
MZ?[BA5-+.+;GF2Z<3RH\U;'5+3G>GAL2$U3<?)Q#@3J+O'JI,3=*YSL>&_1
ME" )ZF(.^M#YSVHZK&LEBP< Y;GQ%JH'G5/MJG"S+<0W[D5R_J'F]R!5-"*J
MY1@3QV+)<MS0!WE_T-^*'F4PTO//9;V&H1X3\VH8#(]Z-H=)Q03; PY&"@QC
M&$4\(?ZCCO$FFM_+-=??L,%QM4=M<G^]CMA()%&5&>2EE0BL4;D%QM[A\U1!
MNU(!@T 7LHG)F&""E12>J*-<)>,UKE_%JO46*H ,W=/L3>8OWJ^?]HM>C 'K
M_P)O"?33\-=8*<9$,?)TXF/42%)9=$*AX)A!$NOT=SW"#<+HR65;)-+#43"D
M,H&:5@1%W66:O$Z8ZLNQ)TEJ"W%ME,HRJK!"RW?R&ZWS04!HP#?G4#J,N0&=
MS6 T<&_D%$R<W=/M$V@IM?;NTH8]3T/7OK5:4 WEDWOD8@V9.9:-3"L5R/%D
MBTM!,BF8GIEI.B)+FV,5L:<?UMH?G&"50OGYDEU#!- %:X*S>6J[TJ.NE,96
M!\8\BJE 1B,.RZ-\\H@>*!3)Z>86KVLS?H?) V02-1M%',YAI(TG3YIN8_D)
M6Z3.>47'SRO<=BZ).G9P7M@O8X,PH3>PK9\NJ5B7735EUONU]JMA* O$/C"5
M9 ]G5.<6'\:^;NZIO>Y"-P)2OF8@.FO:Y82_+0/Q_>,RG C0@/(++,)60X4+
MFP X#IR92DD-EKF^:>KZ6A/#C-'04'.'"\760>'Z#*((,.]Y I1F%#A\VMT0
MZ%@K\'0@HI]EZ-KL)D81%96^EL^3//7TE)I,D)]IQW!='H ,"(W:JE31G/(8
M2BVI2)?&#)5XW"F%'MA^N?#P\Q\^//SB(3S\?<;KGOKQN@])B=Y1SIEY"-35
M W6<#C2Z5!4SXSS%LF<.,9MJ0[9YZOE0Z!>"SSYF%+<XJJC?^@[]'FQ79[<2
M_(E\KFU6]H"8F5@?(M'L:SFJ,QUZP'!&-: _B#7RV/TBT C\EHEVHFAT4[H)
MU)BJHMHBBW48B$/C(CH4E[+.=%+%1QIBQ_M- UPG9&Q#N1B]@#^W590M$[]3
M#:554Z;92\_3^[T7-DLJ).N1-.#RS)'G$]+M"(S4&);Q'_F\0+3.E;T_@IB5
M6IN)#DN/SRDIK(4*#X=/>YQSVZ8.*'[DDL[A1&$? 9/[ ;<3-DJI*F[:C3NR
M'95G1O'4>7AYS#G!DK*G+0GA),$X-BGPMDL+^33YN!1V39%.A:]'EKTTZUIC
M,_QQ:X3^\<IX%4S(4+D:O6P]:J[A_V1S+?BDX^L"V&B3C#$BZM[18)35-=#,
MH1!CXBQ%J,RBS?E3Y\5E"3Q>&:U*(W4S-F7>2F2SO6F@O"9IT?YGYZL2C*-S
MGN62Y<AR29-71>%(H<V G#1Q29S@P2/4[/J'8Z9=L._S$M-UP4*;@.3;B:U'
M#W?U V)061M$)_1X_KM1#KOD3#4RHH@;9G6_'WGM3/9 !\H![:=K'I+B O%?
MN+ZQO[ZIMSX?>K)PQ2J@$A<5)W<;^ J'#^ ?!1L0Y^)4&%7-ST%QNX*00(B
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MC"AXZQ;[X'YK.%O2IYP%!\$-"0>S5E]OLHV5(ZXJV>2J=N51+]5"3D%E^/7
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MCE).LQ04I30B(:M ERQ7N#"%*U07SJ'D2Z>IRETQBR7C Y'K>$$V*,4#F;2
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MB+9Q5ZWU$!9NNZ"TWYLOE,#W+7O+OD+L8_'^/UZ%VX6)*4"/6!%-07@JPD6
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MP41-6R%6$W)/14+1LMO<\*9=:+\$5MW:!5HI)/+]5Q_]^$:)Y+_88SOPHN>
MK?[0<5M@\$:6K@EXDRE,7%C4CY"<<^-"<4LP#/\B0T]E.DPYAZELII16VMQ
M+<*-G.'WWCHJ)06>5GM1KW+?EPQ9>F8-3CU'7W#*UCO.9!KI03N4]@1=/);[
M=]3!"/1D/FZ$H9^LZNZ(!AHAN&JG<\PIL.7)XGB@FR7/8EGLS?.681XUR^2$
MKWMFIPT8Y*3<TZ<ELJ6=\J)!6*2\*H=82_7/K;W[^[ULZ^^]_X8_;.WUL ,K
M8.H_)^5P^WB5CP.E_/3]Y?N.MVLA0%:H,'CTX^J/<UN6M2$GH_RB',]_7KP
M]W;_MC+RI7L"$%91S^1GB@FY@_?'GWNOQ(8T/B'T/RJ&I9,-8V@)Y4[S, [8
M+ ^?E&SNI_U'H#5T^N;<A]_ AO=>I>7L\K&0O"?2#6,MPWQ.S9]$M@0OX:X]
MQ+P^>A3[3,0?:*#RLL#6=.Z#+#N<%)V-\QI"1OB5\\H-(.(C"I"]GKEU^WYG
M9^L4 R2O\:LX@Q>_'X,HO9B-S]#(%XO4B<S"_<O)C:C9*<(=<+'-7/L4W&,M
M45U:)T9D:5$B)]?6^]L_#K ;<QIFOQQRH,ZC"$S_Z0GKDG(R*"_=R\I,?L_K
MMTX/YAC4KJ3)]/ZXJD#&GF7/MU]M9UO>J-:_A%@2#7B(XO0+HK4[=%S,@GW,
M4=>S-YRA>EWEK+0.'G82LV$7B>EP9!>_;6 H;O.UR3,'M()/^NC]8%R1J_LA
M\^HMOT(PE3(A;ZXE25H1C/12M]=LP8<_1C!\^/+%U[2S&NMS; 9T1UK[YO7Q
M_AWKXS82*1'@:CAXP%DB5 ._P$%='YD[.#)_[V5_^]@M[W0'T(K1IO#H$8$P
M1#1G$:1X;<//--^JX7*V'V;!J4][!^YAZ &!Z^,_X)S$<Q1R$.MN9ZZV;^T4
M,HGMH^T5B7[O/\((S>?A]J_6V?59(D!<%]*_51A3$ZO.'50AQ0+?Z8R!IPZ'
M*+)'3I%M_229Z@"ZMC?@'JU)?DUDGF;U+0$#-]V!^TP^@. !8)OC9J:0[@)=
MIY[YMFV68=(/D-!UTR=3'DQL& W)RJN&.DMK/ 0-<'>XCP,*X>(]9 O$.B^H
MJZVF B&=$#6\KIT)CJVF:S6^FZ^RU^J'S<%;TF*P&TMZ<P,%AV\##>:9]/<%
M?6;:X'*_6VI^R*?#IUP&8^BWR#(0MPC*/\#8*A/N0=E0!&A<HF($-#B$3R@7
MDD?. LWGU$W_LM/?D# 4N@/NUOR_&;#_ >B:_S IX I,C><#K]J+'*7-#?9/
M@A3JXJEG//-.EV;K%'-X+6\ 0>0__?QH)\O;"/C-#8+ NWOP^.>=A]T@>7=E
MMB1! FO]\N3@_^[#M. ??V\[U79-KZKQ[ *4",",X!6<AH:PKUUGS F'"XUB
M#0WY%58WFD\0PW!3'W0>$$;DRTIO;OBEQMWF]TD, 5[6B%ZBT9,1/#XG)-/$
M[YC[$TBQ5^7D;?;RTOV%#P*\89XAI"@'\,A9/F%$!$[(K=9D,"?<$CO4%2*9
M1K/)8"J92AH%_DJ3ZM'R7U3-%,.,3L+YXQUDI%HS;RJ=,T9LMX:\]Z6;$*(:
M4-\#]J!A/J>\K$&0P-M0Q0":"6D(/D8W[)5W9@-(E,L"Q0KL79V7"%'&OA6D
MY\ZJ"I!7H)Z@HP6,*O#IFJV2B_Q?50V'%H+(D&8IO!0QJ@LWQ2;U83,I">P.
MC.:2L;%$ /C@=P7- U\IWKL9-XAS&_%-UB#O)3"@LS03O,-:4:R4H/OAJT_0
M?:.-G[[88^OM&PA+?9FFS3 OG6A;11FWC9Z5=3$B?FU,^,XLG<V-9+'?75@Z
MFQLWM+H?:^F@TDPL]:>V=#8W4J9.]@DLG<C*V=SH,G.RN[!R-C=B,R>[$RN'
MC*N6F9.MK9S5YA"!-9S)O R>+%(SJGGH=X#+\IE3[OF4L<H>'GQ5)N) FJ'
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M"[L&PSI8<6$Y6>L10X;O5P6?@T&D1%ZS<4Z.SB[<?X$OON2 AC,_+DZ=TBS
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ML$R'FL5""83IN+K@]7+3;E_2A# )=2*LP7)YSHVJ)1+5(<@@)Q=,T,>9Z#+
M/F3#LAG418JS638.>](UC<:*%[7VXEPCE[0FS(8/7=GL1A>63+L/7MEH?A@T
MPX(-3L,&;="7V!-L9K;A!FAE3BJ;$G1/!#C4:,X*!/$7:-D-W%+D@[E&+L-E
MQL!C\%"W#*=N+:;S(.+6L"JR+;^04*8N4&@$ L ;<4LM)AL7;-_3<H)9+U$M
MJ "\&6!+03HM%0^0#]DD-,% 4='QG" M5*,,-9)0/0M8G\N96^4!2!GH^]QG
M&0Q) \Z-!6>K%Z"B*)T7K+=F6<CN!63 #(.T((0*MX*H*PB+9.Z.TGVTM0B2
M9]Z4&LF\%NGH!K;H\&'!\VV<OM8U6W+XR,"^\=.77?/P 4'/;9V^+'GXGJY@
ML903W89V%[?E[]7WCB]%PL?SZRV/X# P>3SR/'Q<C]_*65OZ'2K!<BN"5L$$
MTGK$M,-F@$J> T5%]:F6C"M<*!?2!_P.I/MQD>79M-;NL=7,'20,W8?;AA7Z
M![TL_%Z$=FA_9=K&,T)5&>9NP02ET[K4OS%K*O;L&TGLRAP@9%#CHK3J/A)Y
M5]LW+ZA3E#L,SQHS\S]5B::,PI6002%GD+S ,XK4^6:3IGO="E<L)2$[8B)X
M M*^"4R[RU_J8Q*&NQB$09N6Z[>:S]>4;*$24#.W]$>8OEMPB5 +ATZOH3.C
MD):!,"Z6?R8*XA?RGX^W?_KINY_<__SW7V4I$KNK^-WD\0S01POV(TBK?DBL
MP> 73HQ]BI]-0LO[* "X4K<@N!O_>Q6-D6CA& G7L!YOE6>6$VR/A5E5@6+"
M^B]:_FS1ZKL3>V/+OSC"<UZ,4Z$G<J=EI;SE&'A53(=3@9_)>&CG9\VWL[V)
MV2#V1Y:MH28(3@M#X^*[Z'[_X-?C-Z]VF^FOW\'_.V<CK)L6H%J[J:RRC^$!
M6]3"TSC][N_3>L8=/4K )EY0^W-,B'-:0D.[<)>H#M-]JW3; ](7TJ;3>1>C
M?K"2"%.L:]S8<$9;[#N+LT+IBUY<:,OKA=9;"9&E!BA7)(*')P4B(G"JEVT$
M!W"\1TVE&Q? HT[V**&89I>\*$TV*2#&"A71>!N;LE94H%MNI_#'U)$TCF][
M!Y[VQG+;M#WZ>)OPL%'\RK=M]S0<4<G?[?%A47[CSGGHKCF)5?+.CW:^^KSS
M]]]PWOD##^Z-'M_KG-@WN]I[ M-_/O]<U" K-C?V%%_8, W>M\XWF?O^H9P%
M."P18CVD(,*Q\[G3M8O]S);P.7TS+EIQ,F.R4#O 2R3SH=0^]9XL)L,@"XJ*
M!&)T$)STIC4H#O-S@TVNU* !LSRTE6J3Y6!8=J7_,G48QBM@L'I63JP1'#QV
M"]4J4S9?5>50;*MA-3N=]DV:6+)M,(NX=HV0<Y$3N= ,@\(D3"(ULU-:M6:E
M\,2$LC> G:Q;1F:?&;T&U<4IM%*WS=R@>$GZJH,_5?"6-7 <>BLY;CQX<P%U
M^ZG1L6?;58_6 XGRG($SAL[LR$K H=>.I[.#*P[3(+\L 4)'LXR+!M U#<*T
M%#X+@, >>!I@AO, +.U!TNY]BCJ?5IX7;$4??XLRGNAL@@4\J^>Z)%+;U>5H
M<7$B@:W1G0@BUI2]F%08?8."PX!\Y#K1AX1[YP?UV8'6(].^7#NR[,&RSOXC
MTY7'DEYDU#]7/*Q.FI/T@RGMZ[P#,DB'Y')X=/GF!J*+0P20,;JA=Y'.$2G<
MO,O17AE*-".IVU"87)*))(-H\DR$: 9++U^*H!JY& A!'TQ=<5;^[SBQ%@\,
MBY.&4A$D")10.[Z-:VVY>VJTY>RT06MP*@7^V4NWV@"0;3IKI_T)3-?JX[G#
MS(#TWE8%:W7%&3++]$5R5D@#/FZ(0RFXTB:ECUM*$[75&PT%?-\Q74T_B),)
M@IZ\M"FBBJ%C6RZN,Q][.=,$4' G"0[.(ADX#:)8PE*>>:8$K<@EX6W"#Q@(
MB&I1\@%CM;4,!IUIMR!MFKQHL'XD7Z(_M\MB!K[XD8<=1E6)4 :)<1,O(JG6
MJT.5X5.\U,1$AQ,=W4&9+4%UP)SKH9PNZQY;8X)B OW,U!:G8"$K1&%Z*6VD
M<<Y*.C7D<BZ L->9<Q,5B6<45S7-V.M,R'/3NU,AF0#$S_#OT8/[?G0;94T?
MS:[UKRD4$<:8$S/&8.*BV69;*]99)%)1J7RY+TT43CT2XFC\M,=G8)1[1V?!
MB+#G,TEA1TD&+4M+QY=.+ F)O]DRL'!JJ6EY2@-\W2UD64A :F15N_8)O0)^
MN_0.1$/U?-7-XBFI.8+7%E;XM)BC;2_'@)?1,BR"6,:S66 Q.W#W3;6<E"M1
M:$<(<_.QNW+3=/M?H@(>> 7\JJZ<Y@5==&@=0]*]AS-/'$.D@A'99.B<]F.F
M<3H00[" :J;9YC:1+:<U,-%0SL,Q</JO ($0*%W6%^8#&-I=*J+Z@3\VG=5H
M38K/$WC/!ON7EO+T#M:S'C%G:R.><XRPZ7O]#W^]) WCIY3KHKB'7$*R<>2T
M36P^HH$I3,G.\8%].,, <1^17U0N9GYMIL*518:LI!>D]H<:LVC%"0P@1_,X
M8&;U0BX0>X9"^\,:8=ZR#IGA;<X01*<'!3&4+D4EC3QTRT2IG9>H#2BDZM =
MEIK!/(Y!']#T)6FIK.BZWK:E0K27@:F2!+!^O*4R6F2IL'RW2_^)[) L-D.(
MRPFS;;J;G%%L'X\;M3ZRE/&!A+YJ?02#WYKMD25-#TH>K7!A8LN#I]9E@/BX
M4L+^R%KFQV$@^U/6!^Z=1Q*VY[C<]J"Y1KT]./69L$2<E;0V16Y_#BLER!Y\
M]0FR'[[I!-F7=VR'WH)^.IL,\PNL/=_<./&VE61[KIGAZ5/_!AMXM]A'H BB
MG] ZLA!(A'>#D>+GX'P]"EXV5.=98 J#L*=XY#6H:LUV1#/@6&AHV)*T%M;5
M=W &$H(K1L^ >IGW?:\)W_>(4TH0]RN=75'/>]WO9Z<. 8-^-B[0!AR7 V"+
M &]1* SZ2@C0)_0:"7_K7FAK>DA((0\%A.-/8>&G5$'#Y!2,@.,%PDZ8Z(9$
MR^27/W=F?LV0N-0N2([([*9]5ZJB9?:J$;["5-BF1[1?A8"4Z3=; OEO8RC#
M_4)&<C$P0^HALJV,016!3NM"^CB170W!43\Q,R4W7*FT2*.DYX.T-)6)@,(Q
MT@8LU ?1)_-X3N@%/MGYJQYP7G^;8+FJIE2)Y,>2A-CM7*&6/^9^$_?0=)\A
MIU)_E\*AT46 O9F-FTK25WY96WN5@!)"$84D)Y B3FK=\.J:31JNNC%;X&\!
M<MD[=4; 99%\BQ@?.7),IJT$]KNK@]OF:8HC%U,ZIK])R"<:,>F!-PA9RB"!
M%I+ZA81OAC*W @Q^75CVFHY7[R<9#;7REYTM[-V5=-?@V 7(M"K-.N43URNF
M'D<LB 6G!8<,O4T,5UO&D:J.Q!E:ON64N\,986Z^Y<N4)263(S+1B?*"GQOE
M)/;&SG*"I*0;QGS,GAU8)MACW*^4=]"Q"916MDBT%5;(\T(N*$8*<:%Z1A9.
M9JF+?NT]W][<B(L4U&<,*<):&=)%>7EH>ENY=XH2Q0(KU1?5G0/PAMUA;?Z,
M&1\E#NS8:7\50[(HD+I)6C!U0;ON7E>QEYL^.XB)UW?S9)^L<YX3/'G<G+<0
M\"D77HA'1R5T3DAA\V%BW,50(*AE$'8@S]V[3;RYT#$@ H%:VM<$,0#*R:#_
M\PK?04N"8PF."2 5X13]T#8D^&*=@BP=)CB5X350UII#QVNYNS.5L1NO#CI#
M6[Z)V*)-;_?DT8:^OF*!._F67/]&R X,K"YZ^]!V LM4A.<16K$)LH*H=4C<
M)?22GAT(%.L"N*F2H@%[!%X*;1;MY5:B&GZTT\N&VLBPKS;I[.(BN.:=\H@C
M;6#/U#ZNIH7RJ1J>JM73J^/IO;[M-V)W$SK F],$G2[S>;L4!OBSO>A (T2I
M!S%P@J[Y\0#8 QOR_5/[4$7T!$'Y?U?A:14TA"*C*E[916?QEVQ5&KC%.\2>
M$^U[0/.N1PD/=36V@5QL_(9-G%K@-_W:?I539\1#M'.KNDF86M4$([I!Z%SP
M,[*-GOFVZW*H?)C.+]&,!CP^[FEH%7!AE'[< Y9Z>H]2FUXQ5_0*&TO+#LM*
M%?WH*7%I 9()\MGJDKEM[R[!H^UT<I<L\578^31Z?5\OKLL3YHK8$U#<T%0B
M^&BNR'/MW"-(I5<8>)Q)6,<[2DHP9\&-OZZX6&(0Z\(4AWC7A4@3(XYF-<S;
MWPBX$"LNOA2LRAZ">H,MI'6*IAI?UB *TZ<_=XTK,!A?=(\NB"K/ 7TX $2V
M-019E/'O 1XW%]B@=G!82=_UEEE!V[9ZK7UO;,4:MNHC^7+E[Y0E:[$&'3[L
MOCSL)?DW8$-A![YJ6(P]W[U*>Y[+RS]D3"$OA*?NCZL*K/*S("&3JWTTI/1G
M2KDMUT3$/,+34U.9BG_5<(-ZV1S8PM_>']4%%>G44/19HT;$FB#@T1@:1?5F
M^WC;#<3(TEH B3D7UH;J"M7Z:3%]5Q3M%IG7UK3!^=6 VXDQ\:G+##+K3Y Z
M%2N#KRJP3<<,S?:S>["S@XML_M[>PM_^.$GOVN;&EL'SS. !_R96^$??/\'G
M4GFQQ#J@&455]S*_P;8%IW6L_%58>9D6B%\H-X8/8TD^-6 @LOA+X>RFEI=R
ML2PQ2P#P/7.;/BU\)UUTAB]T-^&9FQO^H:&RT=:MTK_B<CPCAUKO'DB!236Y
MCU9/(,Q,UXOXH8MD 3E$&FL]+\_.X7!C&]<A(3A0]8# WWK2@^ 6[@>:EYW1
MD.N81$3/=-@C9)$88QP<P<MQB]>E-1%4T_%UH2D>@2#X=U%#(2 5?9^ZRU^]
MXZ+%L"EDRAX1?8' 9\!N8+M?*5D'U(I%$ OA_>:&NUI#PK'@.E(@+MC\GNWF
M/+8G$#=N?]9 =4%#39J#@)/:?<()G@7G01;7;JBZ 9WJY:3E7U/+(0Y!L**C
M0/]"%Q/KX36-'Z8-2"M1J G"MF'L*-:G-FB$\8K&O4]AZ^U-_-YVP8B,"R+M
M"&E^1,K2QMCI'U:#&4&-5^J6% '@A[TPCLOL ]AK59^*1B$VF^1TQ*#PD8BY
M[_%3^?[NIH@X]@:B**1[71/5</H;&DZO%-.B50E]W53 LZN1)=$"4C";DO#&
MZ,@EB#'O-*ND207Q3.>Z>"46#>--#=,W G R2YKY%97J!$^<72+Y8T"31#H^
MM @,TX*/*K9*97 EVZ8ALQU<YA@=HOO2LZ53$M)9BA4BHT8BI<E^$]>&#"T,
M0*YV2C@>QPQ1_FFD?!D?1,1@X7#T <^B(^-TK?$6L!U.\[=85X.927<99Q-I
MWTIQN<T-8^-VKJJ]DDOU6J"\%\VP;VDI(JAZ^"J*IXT6@]2^8I7(G(6ONQL^
M-5'(PLGRZL)IR;1!;W00$.M\H%+GEFEZ3;HDTH+;)J)@>W-#"5C"+(M&M!>&
MZ%K7BC02ZB'TVFBJIP5-H)P".SVNXU93D>])#C#(6(\^%,VX? ()&6\[4BW3
M',X7*>K:>!>LY#1PPUW5I>QJA-*SF1:Y1BWB)>#= 0]3#U&!'/"4.L.H1_6N
MB-,\IOJ)]6=:::J%T*TU5WIU59,$MV3.X 8LW;3$!# EYO"@]0$YBG8:!,!<
M Z=6 TX]_.J!4S^N@5-?U+$M/'#JP'O@5&^PN;&'?H;_M94Z:E1'S6VTW5".
M,9T!8][M[QY\]V!G!S!-OD]3JS; <)])X&XQ2USV:,6L?$#HR67K6'!L<"P4
M+<DYAHN*R:/;HQ#$C=1&I^>QEJN[HYYI/S;%8(_;.;)C;H'MXDOL2F%Z4NR9
M8G"W3&'6G1"0?YX7D^**3:XH+>]NDR(0PH;"<V]S=5V\J+>/,_ NIV#QIKW1
M4^@N/$ 7$1-5$*8:0]<E8K0*> 934S7E^Z:_FN!A"+*"-SE<D?#"QGV@P!8+
M!LZSTQI:%&(C5!N, FM;&)TU>^#'6I_*7=LJQ=S</0@R^\UTQ\#<983G"B2W
MZ$;DAH2;4M'6F)HMI1!+5;-A",QM*)Q*\)44_--5J :A_8X!,6SLR^<FA#^M
MBR$T5S6QF8Y';VY(H%P=@MGTO*K+?[-_CI6Z[*H@),]GSA9XU%R=!^E*+H$G
MW_H4VC">4ERE\IUFJ;Y]030%$WU4_E[+SS77,F\=]B0<[$1$/E8_TO)"Q-E<
MPX;>SFY"W+K3_P,O\FCADEU5XYG[7LWH4O^C.P7./N;2IW'IQA? -> ]2///
M+C6\/1KE9=WRO.):.%\&EXK/2NF3D/.EQ5X41:26DFZYI_[#GD!:9>5P6$,$
M&NMB/.C*V5B>,$!NT.OB#*CQVB!#Z/1:P$ /=\#2<V?8?1TS$4&@PJ9\N/0+
MYA$2<9 OR(*9.L!BUVF5Z1#I@OS?>QL)3Y;7$]EZ4&1OPB\@;)U>T?+,85#3
MYN]>/W$/\ "!U66&0\2\'W)!V5OR]K7)31%WCD^GQUI01T"&$LZ]63;Y9#4=
MW@AJ@0[\D'9-I:@O@D@'U09]+D/H,Z;?9T\DI:918PS.<G839Q'1M4 A S2Z
M,IC UBJ6T_ Q$ Q:3:;Y156'PZYK$O_>WAKLV9= 7$>4('QC(]#RAR\E2U>=
MY2\)PE73XUB;&QN23U9H1'L)7\#25U_\IUT'IX16,26&^4B^@P'9<FCB_+Y\
MF8-%49L*O<F^3R?.9SM+-*B@9"I.5]]/F"Q%%B'+*,8$H;LJ%;] ^KL!CEMW
MJ,M\C'UM[G/JT=*94_1<XJX1&DH3%US+HKTO0L'LY*FS#?-)4<T:2'NC<+4+
MG>#B#JWA[(#P@DZL(H6W^SMV[/SQ_G\E&HTS;5-X5MG\"1:&DL.4A&-8 ^!=
MB@FB*4*<7' RI/0U%,>\'-SVU F3L\*;JOS-0OO*@(MMNR)O;K@["OH%XLO:
M<V8=[N,YG'FW] ^Q+RP38[8_EV-'ENUQV$(CW= @0FC\GM=OBVEXAF&?+'K5
M( I (3"$TL+PHN8=I-<E>0>7T;@UDD%TUW_&9-]@[60,D(V=,"& (N@HO(UT
MO:'S2[833I."+@;M+OG14T%'#@4=&1DI-W[:[I*X]L.8/Q^'S)_"R8_+R_N\
M9OZ,F3]EE;@Q!X<TS3V,>F_04?:8%D,9-L[?-9I>T:;)43,NW2Q &; *QN_(
MO3,Y*]_[Y(FJK5=[V9X3'4,NGXPS.ZA*R"+T2=I5FJ+5:/LS/I.>T"-#4A=H
M7/39*Z[(+7'_!AJ"OM@^W,ZZG6V;BDR9 &,!^'XC)3 ,%#1X-$"2?3:A$LXS
M>LNPHY&()4@S:3/L%JXX1!E8)&^J9?:^;9F]O]L/>V:GFR'@[-!J<T^LZDE!
M>3I"#87-L+&'==3_VM"NJB=V09ERT=R^.C;J!&[ (0*XP//"/JZWVV!_YO)8
MMDZI=P9:8HQU56..WU,VCKIY&&I4=W# 4L3#PSE<M,5QP\ J/9OE\,V"JVSD
MYXI2HV#/E>IW0!S1\UC@0!#I;S\+;L59G5^T4#/'_O+Y#B3.>Q^47*T#"6PV
MV_SQS,&C*D?ZU@P!8"!9RACD<X#;*T:W<UB=@-+ZA%K^V:3:V--!+8CT37YH
MJ+^ZRI*^="(A.YVY3#GR8']N$N:VP=? PIL2:Y\[)B(WDC1R>:KX3?@\*<*S
MHR #CD%3R;L,A1>U14<J$5YJ%^C.Z7@,G*1191#2-U)I$'LLK0JA:6PQ,RN*
M=40NS^<-M.4%:U2W.^RL%+0]R&:3,01'_+,W-Z# 6=XJ0FA,W-T>8V$'G^ T
MN=&*8RMR$-#-6X]Z%G+KXTFAJVZ&XG,(&L=L-TFX:"3Z<]SB1=Z'G!&5F^7(
M-R:0=2#N&P^CD_Z#?1$@OLX#05]PGKC&TP1FI%8^#JB+2CK/KPBC;(\CI;S6
M-LON9S+Z(N#"HZ\>N/#3&KCP15T:0UKL1M%^2LR4^.O3ER].=)/<*8.NA9/A
M_4$UKNJ?0>1.BWN[)T9F_OH=?&57F\N4%+S"\!0RR3.FDN*$:A&@?<=]9QG*
M+:8_<WS#T6B@6"II&G>:P!HT1WM@K@WO\@N.&X1F@RHN(V&!653CQ21M^QFK
MOX5F;R96;Q"VB-TE[^_DO;YI$*F6L';K0=0$)F*NC%TC'-U^C0T1WD=::1'0
M694@6FE_FI18QU8GL.5!Z!. ,7X\PFZ H<^OWEBNC\9T>Q/60E"[)3@PGG+1
MQ^PBQ\_WN(4+ $:01"C-!WT@;UF26PD )*3)'9BGU5H5W[$J-CRP>EXE<T=R
M[:3EPM'I@ @SQ-"=AJW>-G'E1IP%#"HWY(8$80(!H-:E>R4H@=-CRB'+\*/^
MV(_L;6NV?:/'UGF//JHE#7'UM,A#]FZ)VB:Y".0$^0D6P=4/O#>=*5-@0-!<
MLE"2/E$Y%0A:1&A)G#RVGDW?,?#9B+"HW9HMG'Q8-1Z6^DC,*?P&Z"@(J-*?
MH3Z.%D6D^2ADYF$H77Z*R>^"J"'C]??MTX57]72>RKT&[!&R5)*:2O)&VN;;
M&!X&@#-EVQC*UX>Y(7QG,(6ZM#"M(8[B6CQ9FCL? WY=4/L]Q6T*R1U&[TL?
MJN@.XR4*S --W@K!X:.COZH-%G&;4L-@J)R3:]E"EYG452!;/.Q*@*=!9$@Z
M1'/;9X-1P"]&31].H3:C>3NG:"[2DKDYN;MY5DJI$5AJXT+=5D".7#!1-K#/
MW*]&]_$#M5ERM!LX/=+.6 )< J,8[?88KV?N20\>/V[G=_@K%$3R\6:\?D&Y
MNH\BQHS)5:U_+(17PVY@JK4P&GCSKDHZ#5AO_R '2NGG]Z1^;GU'+:+Z=1%Z
M!H'1[16Z"$C^,]'O:32F0M9Q?A#I'X_I0AH'1%0HKUC+@.RW:7\\)346T J#
MN]4TL;789FXC#CCP&YQ"T>HOF)_PJ+C#>U6ZE2;N._BTUQ 0"Z_A=@"/H1[H
M:'1))N;UU*KEJ[(:!W9*)!/X:S:7$\L#)P/Z8C0;0[A"Y$9C)15:\H#)*8:=
M4FA][%<+(SW^ZL-(#W;6<:0O*;/^),RL_UXVD,<@<- ZI1ZGU GW-)B;\J!A
M-88:;X* 2&DEN3HQ\ N"4>YW;R:883R>8K/Y0_R^<UF]NXI<+_Q[ZZI2V$5&
M(C,()7)HW)@V?!!V@Q'- \.'J&]',1_F@:"W+&WDQE*YH@(PSS3EXTJCUN$7
M'DE<ZC4G?RRDRU1:63ZAX#LM)J$^$3FR/J007$#FQEO&P:Z(DM:N3+MQ8&#N
M!R\L4ZH9WHF&;W/NE^=/+)8Z=LYI,<W^LYK50$VZ]>(?64&VK$+NW=2+*T2_
M)59A??ELF+O2GGQNQ8\]NM[=*&B:(-@LIY2@*\QT2HW*84<.\N9<[$T+.*P*
M C\S-M$Z$!S,94)GP?IK2QH,I-)UJ75.N<7\QQB0 $\>=7&#+R>Q- ^WACWG
M.?9-?#. )6(GD? KC[:S/RT2AMDI%4T-V 7_CD+(%AN>$T^Y# AAS"7+I.7^
MF?OB\3P/MP8];AXOST:(,6,0TAT2^371> Y_=]7CM#G>\TG%<$Z22W9Y3;X<
M[=B)6TX<N,&3$'!!1.[\^IK9R.OSJ@%<LG/,1D[R'18:R(-=_1T(M]3UL-"[
M(&PWJ-PN>0\-?2<\#9=QN ^#=8+SZ:!TP/WTG5+&,$'X%\QO&,[O(IA?R+-9
M^ZH<9PG74T*Q"U>')T,(KX)"5Z@2USW5C$_P%9U!'QF7W,I>3+@UM9+*+.#/
M*:?:@3IJY6IFD^A"S4#IJIDRL JO0349,A=#!%V#7S%,)>3;, O46AP$3?"B
M0O8L1'E@X/UM0=4.G7FI]HK#(I9O ;"+()W),).^!CHI.U-<EW%9S%::\OHV
MVS#I,0#.H)ZI#]#/"?X+Q'])_RJF@Z +/-9<51A+K$H,A0.CGH3!IXKAP_""
MWCK2:)>ESXBHPO$@)O<YK.4#^<Q(J"!.FEN4$!-!4U4IC2/DE5@4)<1E-$8+
MJL.VU<2MC;"RP(/- .M38@-U>U) Z/:&Q-YME)9WS.Z6RG6OM1;=RJMO*@R0
M9Q'*4JR::/6<G))DA,A>+52WB"[01>:@/>?-NZBV+- VYEB@1FE48:37LR.U
M*#:=8:*T?U6$KC6/T&"5Z#9;CFW&G6TT$SR7+#'LQMJ_9(A JK&BU(IJ213B
M]C(/]D7]V#!VI(;&S17ZT6YF]9E@4G!KAC/"!L-0BA8I@,P'2E_CM4B]= #F
MZW[IP-+!K9YB&U%B@#J'F*Y"F(6WJQ$9Y6?$C('2,R05_N7O"#=&XVO*6(!J
MHL8&A,/0[^;&.']'76"DSJ9OBYAM=B99?D-K%5 F^D/*,QQ#L'BXR :D#D>+
M3F2+"B]\^Y5WS.9QT=:T#W:[U4]2U5WO.<3A/1=8:G+SNG"E (,!!+X7!WTN
M2@0P/Z.4X!;,A6,:$@H3Z/G4-,J\A\3!1"*&!_ ]"$-G(W&&GJY'DPV0/#9F
M9H]Z7XCL*!@)XWYEV[ 2H#_\2I@=10HUZLWBENL"RBFENM!#AW"$FVXQ>#TI
M?_=ZYHC=>"V+@3)#+!]UM_M=CAS?5!$J2(0JA*JET&%H0,V-368(^CO*8J#.
M!HD+W4$WMC,U.IY$C7FFYW4U.SMG>6&[2_6#)#BU)>NL"0[8!]J=UVVN&D'S
M'%[Q] 7:[.BJ*H?D715O48[B+Q"P<PI*5UJM.6V-B6A#[L?''4H%6]QY?:P"
MH8S@-,, WA2/@SO[9Y53^Z,<DWI-X\2=]]7J&B48K#$EJ#DWC4.8N@=C/<MG
MN*574C^0%2[5@J+PIUS';,(YPIH0A9!"@74&!<9 Q>AD2HV9ZG:4"!Y[5DR*
M.A^;.AM(R9Q5>)2FM@4#KA,$;=@E!:U'$;3+O [II6.:F=.*VVIQF%:*A5#Z
M@#Q=I4V6!]CHX%2U16-+MS^KFA>IXW"Y,1A>#Z5]0@Q0$'&-!([CXHP*L?!(
M+Y3<JUDAD:*A7GU IH'5T/6 ZKYLH=0(=IV,0J)2-Z_,:B9G@@7*Y2IP@P1-
M(WR4<X%PL+4 (8K3:CB7"H9_N3O:# GY(1GIOE_/OE]0G$PQD7W5Y8-C3->2
M##O#BYRPM;YM;;%23OG)UY]3?O -YY2_M#.[STW92=E1,FY@2B/CCN)0X^59
M P2BV@7>7JE?GN$$">OU^T%;(VD\M%!@>O@+_J0BS\I.AH_WDWJE6[!N;J!D
M!61>-02[9X&,78>K+!'B?YH5,JEXQ$?C-D%+LZ*>B%&#X06-T0L!C-.%@%/D
MG@YDJ#E1YKR^:3J#X,L8//=0X.5M;G2R\*_!@LMH1%HP7@HNB74[>#NIWHV+
MX5G1>)LL-BP''&M>:EAA7@,,5P]TXT1/T#H5$L2;&_ Y:C1#N<P@&<H00F[3
M9&"QG/1"_\:9W167D"(2SSGX!33:&#,NL' K%?,MK$_'[KE-_D_0/:XIV73T
M_A(Z;C/>^P449\UJVN9AD8\)7<ET4>,<A:QAE])3X=,4GE*"3PYB+KUWQ;KB
MLF#$!U#TT80T*44/$EC .Z+1+_[EW/"!119H88=@"I 6O:$0'?@X1=.1P5>*
MKI"'5''G_0XYTY<<342Q4<9MUL=C\EY@A>&ZN8&!(,HM7*,%<',/CU\T$U+2
MI.8I%H:N$]%;9</\(L>+;'G_DBRJ>=QBA'0TPY=R@U#RT7)T/2#\*(WL&L8-
M%WQJ;'@D1?Q@ [A<"=CPMKF+B[3%2ASA]HE#YI>7F+!$V<\9IP9I11""%)<<
M8LG!6%J">1:A)AO.3+-M)O(@B\8?+-)<>C!&Z$MU'RA_O-=29;>,&965[5O)
MV_K*):(HGR&W$ @2FD%#>FU26]7MDB?/^ML^Y %!)O3>3"'G+*O<$KN"ZB;@
MGAL^$7OUUX=@]U\&\**!40Q_/B\M81+H%B_GQ/IG[P*KMGQL,7<"",M>KC3Q
M$][Y3N8["(K(-FKEH\6? /#).47295*X#T=!*! [#UZ5X^+,U_>):*63=H85
M1F6CS&5C>=GP\RUN"^S;8EJD=#!4ULM0<+XM*<IQ/WR)U"2$S(P10GAM!C4@
M)ZLV'^WZ,*\6)_K^ZX\3/?R&XT1?XKE]:[T_LE1:GA\*VWS(%8"H9L'L2;*)
M&HHXAAJ!Y,!2)V^P 8<NTL2"KT!V:%_[* 9$Q<1$-4#4A\TC>5MK*3P &^NQ
MP^KD9$$TW&S]4BA,X$]#Z$DYQ2 _6*DDZ(5.$C"'H2E)-BK!>>$$.VGJ?NM1
MDDM:1'&!L\RO(F=&J]<(G%!0V1E2[DXHOV(#>ICYYD4*<FU$A4O6)[)U @2!
MWM:\Z5IP[XX-4$\:3S7DX>XA0573(D_M)FA,<"8:ZP#K]DVR1;L9RE%@#H$)
M^\B8ZSLM)L6HY(P_;MZITL1+RP"=-Z$BU"(FAJT6\[U,:Y7O:;>VDR4'NJ8F
MRFCPDB4N!DSP!G,U;[#-,)2&PYMJB7@7\0C'"0E.TV*.\89.&(Y:G^_="P,Q
M%.=#);Q9;8Z:7U1#HOX#J<?^BQBB?O<9HL)H"760.AA]XW/'9VJ]-Q,C>XJK
MF";V3UAEB*!<.LU3(H4CZIAV%YQ6=%RCZ(;KB/@#F)[GU%)UP[Y@1+[%8H"*
MV]VWV92[1*TRN/L(DIV2DJ3^%]U/9WI,?:QY!S_#"*@CX3X9B4$R/ [F%01R
MP[_+%5U!5.A#$S2T4JTVGZ%^X5T2;WU\=RM_?'\K$*]H;<=S_I7V6&_I"U$0
M6! X*<6/Q_I-^F$RMMTIG574]^S>1-Q"8#YF]M:(\7JC@CE<RD:M1$EGJ9^(
M[,>FR][LA@5\I9*/123O(5^0?T34LV&Q4'%'8^2D!0!K5,MP]5TB#M<QY-*&
MK1R9 9]D(E864OY4R OA&V4X67A>O0.AS'0G3$(K#\8Y"D93:/:E;G%&W3Z,
M!=C7+K[X0WEQ,9N0,0F3: 6&@M?;W,#;D4J(!GE4V)AJ#) MMII67K9MYB/\
MJNY/.#)%1.[M_I_$?VYYR%^?Z:L]N[DE[AQKZUB9KS'P\;0"%I^F]VE&_Y1O
M&HRR*!KWP]<?C7OT;4;CEIS#6S^-:8'V ,39LQ?9G\].7AP='V=__G;T^NCE
MTR#G2@SAV+<MX@=GH]WT##!%.811F@&=0E38P 6=4^%X&)5U,V7X+\01 ')^
M@P38*Z]#)-9/]O:?'V4'1\^?'[_:.WCVXC_^=F_G'O[\:N_P4'Z^]MS>E</I
M.7QTYZ]Z42'EFU\V[F3+O^[A@?SUY+4, /040'(J[^%._3TYM">'.G?W3_UE
M=O 2IO[B;_<>NI-F[2R8[?U1?E&.YS\OFR]^MG'[1J_'"T< _ZIVUVQV>5G4
M4)OL!MG???#C3O:\'!79\0"MY\8=H_IR&WI,J.[VD_SNY/7U7E0^Q:OX_<Y?
M[Z7?/?S<D]4^]@@^=U,KY4?\^-=.3OX&9[H__SDQ3;\^RQ6*%6.+__>S7@A4
M5\FE2(S\V<W^!+(4UY_^=RCJ;E':+I"M5I;&LO;:,^D4IX'872I;Z9C?2TO2
M8*/>%>!)P3?&[@[L'1P<O3HY.ORY>^E7.3,?.GSR<'VBL0_<B7OVXNC%R=YS
M]ZF7!_^5G;S>>W'\].AU]K_SBTMG%;Y^<WSB'O:[>]8_^K<XR=V\";W'VQSK
M=I:\K;M0/G^(8-:#_\BKP(__W_1<+B$?.SGS]C=,0R<0J^H/6AJ1STLDVPUL
M@LK2#QQ*9>HGL5\?WC!/^S7&O-5@B.J/7\%\W%_-B?[QZW>B'W^13O2-'P^,
M8^+AD)GLW]8=\$,=_?VW9_O/3K*]6QQ-X@.?)-+HWNG%RY-G!T?9RZ?9T=^/
M7A\\.SZZQ9>[+8*7+M%AS>L%SNO)2S?FCSN;&\^?/3W*C@^>';TX.#IVZO[U
MJQL/.]_A@J1#VEL/>HA0PGPH-\,A!,CF1@%P]"9 H_X/_Z=%$!B1&P;4F4%]
M?>&[4LHSMC![4(X,8Q-W;"/JLLT-Q'+4C=)F*-L&/U(A7P1+U?YU43,AJ.3W
M&=^P166?L\J?-O[T*1(+B_?_8<_I%UI,9E&$$GG,<&-5-K!_N-T"!B*_=*?5
M^][/-YN+^6%G^X<GUZ(MON%%X__^N+/B)% /_J^??GC\^!=$Z8_S=^[0(:Q/
MLV0!M^\O657?<"GNSO?=B_9Y+=#(%D><%P&A'T*XJ9]45Z%O#IE=7T;;[R(4
MAB,[&^<A]04TR#5TI/U.X#TG=J.DZ47^OKR8771/CJ5CT$5*N[7$!8)4#C2$
MY->B27YK8NB1$T-C8NU W@QL$1?5/J3ZS5J]1551>)"H2 <_2$?']Y$]+<;5
MNYL37G=JXOS/XO]\TIV\_^3'[4=/0N_@-M_]I%WPFZB?XFLXJKA1S.;&X9][
M!]D>M^=X@7=Z?1J^^-.P?O<[>O=/]9*?E\_XS^-G__%B[^3-ZZ/-#><\__;R
M^>'1Z__^1-[BJI.,TI!?8'H[BH@_OMDT[0NV(YY-K@IBS3Z">A_WI(_*B>I:
M/'F2C'RGTVZZ\??66]7>JE^?[7K0F-LRSU"<T>\KJN"*MQ* ->OM_.RV4VY>
M:AO7V_79;1>FQ-;[]<7LUV$^+6YY6VX_T_F1=LZ27.%/7W^N\,FWFBMD;/_#
M+G#_+3L3[8SA_MTGU0"M<U-YP[UC\'Y^/W*7\^G+U[]_BB'O(#+Y8&?["9N>
M6R<5UR&'%,B&X(K!T!1.QL0)UHHY*36>>XX@TPD9FL=A;?VLL=\*0]-%DA*&
MZ%:V;[->8NF2W!5NG6?@SEWVQ][S-T?9ZZ.#HV=_'!WV.[8&]\$P0?A"]ZF0
M'M2%\A\T'$J>5G?R6A^#1 _LE!N 3GZ@11/G@+PA ?,2J%A-&$+\N_QN7(PD
M;<1/O25)R5BR5Q]L&MW .W:<BK;CNRJ0;=7=N-'9+4(%WO+06YPN>E67DVEO
MO4S+A_YLEV=O.(0BV@]&NM[R]'Y]LPNEQG>SAK<M"TG7W/8(-WKT;WM)8LGR
MR1;H#@[7+4BFNY4Y]W9?G5>3PB=V/ZE(N>MW_^JV<U49?721E^/L,U<D7\)"
MKDV5A7.$R.KPYRS*L+N?^YDDV]<K]_D?K*5)A:_2$;_!1?5ID>__>F\W8K+7
M3.W/UG3^W.2QKY![M&(M^8/K%[)]PU?M@TOR[F3-HB/\Y5@2GZP<<5E6Y78A
MQ0M39+>;,_B H??O/_@^5;+X>C8N[DNVJRO;V#E24,INOVW/A\E*XM,Z*1LH
M&\?_:[-QP20_^=*9_.UW^R\/_X':^K>3WY_O_G]02P,$%     @ 1$%]5XB@
ME6N "   62T  !D   !E83$X.3$X-V5X-"TT7S$X,&QI9F4N:'1M[5IK;]I(
M%_Z.Q'\XBW:K5C+77-HF%(F LZ4B) *ZU>K5?ACL(4QK/-Z9<2C[Z_?,^((!
MDR5-TK1Z$XE@QG-YSISGW,9NOA]?]%O%0O.]W>[B-^B_YK@W[MNM9C7ZQKO5
M^';S[++[)XS&?_;M=Z4I]]4)U&N!@C&;4PD#NH AGQ/?BAHL&%'!IB4<B$.O
M[CKN%.9$7#/_!'37VBDH^E65B<>NL4FPZYDJM9IG+?OKC$V8@L/*8;-ZAJBO
M'F,]A_J*BE+KA3^1P>G]%RDK'IB%TH8)5XK/X[:\I5'63^WAL#T80_O"'G3Q
M@U>_#VU;7SVA[-F^GT.IV'1Y"O=;F?DNU>-KE2/FEUKC&9/PB0A!? 7M.?5=
M_.#5M:#47+U4NL<+S_T[Y*?-CZVT3[/ZL?5"F.97Q0+V,;)0%YBO.! )? IJ
M1J'QICGZ>-52LV95?X-+EOK6@-_0^80*:-0:!Q9,ED!\%\B<^]=0?U.#/IM2
M&#F,^@Z*V.$BJ%A H$L]LB""@H,M7!#%N*\QT@S$#I\'Q%^N ]2SM\6<X28Z
M%#HD8(IX<$$D@H;S$._VE5O9G.H]]UPJLC-5GD)+3\</;1KO[:'='FDSL(Q&
MX_V%&7$A$/2&\5!Z2V!2AM0M%EZR5["(&"4!J1"$PID122$,],^#VK%U7#L$
M.4,UIBR)YWPAI-YEB>J=(Q5 *NY\L>#76J56J]4A( )NB!?2')7K[B/=/:LM
MJUC Y@\APFO4+,VUAJ6Y232+D:MXLQT(YL&1N7E@2-@.KW$OH7X8MVVL96:+
M349F%SN%EVR'[,5")'S#.GI=MPX;;S/B9[%;&E&7.K%I-/(A?R!^2,02ZM%]
M-)\["Y&L42SD2Z*G0&EN5V4=I:E9QVBMMT@30:O7$J@;NY_"+!;R<$:C\S!J
M +IO9*(6NAV@Q)F!H_$A4!EJEZ9=$4CJA((IA@A3"4CBX2ST2 K!1!Y+ALZL
M6- MZ).H6E#JKW%>[\MJU2<QR1_3&6PY@I0XQ<(V<PZMX_J1=?#FZ%;FW$[A
M^'8.-R(M\6N* P0LF)IIJ,7"FN5&\%-;2YI3#:\S+^J]6GP7(QTJ%$$J,O^&
MHO,24A/3\4*785Q;$4=[R8A8AJZQ$TRH?"_VPK[D??5_SE[C+20.7T6AE 1S
MLBP6)A3FW&53IEV52+U6PB=8H%84;K'#?:E3I7B2F=E=,R?!B3YS[+9,;N+'
M+_-0287*T)Q(ETS4%R&R$F45"Y&VT*HRLV]/GB--WC)/M?.)VO-2Z:=U7.M&
M 2Z53%#CLXS"@7C>%CW0VB15B%$@%2;4XPOC<Y[WMF7B,!J$3QV3FL?&@N1-
M"P>,]-G]QW(!;YCT0E+Z)4KY8I:3(! <$[YH&HP3 4Z;!'X=9@A6!UH[451Y
M:]6.#ZW:VS<[H@IVPTOZE0J'Z9QL4ZT; 6:40=*.D?RPI<"#U*,IY-L4?7XY
MM%=FA"FY#DV8,W' :$MU(:>#D[:1*??0-.3)4Z#=V*=Q^ZQO0\?N]T=7[4YO
M\/N[4JUD?E^UN]WD]YW1+9BK9KIK[;>2.>1ICH?)+#>8"C"'> E<Q8-2?!#4
M''>37O$,&ZC'W5MZ-K!KQ*JR9/_0"&FI5:_DC]O)R;71]G2J3?:&1D:B58N&
MXH3&BHVAK-EPTL%8$B9_S*%;7A*-$'TG1M$D<J*)8B57?PT!6I0Q40MCWN1S
M;-334)B$C;@:ICE]6'.T<<:4S!^)B_^&T<Y7C8Y;#T"SGY,]6TK-M9;[<:RQ
M@V/[K7Q7CNG0G.%'GC^.B*BHF"?T6VS1#Z%$_#/YE9H1M8.G;#ZG+L/T&<N$
MF-MDXE&8"CXW0W1JO98\\(G.]F4NM'W""71QQK4:(O05EAUZY)1-D?3$]W'#
MA-3U?BSASHF>+>(A_>G!=^5Z#B-]KB+ZKI@8L2.7 %@78F\L1R).4O>9#=_?
M/Q[>+P9_=6A@@EY:=^J4BODK+[==JD9<$70>'3M@%,6?&# Q(&O_20T/G[GP
MD)[AZ%Y:'J]9OCYJB*T<G8-Y? (ZLOBA.99";3L\U$]6=*(MXU,+;%W,&%XL
M9FCPDJ]&I[',U>=#)N72"1AZ!<%0:>@G3%!->DU8=#Q@?)1NB]-Y0S@F=,1T
MJ)1<1.=B1$H4+CZ<B OC"(@B7_1A4W+F%BV@#T844P@,N$_32EMB/KC:@ JT
M0<]*5"@T;$^'.T2.A<24.)+-&?H]+D 3W-N>."/:XY'\<9]8WKK(_YJ]UBC=
MGBMR3>$\*JN:U5[KK^_Z8!*7^:5<AG-&/??$8#G%N?X.]3,Z7!+*Y<0FNKT_
M$CS9I[+U1LYCV6/=-N$"HUG:=N81+-?KE2.$)KG'7"P_[R=A5I9F%?'E0)T(
M2KZ4)Q2])\H3&/FR\(]ST&N1LN#V63*SB56C4;-Q/QE/MT\'>@/XU!L/[-$(
MS$'!Y?G6,0%F*3<K7Z</@M9\X>JIL<FTITQ(E1ZSD@F_H3EG+H]YO/+XP2RE
MOH-630*)Q$NN[AKG.I<:Y>!=J6'489ZB]\YM&'5Z]J!CC[##\*H"D#TOS(:Q
M;$Q<>=%O#+-'O^T58P_V['=<6^_W[?CV2P+/EB?Y>#8<U6334>V;9:);K\HJ
M?""&*!7XQ+F[U"[],72R'Z0!8MDA]7X3; KS5(*,F?+N)TEGQN@4[*A@0X]U
M.9TR1S^::YX-6[O>3WE(@7-MXC\;OV%C-YQ&>WC1&XU['71Z[:O>N-V'B_9H
M; _A_..@"_UQM_)([N.["?Q#NH&1HC<8XL[XTOW)?<":)#^Q ^A=ZE1DZXTQ
M"_K]CG$".DOIF:?\)G6Y(#YF<F(?F=.ZY#&RF->F9+WU8..Q$JCGI3>-.UDT
MD_ /0X^6DZ1_5YVT\^W5M5.0[.@LJS/UE)DMIYA*-D47)?'_;%&R!O*I-5;5
MKT9'[TKK5ZK_!5!+ 0(4 Q0    ( $-!?5=N+MU+T0,  .H.   1
M      "  0    !A=&YF+3(P,C,Q,3(X+GAS9%!+ 0(4 Q0    ( $-!?5<Z
M*1B=  D  )5H   5              "  0 $  !A=&YF+3(P,C,Q,3(X7V1E
M9BYX;6Q02P$"% ,4    " !#07U7D\*U2.T+   ED   %0
M@ $S#0  871N9BTR,#(S,3$R.%]L86(N>&UL4$L! A0#%     @ 0T%]5ZBN
M!#A'"   +V,  !4              ( !4QD  &%T;F8M,C R,S$Q,CA?<')E
M+GAM;%!+ 0(4 Q0    ( $-!?5>0!MFAR!P  -"O   7              "
M <TA  !E83$X.3$X-RTX:U\Q.#!L:69E+FAT;5!+ 0(4 Q0    ( $-!?5<J
M%-H=*4$  '., 0 :              "  <H^  !E83$X.3$X-V5X,3 M,5\Q
M.#!L:69E+FAT;5!+ 0(4 Q0    ( $1!?5?]L!4.S[4  *CQ P 9
M      "  2N   !E83$X.3$X-V5X-"TQ7S$X,&QI9F4N:'1M4$L! A0#%
M  @ 1$%]5XB@E6N "   62T  !D              ( !,38! &5A,3@Y,3@W
G97@T+31?,3@P;&EF92YH=&U02P4&      @ "  C @  Z#X!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
